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Abstract 
For many decades, cancer treatments basically include surgery, chemotherapy and radiation therapy. 
Over the last decade, targeted therapies using small molecules have been also included in treatments 
many cancers. Recently, the development of immune checkpoints and adoptive cell transfer cell-
based methods has largely changed the paradigm of cancer treatments, while the new methods are 
still accompanied with the low responsive rate in solid tumour, high recurrence rate, serious adverse 
effects and expense for patients. Thus, a more effective immunotherapy is required. One possible 
solution is to silence the inhibitory immune checkpoints (such as programmed cell death-1: PD-1 and 
programmed cell death ligand 1: PD-L1) on T cells with small interfering RNA (siRNA), which 
requires more effective and workable siRNA delivery systems.   
This PhD project aims to develop effective nano-carriers to deliver functional siRNA to T cells to 
silence inhibitory immune checkpoints and thus enhance their killing efficacy to cancer cells. By 
taking advantages of the low toxicity, good biocompatibility, excellent colloidal stability and efficient 
cellular uptake, MgAl-layered double hydroxide (MgAl-LDH) and lipid-coated calcium phosphate 
(LCP) nanoparticles (NPs) are examined and compared as nanoplatforms for cancer immunotherapy.  
This project first optimised the LDH-based delivery system by examining the delivery effects of 
operation parameters, including the loading method of siRNA by LDH NPs, the LDH:siRNA mass 
ratio and incubation time. siRNA molecules directly mixed with LDH followed by a dilution with 
culture medium resulted in >80% cells being transfected in 4 h. MCF-7 cells took up most dsDNA or 
siRNA at the LDH/gene mass ratio of 10:1-20:1. However, the most suitable LDH:siRNA mass ratio 
was around 5:1 for efficiently silencing PD-L1 gene due to the control release of siRNA from LDH-
siRNA complexes in cytosol.  
Subsequently, the PD-1 silencing in T lymphoma cell line EL4 and human tumour infiltrating 
lymphocytes (TILs) was examined using LDH and LCP NPs in order to compare their capability for 
gene silence in T cell. Under similar conditions, LCP NPs more efficiently delivered siRNA to EL4 
cells and silenced the PD-1 gene. The better transfection ability of LCP NPs was also confirmed in 
TILs to knockdown the PD-1 expression.  
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As a proof of concept, LCP NPs were used to deliver siRNAs to silence PD-1 in PD-1 positive TILs 
from breast cancer patients and PD-L1 in breast cancer cells MCF-7, respectively. The siRNAs 
delivered by LCP NPs efficiently down-regulated the target genes (PD-1 and PD-L1) in target cells 
(TILs and MCF-7 cells) in terms of both mRNA and protein expression levels. The PD-1 or PD-L1 
knockdown significantly increased the killing efficiency of TILs to MCF-7 cells. Moreover, 
simultaneous knockdown of both inhibitory immune checkpoints PD-1 and PD-L1 further improved 
the immune cytotoxicity of patient TILs to breast cancer cells MCF-7. This study thus implies a 
clinical application for breast cancer patients by silencing both PD-1 and PD-L1 using 
nanotechnology.  
Finally, the expression of PD-L1/L2 in breast and colon cancer stem cells (CSCs) was determined. 
The stemness of these cancer cells was confirmed by their surface markers. We have for the first time 
found that PD-L1 expression was higher in both CSCs compared to the non-CSCs by flow cytometry 
data and expression of cellular PD-L1 proteins. In contrast, only trace amounts of PD-L2 were 
detected in both CSCs and non-CSCs. A further investigation showed that the increase of PD-L1 
expression in CSCs may be mainly induced by insulin promotion of the protein production and EGF 
promotion of the transport of the protein. Thus, breast and colon cancers may be sensitive to PD-
1/PD-L1 immunotherapy, and warrant further investigations of CSC-targeted PD-1/PD-L1 
immunotherapy using the developed nanoparticles, such as LCP NPs. 
In conclusion, this PhD research project promises a nanoparticle-based PD-1/PD-L1-targeted 
immunotherapy in the near future.  
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Figure 12. Intraperitoneal administration of the Au-CGKRK nanoparticles (NPs) complexed with 
both PD-L1siRNA (the immune checkpoint inhibitor) and STAT3siRNA (the JAK-STAT pathway 
inhibitor) results in significant (>70%) enhancement in overall survivability (OS) in melanoma-
bearing mice (n = 5) when compared to the OS in the untreated mice group. 
Figure 13. Immune interactions involving antigen presenting cells or tumour cells, T cells, and 
tumour microenvironment. 
Figure 14. When PD-L1 expressed on tumour cells binds to the immune checkpoint PD-1 on T cells, 
T cell function is turned off (A). Blocking PD-1 or/and PD-L1 by antibody restores T cell function 
(B) to kill tumour cells. Knockdown of PD-1/PD-L1 by RNAi activates T cells, leading to tumour 
killing (C). 
Chapter 3: 
Figure 1. Schematic outline of MgAl-LDH nanoparticles and loading of siRNA/dsDNA. 
Figure 2. Schematic outline of LCP preparation and loading of siRNA. 
Figure 3. Schematic presentation of TILs collection, culture and expansion. 
Chapter 4: 
Figure 1. Characterisation of LDH NPs. (A) Particle size distribution of Mg2Al-Cl-LDH NPs in 
suspension; (B) TEM image; (C) FTIR spectrum; and (D) XRD pattern of Mg2Al-Cl-LDH NPs. 
Figure 2. Optimisation of the mixing method. dsDNA was loaded to LDH NPs in MM 1, 2 and 3, at 
LDH:dsDNA mass ratio = 20:1. Then the mixture was added into the medium for MCF-7 uptake. The 
uptake amount was measured in terms of the mean fluorescence intensity (MFI) in FACS. Data 
presented as the mean ± SE from 3 independent experiments. 
Figure 3. Cellular uptake profile of LDH-dsDNA hybrids represented by the positive cell percentage 
vs. culture time. LDH:dsDNA = 20:1, [LDH] = 20.8 µg/mL, and [dsDNA-Cy3] = 80 nM. 
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Figure 4. (A) Agarose gel electrophoresis (AGE) for examining the immobilisation of dsDNA by 
LDH NPs at the mass ratio from 40:1 to 1:1. (B) Relative cellular uptake amount of dsDNA 
represented by the relative mean fluorescence intensity (MFI) of MCF-7 cells vs. LDH:dsDNA mass 
ratio at [dsRNA-Cy3] = 80 nM = 1.04 µg/mL. 
Figure 5. Scheme illustration of the dsRNA loading amount per LDH NPs and the relative LDH NP 
number at the varied LDH:dsDNA mass ratios. (A) At 2:1 to 10:1, LDH NPs have the maximum 
dsDNA loading with some free dsDNA; (B) At 15:1 to 30:1, LDH NPs have the maximum dsDNA 
loading without free dsDNA; (C) At 40:1 to 160:1, each LDH NP loads fewer dsDNA molecules 
without free dsDNA. 
Figure 6. Cell viability of MCF-7 transfected with CD-siRNA delivered by LDH NPs under various 
conditions. Data presented as the mean ± SE from 3 independent experiments. 
Figure 7. Down-regulation of PD-L1 in MCF-7. (A) Real-time PCR data for the knockdown of PD-
L1 mRNAs; and (B) Western-blot showing reduction of PD-L1 expression in MCF-7 treated with 
LDH-PD-L1-siRNA at the concentration from 40 to 160 nM. 
Chapter 5: 
Figure 1. Particle morphology and particle size distribution. The upper penal shows the morphology 
of the nanoparticles used in this study (A) Mg2Al-Cl-LDH; (B) bovine serum albumin (BSA) on 
layered double hydroxide nanoparticles (BSA-LDH) in PBS; and, (C) lipid-coated calcium phosphate 
(LCP). The lower panel shows the size distributions of the corresponding nanoparticles (NPs) in the 
upper panel (i.e., (A, D); (B, E); and, (C, F)). 
Figure 2. Cellular uptake profile of LDH and LCP NPs. (A) The fluorescence-activated cell sorting 
(FACS) results show the positive cell percentage vs. the time course (culture time) for EL4 cells 
treated with LDH-dsDNA, BSA-LDH-dsDNA and LCP-dsDNA hybrids at 40 nM of Cy-dsDNA. (B) 
The FACS results show the positive cell percentage vs. the treatment dose for EL4 cells treated with 
LDH-dsDNA, BSA-LDH-dsDNA and LCP-dsDNA hybrids for 4 h. All the tests were done in 
triplicate. 
Figure 3. PD-1 expression and down-regulation of PD-1 in EL4. (A) PD-1 expression in gated CD4 
and CD8 positive T cells (32.0%). (B) Real-time PCR data for the knockdown efficiency of PD-1 
mRNA in EL4 treated with BSA-LDH-siRNA-PD-1; LDH-siRNA-PD-1; LCP-siRNA-PD-1 at the 
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concentration of 80 nM for 4 h; and, (C) Western-blot showing the reduction of PD-1 expression in 
EL4 cells treated similarly. All tests were done in triplicate, with the SEM being listed in the 
parenthesis. 
Figure 4. PD-1 expression in human tumour infiltrating lymphocytes (TILs). FACS results show the 
PD-1 positive cells in CD4+ and CD8+ cell populations from TILs. 
Figure 5. Down-regulation of PD-1 in TILs using LCP NPs. (A) Real-time PCR data for the 
knockdown efficiency of PD-1 mRNA in TILs treated with LCP+si-PD-1 at the concentration from 
20 to 80 nM for 4 h; (B) Western-blot showing reduction of PD-1 expression in TILs treated similarly. 
The tests were done in triplicate, with the SEM listed in the parenthesis. 
Chapter 6: 
Figure 1. Characterisation of LCP NPs. (A) TEM image of LCP-NPs, the scale bar represents 100 
nanometers; (B) the size distribution of LCP NPs. 
Figure 2. Representative flow cytometry data for PD-1 expression on TILs and PD-L1 expression on 
MCF-7 cells. (A) Sorting of CD4+ T cells and (B) PD-1+ cells in CD4+ T cells; (C) Sorting of CD8+ 
T cells and (D) PD-1+ cells in CD8+ T cells. (E) PD-L1+ cells in MCF-7 cells. 
Table 1. Basic demographic data for 15 evaluable breast cancer cases. 
Figure 3. Knocking down PD-1 expression in TILs. (A) Real-time RT-PCR data for the knockdown 
efficiency of PD-1 mRNA in TILs treated with LCP-si-PD-1 at the siRNA concentrations from 20 to 
160 nM; (B) Western-blotting assay shows the reduction of PD-1 protein expression in TILs treated 
with LCP-si-PD-1; (C) Flow cytometry analysis of TILs before and after treatment with LCP-si-PD-
1 at 40 nM. All tests were conducted in 3 biological repeats. *: p<0.05; **: p<0.01; ***: p<0.001. 
Figure 4. Knocking down PD-L1 in MCF-7 cells. (A) Real-time RT-PCR data for the knockdown of 
PD-L1 mRNA in MCF-7 cells treated with LCP-si-PD-L1 at the siRNA concentrations from 10 to 40 
nM; (B) Western-blotting assay showing the reduction of PD-L1 protein expression in MCF-7 cells 
treated with LCP-si-PD-L1; (C) Flow cytometry analysis of MCF-7 cells before and after treatment 
with LCP-si-PD-L1 at 40 nM. All tests were conducted in 3 biological repeats. *: p<0.05; **: p< 0.01. 
Figure 5. PD-1 or/and PD-L1 knockdown improves the anti-tumour efficacy of TILs ex vivo. The 
killing efficacy of TILs to MCF-7 cells was measured with cell-mediated cytotoxicity assays, at the 
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TILs/MCF-7 cellular ratios of 10:1, 30:1, and 100:1. PD-1+/PD-L1+: both cells were untreated; PD-
1-/PD-L1+: only TILs were treated; PD-1+/PD-L1-: only MCF-7 cells were treated; PD-1-/PD-L1-: 
both cells were treated. All tests were conducted in 3 biological repeats. *: p-value < 0.05. 
Figure 6. Cytokine production in the co-culture of TILs and MCF-7 cells. Untreated TILs (TILs) 
were analysed for CD4 and CD8 positive cells with CD3 pan T cell marker (CD3+CD4+ or 
CD3+CD8+ population) using flow cytometry (A). These cells were co-cultured with MCF-7 cells 
(MCF-7) for 48 hours and cytokine production was measured in culture supernatants by ELISA (B). 
Similarly, TILs with (PD-1 silenced (TILsK) were analysed for CD4 and CD8 positive cells (C) and 
were then co-cultured with MCF-7 cells for 48 h. The cytokine production was measured in culture 
supernatants by ELISA (D). In both assays, the TILs/MCF-7 cell ratio was 100:1. CLT-6, a murine 
IL-2 dependent cytotoxic T cell line, was used as a control here. **: p<0.01. 
Chapter 7: 
Figure 1. PD-L1 expression in breast CSCs. MCF-7 cells (4×103 cells/ml) were cultured in serum-
free DNAEM/F12 medium with 20 ng/ml of EGF and 4 µg/ml insulin (sphere culture medium) for 7 
days until spheres were formed. Expression of breast cancer stem cell markers, CD44 and CD24, in 
the sphere-forming cells (SFCs) were examined (A). PD-L1 expression in MCF-7 and their SFCs was 
analysed using flow cytometry and (B) is a representative flow cytometry result of three repeats. The 
cellular protein of PD-L1 was detected by Western blotting analysis (C), note that the protein band 
was broad around 45-50 Kd; Tub: tubulin. 
Figure 2. PD-L1 expression in colon CSCs. HCT-116 cells were cultured in sphere culture medium 
for 7 days. The SFCs were separated and the expression of colon cancer stem cell markers, CD133 
and CD44, was examined. (A) shows the increase of CD133 in SFCs comparing with HCT-116 cells 
while (B) shows the increase of CD44 expression. (C) shows a representative (3 repeats) flow 
cytometry analysis of PD-L1 expression in HCT-116 cells and their SFCs. (D) shows a representative 
histogram analysis of PD-L1 expression in HCT-116 cells and their SFCs. (E) shows the Western 
blotting analysis of PD-L1 protein levels. **: P<0.01 by student-t test, n=3; Tub: tubulin. 
Figure 3. Flow cytometry analysis of CSC markers of HT-29 spherical cells. After sphere culture for 
enrichment of cancer stem cells, the HT-29 spherical (SP) cells were labelled and analysed for the 
expression of CD24, CD44, and CD133 using flow cytometer. The expression of CD24, CD44, and 
CD133 of HT-29 spherical cells were significantly increased (A, HT-29 vs HT-29SP). The fold 
changes mean fluorescent intensity (MFI) from 3 repeated FACS analysis show the same trend (B). 
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Figure 4. PD-L1 expression increased in colon CSCs HT-29. (A). Western Blotting analysis of PD-
L1 protein levels in HT-29 cancer cells and tumour spherical cells from HT-29 (HT-29 SP). (B). flow 
cytometry analysis of PD-L1 positive cells. Comparing with the isotype controls (ISO) HT-29 
spherical cells (HT-29 SP) had more (about 8% increase of PD-L1 positive cells. (C). a histogram 
analysis of PD-L1 expression in HT-29 cells and HT-29SP. (D). the fold changes of MFI of C. 
Figure 5. PD-L2 expression in breast and colon CSCs. (A). PD-L2 expression in MCF-7. (B). PD-
L2 expression in HCT-116. (C). PD-L2 expression in HCT-29. 
Figure 6. Insulin but not EGF increases PD-L1 production in non-CSCs. Insulin treatment can 
increase PD-L1 expression in non-cancer stem cells of HT-29 but the treatment needs to be 6 days to 
be able to display by Western blotting assay (A). In contrast, EGF treated HT-29 didn’t show PD-L1 
protein band even after 6 days and only have the band after co-treatment with insulin. (B) shows a 
dose-dependent increase of PD-L1 protein from 1µg/ml to 20 µg/ml insulin. Similar to (B), (C) shows 
the dose-dependent increase PD-L1 by flow cytometry analysis. 
Figure 7. PI3K/Akt dual inhibitor BEZ235 dose-dependent inhibition of insulin-induced PD-L1 
expression. (A) shows flow cytometry results of BEZ235 inhibitory effect on PD-L1 expression. (B) 
shows the inhibitory effect on protein levels of BEZ235 by Western blotting assay. 
Figure 8. EGF helps in PD-L1 transport to cell surface. (A) shows that after EGF treatment the PD-
L1 levels on cell surface increases analysed by flow cytometry analysis, compared to isotype control. 
Together with insulin EGF treatment can further increase the level. (B) shows the MFI of repeated 
flow cytometry analysis. EGF treatment alone the MFI increased 44.7%, compared to isotype control. 
When co-treated with insulin, the MFI of EGF treatment further increased 20.4%, suggesting that 
EGF treatment is associated with membrane PD-L1 levels. (C) shows the WB assay for PD-L1 in the 
cell membrane isolated from HT-29 cells treated with insulin or EGF+ insulin. 
Figure 9. Blocking PD-L1 affects sphere formation: Antibody blocking PD-L1 was added into the 
sphere culture medium and the blockage of PD-L1 inhibited the sphere number (A) but didn’t affect 
the sphere size (cells/sphere, B).  
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Chapter 1  
Introduction 
1.1 Research significance 
The limitations of traditional cancer treatment have led researchers to turn their attention to various 
immunotherapy approaches [1]. One of the promising immunotherapy approaches is adoptive cell 
therapy (ACT). However, there are many challenges to the development of effective ACT [2-4]. 
The antitumour efficacy of T cells is significantly hampered by the interactions of immune 
checkpoints, which hinder the immune response and facilitate tumour to escape from immune 
surveillance [5]. One possible solution is to silence the inhibitory immune checkpoints, such as 
programmed cell death-1 (PD-1) and programmed cell death ligand 1 (PD-L1) on T cells and tumour 
cells with small interfering RNA (siRNA), respectively, which requires more effective and practical 
siRNA delivery systems.   
For this purpose, this PhD project aims to comprehensively investigate the delivery system of MgAl-
layered double hydroxide (MgAl-LDH) and lipid-coated calcium phosphate (LCP) nanoparticles 
(NPs) for siRNA delivery by taking advantages of their low toxicity, good biocompatibility, high 
loading capacity for biomolecules, efficient cellular uptake and endosome escape. Using the 
optimised LDH/LCP delivery system, siRNA targeting PD-1 in T cells and PD-L1 in tumour cells 
were delivered to enhance the antitumour immune function of adoptive T cell therapy. 
1.2 Research goal and objectives  
The overall goal of this project is to develop inorganic nanoplatforms for siRNA delivery to T cells 
and tumour cells, in order to enhance the killing efficacy of T cells by silencing inhibitory immune 
checkpoints. To achieve this, four specific objectives are proposed, to:  
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1) Optimise the efficacy of LDH-based siRNA delivery by adjusting experiment parameters, 
including the loading style of siRNA with LDH NPs, the LDH:siRNA mass ratio and 
incubation time; 
2) Compare and understand the silence capability of PD-1 siRNA delivered to T lymphoma cell 
line EL4 and human tumour infiltrating lymphocytes (TILs) using LDH and LCP NPs under 
similar conditions;  
3) Confirm the enhanced cytotoxicity of human tumour infiltrating lymphocytes (TILs) to breast 
cancer cells MCF-7 through delivering siRNAs to silence PD-1 in PD-1 positive TILs from 
breast cancer patients and/or PD-L1 in MCF-7 using LCP NP delivery system; 
4) Determine the expression of PD-L1/L2 in breast and colon cancer stem cells (CSCs) and 
understand the related mechanism. 
The outcomes of this research are expected to provide a promising approach to improve the efficacy 
of TIL-based immunotherapy by ex vivo minimal manipulation of TILs collected from breast cancer 
patients, which may become a clinical practice for some particular breast cancer patients. 
1.3 The scope and structure of this thesis 
This PhD project has demonstrated the application of LDH and LCP NPs as siRNA vehicles in 
immunotherapy and the potential application in cancer stem cell targeted therapy. It promises an 
inorganic nanoparticle-based and PD-1/PD-L1-targeted immunotherapy in the near future. 
First, the general introduction about nanomaterial and immunotherapy are presented in Chapter 2. 
This chapter also reviews the current applications of nanoparticles in biomedical fields, especially 
inorganic nanomaterial in gene and siRNA delivery. LDH and LCP nanomaterials, the structure and 
biological applications are presented to demonstrate that these nanomaterials are potential effective 
gene delivery systems and expected to address the challenges for development of novel 
immunotherapy for cancer patients. Chapter 3 then outlines the related methodologies, consisting of 
synthetic methods, characterisation to confirm the structure and compositions of LDH and LCP 
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nanomaterials, bioassays of LDH and LCP siRNA delivery system, and biological techniques. 
Chapter 4 reports our findings by applying layered double hydroxide (LDH) nanoparticles (NPs) in 
siRNA delivery. In this research, we comprehensively examined the effect of experiment parameters, 
such as the mixing method and LDH:siRNA mass ratio, on siRNA silencing capability. The 
optimisation for LDH NP based gene delivery system may provide the guidance for more efficient in 
vitro and in vivo siRNA delivery using the optimal parameters. 
In Chapter 5, we studied and investigated the siRNA delivery efficacy of siRNA into T cells using 
LDH and LCP NPs. We used EL4, a murine T cell lymphoma cell line as the cell model and this cell 
line was identified as constitutively expressing high levels of PD-1 [6]. We found that LDH and LCP 
NPs were effectively delivering PD-1 siRNA to T cells, while LCP NPs more effectively silenced the 
PD-1 expression in EL4 cells, which was further confirmed by the PD-1 silence in human tumour 
infiltrating lymphocytes (TILs). 
Since the interaction of programmed death protein 1 (PD-1) and its ligand-1 (B7-H1, better known 
as PD-L1) is a key mechanism in tumour immune escape, we have thus hypothesised that Down-
regulation of immune checkpoint molecules such as PD-1 and PD-L1 on T cells and tumour cells 
enhance the T cell immunity against tumour cells. So, in the investigation conducted in Chapter 6, 
LCP NPs with an average particle size of about 40 nm were used to deliver small interfering RNA 
(siRNA) against PD-1 or PD-L1 to tumour-infiltrating lymphocytes (TILs) from breast cancer 
patients and breast cancer cells (MCF-7). The data indicated that knockdown of PD-1 in TILs or PD-
L1 in MCF-7 improved the immune response of patient TILs to breast cancer cells. Simultaneous 
knockdown of PD-1 in TILs and PD-L1 in MCF-7 significantly enhanced the cytotoxicity of TILs to 
MCF-7. This study thus has an important clinical implication for future PD-1/PD-L1 based 
immunotherapy for breast cancer patients. 
Furthermore, Chapter 7 reports the expression of programmed cell death ligand 1/2 (PD-L1/L2) in 
breast and colon cancer stem cells (CSCs). Using flow cytometry analysis, we demonstrated that PD-
L1 expression was higher in CSCs of both cancers compared to non-stem like cancer cells, while only 
trance amounts of PD-L2 were detected in CSCs of both cancers. Further research suggested that the 
increase of PD-L1 may be induced through PI3K/AKT pathway by insulin and the increase of 
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transport promoted by EGF, and that the high-level PD-L1 expression in CSCs seems necessary for 
maintaining cancer stemness. These data show that breast and colon cancers may be sensitive to PD-
1/PD-L1 immunotherapy. Thus, CSCs appear a suitable target in PD-1/PD-L1 based cancer 
immunotherapy for better and lasting treatment outcomes. 
Finally, the general conclusions of the whole thesis and my personal future perspectives are presented 
in Chapter 8. 
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Chapter 2  
Literature Review 
This chapter will very briefly review the current developments in nanomaterials for siRNA delivery. 
Especially, layered double hydroxide (LDH) and lipid-coated calcium phosphate (LCP) 
nanomaterials, their physicochemical properties and biological applications are summarised to 
indicate that MgAl-LDH and LCP nanomaterials are potential effective nanocarriers for gene therapy 
and suitable carriers for relevant biomedical applications. Then immunology background regarding 
the development of adapted T cell therapy is introduced, followed by the discussion of the new 
progresses of cancer stem cells. Finally, the challenges for this specific project and research strategies 
initially proposed for this project are outlined to develop suitable nano-vehicles for gene delivery for 
combined cancer gene therapy and immunotherapy. 
2.1 Nanoparticles for siRNA delivery 
Gene therapy by delivering small interfering RNA (siRNA) to the cells to reduce/stop the production 
of disease-causing genes/proteins is proved to be an effective and safe approach for many diseases 
[1-3]. However, efficient delivery of siRNA to cells, especially in vivo settings, is still a big challenge 
for this therapy. Nanotechnology has provided an excellent option to address this challenge and there 
are a variety of nanoparticle systems currently being explored for different application types.  
Nanoparticles (NPs) can be divided into many types, depending on different angles. Basically, NPs 
contain (bio)organic and inorganic NPs, hybrid NPs, and virus-like NPs. (Bio)organic NPs typically 
include lipid-based nanoparticles (such as liposomes), polymeric NPs (e.g. conjugated polymers and 
cationic polymers), biopolymer NPs (albumin and chitosan NPs) whereas inorganic nanoparticles 
majorly include carbon nanotubes, magnetic NPs, quantum dots, gold NPs, layered double hydroxide 
NPs, and calcium phosphate-based NPs, some of which are shown in Fig. 1. These nanomaterials 
have been widely applied in biomedical fields, including gene/drug delivery [4], molecular imaging 
[5, 6], vaccine [7, 8] and bioassay [9, 10].  
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Figure 1. A summary of vehicles for siRNA delivery. There are several different types of 
nanoparticles and viral vectors commonly used for siRNA delivery [11].  
At the moment, there are four major types of polymeric nanomaterials often used for siRNA delivery. 
Cyclodextrin polymer (CDP), polyethylenimine (PEI), poly(lactic-co-glycolic acid) (PLGA) and 
dendrimers. CDP-based siRNA delivery platform has been applied in several animal models for 
therapeutic purposes [12, 13]. Despite the effective transfection in vitro facilitated via CDP-siRNA 
complexes, these complexes require further modification such as PEGylation to achieve stable and 
efficient transfection in vivo [14]. PEI is considered as a commonly applied and efficient non-viral 
vehicle for siRNA delivery both in vitro and in vivo [15]. PEI is suitable for aggregating negatively 
charged biomolecules such as siRNA or DNA due to its high density of positively charged 
amine/imine groups. To enhance PEI transfection efficiency and reduce PEI immunogenicity, some 
research groups have coupled PEI with cyclodextrin and revealed that the PEI-CD polyplexes show 
remarkably enhanced in vitro and in vivo delivery of plasmid DNA and siRNA [16, 17]. Compared 
to cationic polymers (e.g. PEI), PLGA NPs show low cytotoxicity and are developed to deliver siRNA 
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and implement stable and sustained release [18]. Some studies indicate that modification of PLGA 
with PEI or chitosan increases cellular uptake of siRNA compared to PLGA alone [19, 20]. 
Dendrimers are synthetic molecules with tree-like architecture of highly branched peripheral chain 
ends and a high ratio of multivalent surface moieties to molecular volume. The unique characteristics 
make dendrimers suitable nanoscale carriers for siRNA delivery in vitro and in vivo [21, 22]. 
Liposomes are artificial lipid vesicles with the unique bilayer structure that have been extensively 
explored for drug/siRNA delivery. Liposomes are composed of natural cell membrane components 
(phospholipids), so they have no or only very weak immunogenicity, low cytotoxicity and high 
biocompatibility. Over the past decades, liposomes are widely used in drug and gene delivery because 
of its advantages such as local accumulation, surface-related targeting, easy large-scale and aseptic 
synthesis [23, 24]. So far, several commercialised liposomes have been used as transfection vehicles 
for siRNA in vitro and in vivo. For example, Herringson et al. utilised DOTAP and helper lipids to 
compact siRNA into liposomes and achieved over 50% loading efficiency of siRNA. They succeeded 
target delivery of siRNA to cells in vivo with enhanced silencing effect [25]. 
Though (bio)organic NPs have some good features for multifunctional delivery of siRNA, inorganic 
NPs have many other advantages in synthesis, biocompatibility, and cost-effectiveness. Thus, this 
PhD project mainly focuses on inorganic NPs for siRNA delivery.  
2.2 Common inorganic nanoparticles for siRNA delivery 
Several inorganic nanoparticles have been emerging as potential siRNA delivery systems that can be 
devised for simultaneous imaging and therapeutic purposes (Fig. 2). They offer some unique 
properties over (bio)organic NPs for delivering siRNA such as simpler synthesis procedure, normally 
less toxic, easier endosome escape and higher payload protection. These nanomaterials include 
carbon nanotubes (CNTs), metal oxides (such as iron oxide), quantum dots (QDs), gold NPs, 
mesoporous silica NPs, clay and mineral NPs. Very obviously, nanoparticle’s physicochemical 
properties, such the size, shape and surface charge, significantly affect the biodistribution of 
nanoparticles and phagocytosis [26]. In specific, discoidal nanoparticles may more readily attach onto 
the cell for internalization and preferably accumulate in lung, liver and spleen, and probably in tumour. 
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2.2.1 CNTs  
It has been proposed that CNTs easily cross the plasma membrane and translocate directly into 
cytoplasm of target cells due to their nanoneedle structure, using an endocytosis-independent 
mechanism without inducing cell death [26, 27]. Several functionalised CNTs have been designed 
and tested for the purpose of siRNA delivery. CNTs functionalised with amine-terminated PEG 
(phospholipid (PL)-PEG2000-NH2) were found efficient in siRNA delivery into human T cells [28]. 
Amine-functionalised CNTs and dendron-CNTs have also been reported to be efficient in siRNA 
delivery with low cytotoxicity [29]. However, several studies have revealed the potential toxicity of 
CNTs although the underlying mechanisms are uncertain [30, 31]. 
2.2.2 Magnetic nanoparticles  
Magnetic nanoparticles, including superparamagnetic iron oxide nanoparticles (SPIOs) and magnetic 
iron oxide particles, emerged as feasible nanotheranostics for tumour imaging and drug delivery due 
to their distinct characteristics [32]. The large surface area of SPIOs makes the functional 
modification feasible, enabling the conjugation of targeting molecules, drugs, and imaging agents 
[33]. Moore and colleagues reported the synthesis and characterisation of a new dual-purpose probe 
for the simultaneous non-invasive imaging and delivery of siRNAs to tumours [34]. Lee et al. 
developed manganese-doped magnetism-engineered iron oxide (MnMEIO) NPs conjugated to a 
cancer-specific targeting moiety Arg-Gly-Asp (RGD) peptide to specifically bind to tumours 
expressing integrin, and loaded Cy5-dye-labeled siGFP to inhibit the expression of green fluorescence 
protein (GFP) [35]. The constructed nanoparticle (MnMEIO-siGFP-Cy5/PEG-RGD) showed specific 
internalisation and target gene silencing in integrin-expressing breast cancer MDA-MB-435 cells. An 
additional advantage of iron oxide nanoparticle delivery systems is that they can be delivered in a 
targeted manner to a desired region by applying an external magnetic field [36]. 
2.2.3 Semiconductor quantum dots  
Semiconductor quantum dots (QDs) are light-emitting nanoparticles and have been increasingly used 
as biological imaging and labeling probes [37]. QDs also have the potential of serving as photostable 
beacons for siRNA delivery and imaging [38-40]. However, the major problem in using QDs as 
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multifunctional imaging probes and delivery systems is their high toxicity because most well-
established QDs are composed of highly toxic elements, such as cadmium, selenium, or tellurium 
[41]. Therefore, a more thorough investigation for their long-term cytotoxicity is necessary before 
they can be used in vivo.  
 
Figure 2. Common examples of inorganic nanoparticles for siRNA delivery (A) and shape effect on 
the biodistribution (B) [26a, 42]. 
2.2.4 Gold nanoparticles  
Gold nanoparticles (AuNPs) have emerged as a promising siRNA delivery carrier due to their 
excellent biocompatibility, easy synthesis, high surface-to-volume ratio, and facile surface 
functionalisation [43]. Gold nanorods also have the potential to deliver siRNA to target cells or tissues. 
For example, Prasad group developed gold nanorod-DARPP-32 siRNA complexes to target and 
reduce expression of the key proteins (DARPP-32, extracellular signal-regulated kinase (ERK), and 
protein phosphatase 1 (PP-1)) in the dopaminergic signaling pathway in the brain for therapy of drug 
addiction [44]. Kim et al. reported that AuNPs functionalised with covalently bound oligonucleotides 
activate immune-related genes and pathways in human peripheral blood mononuclear cells, but not 
in an immortalised, lineage-restricted cell line [45]. The later findings suggest that assessment of the 
toxic potential of engineered nanoparticles in immortalised, lineage-restricted cell lines may not 
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predict their phenotypic effects in relevant biological systems.  
 
2.2.5 Mesoporous silica NPs  
Based on the large surface area and ordered porous channels, mesoporous silica NPs (MSNP) have 
been modified as multifunctional and efficient siRNA delivery platforms. MSNPs are also known to 
be safe, biodegradable and biocompatible. The versatile chemical properties allow the attachment of 
functional groups for imaging and targeting applications. In particular, MSNPs can be hybridised into 
organic-inorganic materials as hybrid carriers for siRNA delivery, where the siRNA can be loaded 
both on the surface and in the pores. Modification with polymer (such as polyethyleneimine: PEI) 
can enhance the particle uptake into cells and facilitate endosomal escape for the nucleotide delivery. 
For example, Xia et al used 10 KD PEI to surface-modify MSNPs and efficiently delivered siRNA to 
HEPA-1 cells [46]. Meng et al. similarly modified MSNPs with phosphonate and PEI to co-load and 
co-deliver doxorubicin and siRNA to a drug resistant cancer cell line (KB-V1 cells) to induce the 
cytotoxicity in an additive/synergistic way [47]. Large-pore cubic MSN modified with poly(L-lysine) 
showed a good advantage in delivering siRNA to cancer cells and killing > 20% of cancer cells [48]. 
Another study demonstrated that the tomographic feature such as the rough surface of MNS could 
offer a benefit in binding more siRNA and internalizing more into cancer cells, which results in killing 
more cancer cells [49].  
Besides above inorganic NPs, anionic clay nanomaterials (layered double hydroxide: LDH) and 
mineral nanomaterials (calcium phosphate: CaP) also show excellent biocompatibility, endosome 
escape ability, low toxicity, and low cost in preparation, which attract us to explore them as delivery 
systems for siRNA and examine their delivery performance in target gene silencing of cancer cells 
and T cells in this PhD project.  
2.3 Layered double hydroxide nanoparticles 
Layered double hydroxides (LDHs), also known as anionic clay, have been shown to be an efficient 
delivery vehicle for anionic drugs and nucleic acids [50-52]. LDH is able to intercalate anionic drugs 
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and biomolecules (such as ibuprofen, nucleotides, DNA, RNA and anionic peptides) between the 
brucite-like layers with high loading, providing protection against degradation [53, 54]. Moreover, 
the typical chemical composition (such as MgAl-LDH, MgFe-LDH) is highly biocompatible [55-57]. 
These properties have shown that LDHs may act as an efficient drug/gene delivery system. Indeed, 
in vitro studies have indicated that they are efficient carriers of anionic drugs such as anti-restenosis 
drugs (heparin) [58], anti-cancer drugs [59] and nucleic acids, especially small interfering RNAs 
(siRNAs) [53, 55, 57, 60, 61]. Recent studies also indicate LDH is a good adjuvant of protein-based 
vaccines for immune enhancement [62]. Therefore, LDH NPs will be further optimised and 
investigated for siRNA delivery in this study.  
2.3.1 Structure, composition, and morphology 
Layered double hydroxides (LDHs) are a class of anionic clays, which can be represented by the 
general formula of [M2+ 1−xM
3+ 
x (OH)2]
x+(An-)x/nmH2O, in which M3+ and M2+ are trivalent and divalent 
metal ions, respectively, where M2+ can be Mg2+, Ni2+, Zn2+, Mn2+, Cu2+ or Co2+ and M3+ Al3+, Cr3+, 
Fe3+, or Ga3+ [63]. An− is an anion with charge of n (e.g. CO32−, Cl−, NO3−) or an organic anion. The 
x value varies between 0.2 and 0.4, which reflects the layer charge density and the anionic exchange 
capacity. The structural unit of LDHs is made from stacks of cationic octahedral sheets, i.e. [M2+ 1−xM
3+ 
x
(OH)2]x+, and interlayer counter-anions and hydrated water molecules ((An-)x/nmH2O). The layered 
structure is stabilised by hydrogen bonds among interlayer water molecules (mH2O) and anions, and 
electrostatic interactions between the layer and the interlayer anions [64] (Fig. 3).  
Various divalent (Mg, Zn, Ni, Mn) and trivalent (Al, Fe, Cr) cations in variable M2+/M3+ molar ratios 
have been incorporated into the brucite-like layers, forming a wide range of LDHs materials, as 
catalysts or catalyst precursors [65, 66]. Considering the potential cytotoxicity of transition elements, 
researchers often use MgAl-LDH and MgFe-LDH NPs for biomedical applications. In the last decade, 
Xu et al. developed a reliable way to control the MgAl-LDH NP size in the range of 40-400 nm [67-
69]. 
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Figure 3. The layered structure and morphology of LDH and its loading of siRNA. (A) Crystal 
structure of LDH compounds [70]. (B) TEM image shows the hexagonal sheet-like morphology of 
LDH NPs [71]. 
LDHs are featured with inherent positive layer charges, and moreover, the interlayer anions can be 
replaced with the desirable anionic species by ion-exchange processes, which includes basic inorganic 
and organic anions, negatively charged drugs and herbicides, nucleotides, oligonucleotides, RNAs 
and DNAs with various base pair numbers. The intercalation subsequently protects negatively 
charged biomolecules. In particular, proteins, amphiphilic compounds, can be adsorbed on the LDH 
NP surface (not intercalated into the interlayer) in a large amount [72, 73].  The anion exchange 
extent is determined by the relative affinity of anions for the LDH material. Thus, the precursor LDHs 
are normally prepared with Cl- or NO3- anions that have a low affinity for LDH and can be readily 
exchanged with our desirable anionic species, such as siRNA and fluorescein isothiocyanate (FITC), 
which have a relatively high affinity for LDH materials. In such a way, the target therapeutics can be 
facilely loaded onto LDH NPs for delivery purposes. 
The representative MgAl-LDHs have the featured morphology, e.g. plate-like hexagons, which 
normally consists of multiple brucite-like layers stacking on top of one another.  Recently, 
delaminated LDH nanosheets are peeled off from LDH nanoparticles in organic solvents [74]. More 
recently, the green method was developed by Hibino et al., and the exfoliation of LDHs was achieved 
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by co-precipitation with lactate [75]. In addition, there are some other morphological structures 
developed, such as rod-like [76], tremella-like [77], rosette-like [78], or 3D flower-like LDHs [79]. 
2.3.2 Loading and delivery of siRNA 
The anion exchange property of MgAl-LDH allows intercalation and loading of many nucleotides, 
oligomers and gene segments such as CMP (cytidine5´-monophosphate), AMP (adenosine-5´-
monophosphate), GMP (guanosine-5´monophosphate), ATP (adenosine triphosphate), 
oligonucleotides, and DNA onto LDH [80-82].  
Recently, Xu and his colleagues have demonstrated the capability of LDH NPs to bind and deliver 
functional siRNA molecules to mammalian cells and release siRNA subsequently for silencing the 
target genes [83]. In the following study Xu et al presented the first investigation using LDH to 
delivery siRNA to cortical neurons [84]. They further investigated how siRNA is loaded onto the 
LDH and that the siRNA:LDH mass ratio of point of zero charge (PZC) is useful to predict 
intercalation efficiency of selected siRNA sequences into the LDH interlayer and subsequent 
internalisation into the cell cytoplasm [85].  
As an in vitro delivery example, Xu’s group has taken advantages of LDH NPs to co-deliver a 
functional siRNA, Allstar Cell Death siRNA (CD-siRNA) and a negatively charged anti-cancer drug 
5-fluorouracil (5-FU) and inhibit the proliferation of three cancer cell lines. As shown in Fig. 4A, 5-
FU was first intercalated into the interlayer via the anion exchange and then siRNA adsorbed on the 
LDH NP surface. Clearly, 5-FU intercalated into LDH showed a much higher cytotoxicity than free 
5-FU (Fig. 4B). Furthermore, combination of 5-FU and siRNA co-delivery using LDH NPs 
synergistically enhanced the cytotoxicity [71].  
Initially, Choy’s group studied the cellular uptake behaviours and mechanisms of LDH NPs (with 
sheet-like shape), and found that 50 nm LDH NPs showed higher cellular uptake than 100-200 nm 
and 350 nm ones when FITC was used as the marker [86a]. Choy et al. recently performed LDH-
based passive-target delivery to cancer cells in vivo and in vitro via controlling the size of LDH NPs 
around 100 nm. This size can facilitate accumulation in tumour tissues and actively target–deliver to 
cancer cells via conjugating folic acid on the LDH surface so as to trigger cancer cellular uptake 
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mediated by folate receptor. Then t?x？hey injected folic acid-conjugated LDH NPs loaded with 
Survivin siRNA into xenograft mice and consequently achieved 3-fold higher suppression of the 
tumour volume [86]. 
In summary, LDHs as siRNA delivery vehicle have following advantages: 1) Size control of LDH 
can be easily achieved in synthesis; 2) Anion exchange capacity and the loading capacity of LDH are 
high; 3) Low cytotoxicity and high biocompatibility; 4) Facilitation for cellular uptake; and 5) 
Protection of payloads, such as siRNA. 
 
Figure 4. (A) Chemotherapeutic drug (5-FU) and siRNA co-loaded onto LDH; and (B) MTT assay 
analysis of effects of treatments with 5-FU, 5-FU/LDH, CD-siRNA/LDH, and CD-siRNA-5-FU/LDH 
on the viability of MCF-7 cells at the 5-FU concentration from 0-9.6 µg/mL and the CD-siRNA 
concentration at 40 nM in all relevant treatments for 72 h at 37oC. Data represent mean ± SD (n=5) 
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2.3.3 Other biomedical applications 
There are many potential biomedical applications based on LDH NPs [87].  LDH shows no or very 
low toxicity in cell test, compared with pure drug [88]. Many drugs, such as anti-inflammatory, 
antidiabetic, cardiovascular, antibiotics, antioxidants, amino acids, and peptides, are all been 
successfully delivered by LDH nanomaterial with controlled release prosperity [89-92]. For example, 
anti-restenosis drug low molecule weight heparin (LMWH), once loaded into LDH interlayers, more 
significantly inhibits the proliferation and migration of smooth muscle cells (Fig. 5) [58], which could 
be mainly attributed to the slow release of heparin from the LDH interlayer [93]. 
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Figure 5. SMC proliferation and migration upon various treatment. The number of viable cells (A), 
the average distance migrated (B) and the proportion of migrating cells (C) of SMCs treated with 
medium alone, LDH, LMWH, or LMWH-LDH [58]. 
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Figure 6. A novel layered double hydroxide (LDH) nanoparticle/thermogel composite drug delivery 
system (DDS) for sustained release of brimonidine [89]. 
Recently, LDH-polymer hybrids are emerging as more versatile carrier systems for drug delivery. An 
example is LDH-hydrogel composite that can be made as a thin film for eye drug delivery [77, 94]. 
In such a system, the loaded drug is first released from the LDH interlayer, and then diffuses in the 
hydrogel matrix to diffuse into the eye liquid, which is called as ‘double-control release’. For example, 
brimonidine was loaded into LDH interlayers, which was then mixed with the temperature-sensitive 
hydrogel to form a thin-film delivery system for treatment of glaucoma (Fig. 6). The in vivo test 
showed that such a functional contact lens more sustainably reduced the eye pressure than the 
commercial eye drop product (Fig. 6) [77].   
The versatility of the composition enables the LDH NPs to be potential imaging and diagnosis agents. 
Recently, Mn- and Cu-containing LDH NPs have been reported to have ultrasensitive pH response 
and high relaxivity for MRI, which clearly images the tumour tissues upon triggers of the weak acidity 
in the tumour microenvironment, as shown in Fig. 7 [95, 96]. In particular, Shi et al. [97] prepared 
64Cu-LDH NPs as a positron emission tomography (PET) imaging agent. A prompt and persistent 
tumour accumulation of LDH NPs was achieved via the passive targeting pathway.  
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Figure 7. In vivo MR imaging of BSA/Mn-LDH nanoparticles. A time-course (0, 1, 4, 24, 36 and 72 
h) of the contrast enhancement in T1-weighted MRI of tumour (a) as well as the corresponding signal 
intensity variation (b) in the melanoma tumour-bearing mouse after intravenous injection of BSA/Mn-
LDH nanoparticles within 72 h. 
In addition, LDH has been used to immobilised antimicrobial drugs such as 2,4-Dichlorobenzoate 
(BzDC), (p-BzOH) and Penicillin G [98] [99]. The intercalation of these antibiotics into the LDH 
interlayers extends and enhances the antibacterial activity, and moreover, enables the synergistic 
inhibition of bacterial growth between the drug and ZnAl-LDH carrier.  
2.4. Calcium phosphate nanoparticles 
Calcium phosphate nanoparticles (CaP NPs) have already been extensively explored as a potential 
candidate for the gene delivery over 30 years [100, 101]. CaP is found the major inorganic mineral 
phase in bone and teeth. CaP is relatively insoluble at physiological pH but gradually becomes soluble 
in acidic solutions. The dissolution of CaP in mildly acidic solutions (pH = 5-6) facilitates the 
endosomal escape of the cargo [102]. This pH-dependent solubility provides an advantage in the 
siRNA delivery to cells.  
However, CaP NPs are easily aggregated in PBS, medium and blood, and thus they are often modified 
with polymers on the NP surface to provide the colloidal stability in physiological fluids. A more 
elegant approach is to encapsulate CaP NPs with a bilayer lipid vesicle, i.e. lipid-coated calcium 
phosphate (LCP) nanoparticles, which was reported in recent years, combining both advantages of 
liposomes and CaP NPs for ready loading of siRNA and targeting delivery, as summarised below. 
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2.4.1 Structure, composition, and morphology 
LCP NPs are a class of nanoparticles composed of different lipids that vary in physicochemical 
properties and biological activities. LCP NPs were reported by Huang et al [103], which were made 
in combining two emulsions, followed by coating with the second lipid layer, enabling the 
multifunctions of these NPs for target delivery in vitro and in vivo. As shown in Fig. 8, CaP NPs as 
the core not only load the siRNA (or proteins or other therapeutics), but also support the surface 
bilayer liposome. Thus, LCP NPs are expected to combine both advantages of CaP NPs and liposomes.    
Of all current siRNA delivery systems, LCPs have the most potential for successful clinical 
application because they protect siRNA from nuclease degradation, can be functionalised with 
targeting molecules for targeting the desired tissue and facilitate cellular uptake of cell-impermeable 
siRNAs. Indeed, LCP NP formulations have advanced into clinical trials for delivery of siRNA to the 
liver through systemic administration [104]. Nevertheless, it is estimated that <0.1% of the injected 
dose reaches the cytosol of hepatocytes. In part, this low efficiency is due to the challenge of targeting 
specific tissues in vivo and the tendency of any injected nanoparticles to be taken up by Kupffer cells 
in the liver. A second important barrier likely occurs at the point of internalisation by individual cells, 
a process that depends on interactions of the LCP NPs with components of the cell membrane and 
with intracellular trafficking pathways, although the extent of loss at this step is not known [105]. 
As schematic shown in Fig. 8, the typical LCP NPs had a hollow, spherical structure, and the average 
hydrodynamic particle diameter of LCP NPs was approximately 30 nm [106]. The zeta potential of 
synthesised LCP nanomaterials is depending on the outer lipid composition, being around -10 mV if 
there are only DOPC and cholesterol, but about +18 mV if 5-10% DOTAP is included. The positive 
charge is mainly attributed to the positively charged lipid DOTAP on the external layers, as described 
previously [107].  
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Figure 8. The schematic strucutre of LCP NPs. (A) The particle size distribution of CaP core, LCP 
NP and LCP-CD siRNA NP; (B) TEM images of CaP cores (a), LCP NPs before (b) and after negative 
staining (c) [99]. 
2.4.2 Loading and delivery of siRNA 
LCP NPs have been found to be effective vehicles for delivery of siRNA due to its suitable 
physicochemical characteristics. The CaP cores can encapsulate siRNA at a high efficiency and 
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protect siRNA from enzymatic degradation during endocytosis. The dissolution of CaP cores in acidic 
endosome also helps siRNA escape from lysosome and can be then released in cytosol to silence 
specific genes. Moreover, the asymmetric lipid bilayer on the surface of LCP NPs allows rational 
design such as PEGylation for long term circulation and cell-specific targeting. The first study 
reported in 2012 reveals that LCP NPs can efficiently deliver gene in vivo [63]. Yang et al. utilised 
anisamide conjugated LCP NPs to deliver sequence-specific siRNAs (against MDM2, c-myc, and 
vascular endothelial growth factor (VEGF)) to treat A549 subcutaneous tumour in lung and achieved 
successful inhibition of tumour growth at relatively low dose levels. In another study, a multi-shell 
nanoparticle was produced by coating a calcium phosphate (CaP) core with siRNA to reduce the 
expression of pro-inflammatory mediators, and this particle was applied for the local therapeutic 
treatment of colonic inflammation [108].  
Recently, Xu’s group compared LCP NPs with commercial transfection agent Oligofectamine and 
showed that LCP can protect siRNA in culture medium and achieve enhanced cellular uptake of 
siRNA and growth inhibition of breast cancer cells in vitro [109]. This group then developed a dual-
target LCP NPs via conjugating LCP NPs with both folic acid (FA) and EGFR-specific single chain 
fragment antibody (ABX-EGF scFv) for enhanced delivery efficiency of siRNA in vitro and in vivo. 
Their data showed that dual-target LCP-FA-scFv NPs encapsulating Cell Death siRNA successfully 
increased the siRNA accumulation in triple negative breast cancer tissues in vivo [110]. Huang’s 
group reported a mannose-modified LCP-based vaccine that encapsulated tumour-specific antigen 
and adjuvant together. The vaccine can induce a potent in vivo cytotoxic T lymphocyte (CTL) 
response against tyrosinase-related protein 2, a poorly immunogenic self-antigen, resulting in strong 
antitumour effects against melanoma in a subcutaneous xenograft model and a metastasis model [111]. 
Zhang et al. achieved a high anti-tumour effect in vivo using LCP NP to encapsulate both chemo-
drugs and siRNA which is specific to oncogene [112]. In this PhD thesis, we have also successfully 
delivered small interfering RNA (siRNA) to breast cancer cells (MCF-7) and tumour-infiltrating 
lymphocytes (TILs) from breast cancer patients, respectively. The siRNAs delivered by LCP 
nanoparticles efficiently down-regulate the target genes (PD-1 and PD-L1) in target cells (TILs and 
MCF-7 cells) in terms of both mRNA and protein expression levels and increase the killing efficiency 
of TILs to MCF-7 cells, as reported in Chapter 5. 
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2.4.3 Other biomedical applications 
Due to the inherent properties, LCP NPs have been used to encapsulate many types of therapeutics, 
such as radionuclides [113, 114], mRNA [115], DNA [116], small molecule drugs [114], and peptides 
[116]. More interestingly, LCP nanoplatforms also show success in theranostic applications (Fig. 9). 
During the preparation procedure, LCP NPs can co-precipitate and encapsulate therapeutic drugs with 
phosphate groups, such as nucleotide simulants, phosphorylated prodrugs, in the CaP core. Under 
similar mechanism, radiometals and some fluorescent probes can also be encapsulated in the CaP 
cores, providing LCP NPs great potential in a wide range of theranostic strategies, such as single 
photon emission computed tomography (SPECT) [117] and positron emission tomography (PET) 
[118]. 
 
Figure 9. LCP NPs as multifunctional nanoplatforms in theranostic application [119]. 
For example, Huang's group utilised LCP NPs to encapsulate γ and β emitters 177Lu3+ as SPECT 
agents and radiotherapeutic agents. The accumulation of 177Lu-LCP NPs was several orders of 
magnitude higher than that of free 177Lu in the tumour tissues, which led to obvious antitumour effect. 
In two subcutaneous xenograft tumour models, 177Lu-LCP NPs simultaneously enabled SPECT and 
Cerenkov imaging through the duel decay modes of 177Lu [117]. In another study conducted in 
Huang’s group, 64Cu was co-precipitated in the LCP cores with cytotoxic nucleotide analogue 
gemcitabine monophosphate (GMP). 64Cu-GMP-LCP NPs achieved visible dynamic accumulation in 
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the tumour tissues using PET/CT imaging after intravenous injection into mice and achieved the 
strong tumour growth inhibition [119].  
LCP NPs also draw attention as a tool in combined strategy by taking advantages of both gene therapy 
and chemotherapy to maximise the therapeutic effect in cancer treatment. Co-delivery of gemcitabine 
monophosphate and c-myc or VEGF siRNA via LCP NPs exhibited strong efficacy at lower doses in 
both subcutaneous H460 and orthotopic A549 lung cancer models, allowing simultaneous 
interruption of multiple anti-cancer pathways and enabling increased therapeutic efficacy and reduced 
toxicities [112, 120]. 
2.5 Cancer immunotherapy 
During the last decade, immunotherapy has become a standard treatment for a variety of cancers. 
Monoclonal antibodies, immune adjuvants, and vaccines against oncogenic viruses are now well-
established cancer therapies. Immune modulation is a principal element of supportive care for many 
high-dose chemotherapy regimens. Moreover, advances in our understanding of the molecular 
interactions between tumours and the immune system have led to many novel investigational 
therapies and continued to inform efforts for devising more potent new therapeutics [7]. 
2.5.1 Cell based therapy 
Over the past decades, rapid advancement in cancer therapies provides life-saving options for cancer 
patients. Cancer immunotherapy is one of the most promising methods in cancer treatment. As one 
significant part of immunotherapy, adoptive cell transfer (ACT) is making great breakthroughs in 
cancer treatment, which was initially reported in the 1980s [121]. ACT relies on immune cell 
populations that mediate direct tumouricidal effects, including conventional cytotoxic CD8+ T 
lymphocytes (CTLs), injected alone or together with helper CD4+ T cells, natural killer (NK) cells, 
‘cytokine-induced killer’ (CIK) cells and chimeric antigen receptor T (CAR-T) cells [122, 123]. NK 
cells, CIK cells and CTLs should work for treating solid tumours, but they are not specific antigen-
sensitised cells, thus their cytotoxicity to cancer cells is not specific and not high. CAR-T therapy has 
been successful in treating patients with hematologic malignancies, however it has less effects on 
treating solid tumours [124]. Now TILs seem more prominent in specific treatment of solid tumours.  
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2.5.1.1 Non-specific cell therapy 
Non-specific cell therapies are not specific immunotherapies that do not target specific cancer cells. 
They stimulate the immune system in a more general way and can still sometimes lead to a better 
immune response against several cancer cells [5, 9].  
Natural killer (NK) cells are innate lymphoid cells that have a significant role in regulating the 
defenses against cancer development and certain viral infections. They recognise and kill transformed 
and pathogen-infected cells [125]. Thought to act as a first line of defense in immune surveillance, 
NK cells secrete inflammatory cytokines that stimulate adaptive immune responses [126]. They are 
equipped with an array of activating and inhibitory receptors that stimulate or diminish NK cell 
activity, respectively. Inhibitory receptors include the MHC class I ligands killer cell 
immunoglobulin-like receptors (KIR) in humans, and members of the Ly49 family of receptors in 
mice, and CD94/NKG2A [127].  
Dendritic cell (DC)-activated CIK (DC-CIK) and CIK cells themselves work on the premise that the 
immune system can distinguish cancerous cells from normal cells. This technique benefits from a low 
toxicity and high specificity, and is emerging as a new approach for long-lasting disease control in 
various types of cancers [128], including non-small-cell lung carcinoma (NSCLC) [129] and renal 
cell carcinoma [130]. Several studies have shown that autologous dendritic cells (DCs) can activate 
cytokine-induced killer (CIK) cells to enhance antitumour effects in patients with NSCLC [131]. In 
this study, the therapeutic outcomes of combined chemotherapy, cryotherapy and DC-CIK 
immunotherapy were retrospectively investigated in patients with metastatic NSCLC over a 5-years 
follow-up period [132]. The overall survival of three-therapy-combination was significantly longer 
than single and dual therapy, providing the best treatment option for treating patients with metastatic 
NSCLC. 
2.5.1.2 Specific cell therapy 
Antigen-specific T cells recognise tumour antigens through their native receptors and kill the cancer 
cells (Fig. 10). They can work as an immunotherapy for various cancers due to their ability to 
selectively recognise tumour antigens, providing a long-term protection [10]. 
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Chimeric antigen receptor T (CAR-T) cell therapy and T cell receptor (TCR) engineered T cell 
therapy are two major approaches for antigen specific immunotherapy, where these T cells are 
genetically modified with chimeric antigen receptors (CARs) or TCR α/β heterodimers. CAR 
comprises immunoglobulin variable regions recognizing tumour antigens fused to the cytotoxic 
signaling domains from the T cell receptor (TCR ζ chain) and to costimulatory endodomains. CAR-
T therapy has produced outstanding clinical results in B cell leukemia and is moving toward definitive 
licensing studies [63, 64]. CAR T cells targeting B Cell Maturation Antigen (BCMA) have proven 
effective in multiple myeloma (MM) [133]. In a phase I/II clinical trial, 4 of 6 patients with synovial 
cell sarcoma and 5 of 11 patients with advanced melanoma showed encouraging clinical responses 
after receiving T cells engineered with cancer-testis antigen NY-ESO-1-specific TCR [134]. 
 
Figure 10. Three general approaches of specific cell therapy. 
Tumour-infiltrating lymphocytes (TILs) are antigen-specific T cells and have high killing efficiency 
in solid tumours, including renal cell carcinoma, breast cancer, oral squamous cell carcinoma, and 
non-small cell lung cancer [135-138]. TIL therapy is a personalised treatment by growing tumour-
infiltrating lymphocytes (TILs) ex vivo from surgically excised tumour specimens of a patient and 
then adoptively transferring them back into the patient [139] (Fig. 11). However, these tumour-
specific T cells can be inactivated in vivo by molecular pathways that suppress their activation and 
effector functions, T-regulatory and myeloid derived suppressor cells, that may have not positive 
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effect or even negative effects on the tumour inhibition.  
 
 
 
 
 
Figure 11. Schematic presentation of TIL Therapy. 
In specific, tumour-specific T cells within the tumour tissue (such as TILs) are experiencing chronic 
activation and are bathed in immunosuppressive factors. There is a growing body of studies 
suggesting that TILs are restrained in vivo by immunosuppressive molecules, such as programmed 
cell death-1 (PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), cell immunoglobulin and mucin 
domain-containing protein 3 (TIM3), and lymphocyte activation gene 3 protein (LAG3) [135, 137, 
138]. Therefore, inhibition of these immunosuppressive molecules on TILs’ membrane is a very 
promising immunotherapeutic target to enhance the efficacy of TILs, as used in this PhD research 
(Chapter 6).  
2.5.2 Gene therapy 
Gene therapy, defined as the introduction of genetic materials into a target cell for therapeutic benefit, 
is a very promising treatment for many diseases, including monogenic diseases, cancers, 
cardiovascular diseases, and neurodegenerative diseases. To date, more than 2000 clinical trials 
employing gene transfer have taken place and demonstrated that a number of vehicles or vectors are 
safe [140, 141]. Furthermore, the majority of gene therapy clinical trials to date have targeted cancers 
— including lung, skin, neurological, and gastrointestinal tumours — and utilised a variety of 
therapeutic strategies, such as anti-angiogenic factors, tumour suppressors, immunostimulations, and 
oncolytic viruses [142, 143]. In 2015, the first recombinant viral therapy — an oncolytic herpes virus 
for the treatment of melanoma — received regulatory approval in the USA [144]. 
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2.5.2.1 RNA interference-based therapy 
RNA interference (RNAi) has gained tremendous international attention since 1998 when Fire, Mello 
and colleagues reported the ability of double-stranded RNA to silence gene expression in the 
nematode worm Caenorhabditis elegans [145]. Three years later, Tuschl and co-workers published 
their proof-of-principle experiment, demonstrating that synthetic small interfering RNA (siRNA) can 
also achieve sequence-specific gene knockdown in a mammalian cell line [146]. The first successful 
use of siRNA for gene silencing in mice has been quickly achieved for a hepatitis C target thereafter 
[147]. Since then, the biotechnology sector has made considerable efforts to advance siRNA 
therapeutics for the treatment of various disease targets, including viral infections [148] and cancers 
[149]. RNAi is a fundamental pathway in eukaryotic cells by which sequence-specific siRNA is able 
to target and cleave complementary mRNA [146]. RNAi is triggered by the presence of long double-
stranded RNA, which is cleaved into the fragments known as siRNA (21–25 base-pair nucleotides) 
by the enzyme Dicer [150]. In practice, siRNA can be synthetically produced and then directly 
introduced into the cell, thus circumventing Dicer mechanics. This shortcut reduces the potential for 
an innate immune interferon response and the shutdown of cellular protein expression that can occur 
following the interaction of long pieces (>30 nucleotides) of double stranded RNA with intracellular 
RNA receptors [151]. 
2.5.2.2 RNAi therapy for cancers 
Theoretically, when using appropriately designed siRNA, the RNAi machinery can be exploited to 
silence nearly any gene in the body, giving it a broader therapeutic potential than typical small-
molecule drugs. Indeed, it has already been reported that synthetic siRNAs are capable of knocking 
down target genes in various diseases in vivo, including hypercholesterolaemia [152], liver cirrhosis 
[153], hepatitis B virus (HBV) [154], human papillomavirus [155], ovarian cancer [156] and bone 
cancer [157]. In a recent study, combined application of photodynamic therapy and siRNA-based PD-
L1 knockdown significantly enhanced inhibition of tumour growth and distant metastasis in animal 
model [158]. For these advances to be implemented in a clinical setting, safe and effective delivery 
systems must be developed. While ‘naked’, chemically modified siRNA has shown efficacy in certain 
physiological settings such as the brain [159] and the lung [160], there are many tissues in the body 
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that require an additional delivery system to facilitate transfection. This is because (1) naked siRNA 
is subject to degradation by endogenous enzymes, and (2) siRNA is too large (~13 kDa) and too 
negatively charged to cross cellular membranes. Thus, the issue of effective and non-toxic delivery 
is a key challenge and serves as the most significant barrier between siRNA technology and its 
therapeutic application. For example, tumour- and tumour-vasculature-targeting non-cytotoxic Au-
CGKRK nanoconjugates (17−80 nm) were developed and loaded with PD-L1siRNA and STAT3-
siRNA. Intraperitoneal (i.p.) administration of these NPs resulted in significant (>70%) enhancement 
in overall survivability (OS) in melanoma-bearing mice (n= 5) (Fig. 12), much more than that using 
Au-CGKRK NPs complexed with PD-L1siRNA or STAT3siRNA. 
  
 
 
 
 
 
 
Figure 12. Intraperitoneal administration of the Au-CGKRK nanoparticles (NPs) complexed with 
both PD-L1siRNA (the immune checkpoint inhibitor) and STAT3siRNA (the JAK-STAT pathway 
inhibitor) results in significant (>70%) enhancement in overall survivability (OS) in melanoma-
bearing mice (n = 5) when compared to the OS in the untreated mice group [161]. 
Small interfering RNAs suffer from pharmacokinetic and cell penetration limitations. As a result of 
their small size (⁓5 nm), they are rapidly eliminated by the kidney with circulating half-lives of the 
order of seconds to minutes [114]. They are also susceptible to degradation by nucleases in the plasma. 
A study of the biodistribution of radio-labelled siRNA has indicated that siRNA is mainly 
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accumulated in the liver and spleen and to a lesser extent in the heart, spleen and lung, in a similar 
pattern to antisense oligo-deoxyribonucleotide [162]. Within the tissues, they cannot cross cell 
membranes readily because of their negative charges, hydrophilicity and relatively large molecule 
size (in comparison with small biomolecules and chemical drugs). Although uptake by cells of 
invertebrates such as Caenorhabditis elegans has been observed, siRNA is not easily taken up by 
most mammalian cells in a way that preserves their activity [163], and therefore an effective delivery 
system is a prerequisite for effective gene silencing [164].  
The success of gene therapy is highly dependent on the delivery vector, which can be generally 
categorised into viral and non-viral vectors [165]. Viral vectors are highly efficient and are currently 
the most powerful tool for gene transfection. However, some viral vectors show a limited loading 
capacity, most are difficult to produce in large scale and, more importantly, they pose severe safety 
risks due to their oncogenic potential, and their inflammatory and immunogenic effects. All these 
factors prevent them from using in the practice. To overcome these limitations, non-viral vectors have 
emerged as a promising alternative for gene delivery. A number of non-viral siRNA nanoparticle-
based delivery approaches have been reviewed in Section 2.2-2.5, and some have now been reported 
in vivo, including in non-human primates and humans [166, 167].  
2.5.3 Antibody therapy 
Antibodies are currently used as effective therapeutics against many types of cancers. So far, more 
than 70 monoclonal antibodies have been approved by FDA for human use and all these antibodies 
are effective in the treatment of patients with various cancers [168]. Monoclonal antibodies eliminate 
or reduce the tumour burden in cancer patients by either direct or indirect effects on tumour cells. 
2.5.3.1 Immune checkpoints  
Infiltration of T cells into tumours has been correlated with survival of cancer patients. Although T 
cells can adequately infiltrate tumours, they are ineffective at eradicating patients’ tumours. Studies 
have indicated that T cell infiltration into tumour tissues is associated with reduction of tumour burden 
and clinical prognosis [169]. In particular, adoptive transfer of tumour infiltrating lymphocytes (TILs) 
has emerged as a promising approach to induce effective anti-tumour immunity and tumour 
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regression in various cancers [170, 171]. However, these tumour-specific T cells can be inactivated 
in vivo by immunosuppressive factors in the local tumour microenvironment, such as T-regulatory 
and myeloid derived suppressor cells, and/or co-inhibitory molecules that reduce T cell activation. 
There are an increasing number of co-inhibitory signals in the tumour microenvironment that have 
been demonstrated to inhibit anti-tumour T cell responses (Fig. 13).  
Activated T cells express multiple co-inhibitory receptors including programmed death (PD-1), 
cytotoxic T lymphocyte antigen 4 (CTLA-4), lymphocyte activations gene 3 (LAG-3), and B and T 
lymphocyte attenuator (BTLA) [135, 137, 138, 172]. While these immune checkpoint receptors 
maintain T cell homeostasis, when expressed by tumour-specific T cells, they represent a significant 
barrier for the induction of effective anti-tumour immune responses. Blockade of these receptors has 
been shown to improve anti-tumour immune T cell responses. CTLA-4 (CD152) is a cell surface 
molecule that is expressed on activated T cells. Ipilimumab, approved by the FDA in 2011, targets 
the CTLA-4 receptor on T cells [173]. LAG-3 is a cell-surface molecule that is involved in T cell 
activation and function [174]. Studies have shown that LAG-3 is expressed on T regulatory cells 
(Tregs) and blockade of LAG-3 affects Treg function [175]. It has been shown that an in vitro 
suppression assay using CD4+CD25 high LAG-3+ T cells show that this subset of cells is endowed 
with potent suppressor activity and their number is enhanced in the PBMCs of patients with cancer 
and is expanded at tumour sites [176]. LAG3 expression is upregulated on TILs and blockade of 
LAG3 can enhance anti-tumour T cell responses [136].  
BTLA belongs to CD28 family and is structurally similar to CTLA-4 and PD-1 [138]. BTLA 
expression on lymphocytes has been shown to attenuate T cell activation and proliferation. T cells 
from BTLA-deficient mice display a proliferative phenotype in response to T or B cell activation 
[177]. Moreover, programmed death ligand 1 (PD-L1) on tumour cells inhibits the activation of T 
cells upon binding to its receptor PD-1, thereby preventing effective anti-tumour immunity [178, 179]. 
Monoclonal antibodies against PD-L1 have been widely explored in patients with cancers [179].  
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Figure 13. Immune interactions involving antigen presenting cells or tumour cells, T cells, and 
tumour microenvironment [180].  
2.5.3.2 Blockade of checkpoints and negative regulators 
Blockade of negative regulators on T cells in the tumour microenvironment can improve anti-tumour 
T cell responses and lead to improved immunotherapeutic efficacy for cancers. Some solid evidences 
show that blocking negative regulators achieved exciting outcomes in inhibiting tumour growth in 
animal models [181, 182] and human metastatic tumours [183]. Because of these astonishing 
discoveries in this field, Profs Allison and Honjo were awarded Nobel Prize in Physiology or 
Medicine for 2018.  
The first checkpoint antibody approved by the FDA is Ipilimumab, approved in 2011 for treatment of 
melanoma [184]. It blocks the immune checkpoint molecule CTLA-4. Clinical trials have also shown 
some benefits of anti-CTLA-4 therapy for lung cancer or pancreatic cancer, specifically in 
combination with other drugs [185, 186]. The on-going trials combine CTLA-4 blockade with PD-1 
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or PD-L1 inhibitors and are tested for different types of cancers [187]. A previous study has shown 
that blockade of PD-L1 signaling enhanced anti-tumour efficacy in a melanoma tumour model [99].  
Cytotoxic T lymphocyte-associated antigen (CTLA-4), also known as CD152, is a co-inhibitory 
molecule that functions to regulate T cell activation. Antibodies that block the interaction of CTLA-
4 with its ligands B7.1 and B7.2 can enhance immune responses, including anti-tumour immunity. 
CTLA-4 blockade has shown promising results in treatment of patients with metastatic melanoma, 
with a recently completed randomised, double-blind Phase III trial demonstrating a benefit in overall 
survival (OS) in the treated population. The US FDA-approved antibody ipilimumab targets cytotoxic 
T lymphocyte-associated antigen 4, however, its current use has been limited by its toxicity and a low 
response rate [188].  
PD-1 is another immune checkpoint expressed on activated T cells. When bound by PD-L1, PD-1 
causes T-cell exhaustion and a favorable environment for tumour growth [189]. Nivolumab and 
pembrolizumab (formerly lambrolizumab), two FDA-approved anti-PD-1 monoclonal antibodies, 
show highly durable response rates and long-term safety [190].  
PD-L1 can be expressed on DC or cancer cells. Interactions of PD-L1 on tumour cells to PD-1 on T 
cells lead to T cell exhaustion and tumour escape. Therefore, since its discovery it has attracted much 
attention. Anti-PD-L1 antibodies are immunotherapeutic agents that cause checkpoint inhibition, 
thereby relieving immune tolerance and resulting in tumour destruction [191]. Until now among the 
5 FDA approved antibody reagents, 3 of them, e.g. Atezolizumab, Avelumab and Durvalumab, are 
PD-L1 inhibitors. Targeting PD-L1 rather than PD-1 theoretically offers further benefit, including 
improved efficacy and reduced toxicity for patients [192]. 
2.5.3.3 SiRNA-reduced expression of immune checkpoints  
Besides antibody-blocking therapies, other approaches such as gene silence [193-195] has been also 
explored to knockdown or down-regulate PD-1 and PD-L1 on T cells and cancer cells respectively 
for cancer immunotherapy. These studies indicate knockdown of either PD-1 on T cells or PD-L1 on 
melanoma cells can increase the outcomes of immunotherapy. In addition, knockdown of PD-L1 on 
dendritic cells can also significantly increase the T cell killing ability of cancer cells [196]. These data 
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support that siRNA therapy can provide a potential effective way for application in PD-1/PD-L1 based 
cancer immunotherapy. However, the blockade of immune checkpoints with antibody only targets 
cell surface proteins, some earlier studies indicate that PD-L1 can be present in different 
compartments of cancer cells such as cytoplasm and nuclear with slightly different functions, which 
may be also correlated with poor prognosis [197, 198]. This suggests that targeting surface protein 
only with antibody may be not enough, and an alternative way such as gene silencing method should 
be considered.  
In particular, poor prognosis for the patients treated with TILs-based immunotherapy has been found 
to tightly correlated to the high expression of PD-1 on TIL surface [199, 200]. Therefore, gene 
silencing of PD-1 in TILs has thus emerged as a complimentary method to PD-1 antibody blockade, 
as also investigated in this research (Chapter 6). 
2.5.4 Cancer vaccine 
The term cancer vaccine encompasses 2 different types of vaccines, i.e. prophylactic vaccine and 
therapeutic vaccine. Prophylactic vaccine blocks infections induced by viruses that can alter host cell 
DNA and result in cancerous cells. The hepatitis B vaccine and the human papillomavirus vaccine 
are examples of prophylactic vaccines that can prevent cancers from development and growth. More 
recently, therapeutic cancer vaccine has been developed and used as adjunctive therapy in patients 
who have already been diagnosed with cancers. Therapeutic vaccine stimulates the host’s immune 
system to recognise cancer cells as foreign invaders and then attack and lyse them. Most of the 
therapeutic vaccines being studied are used in combination with other forms of cancer therapy [189, 
191]. 
Personalised vaccines targeting neoantigens have significant theoretical advantages. Recent studies 
have explored the potential of personalised cancer vaccines in preclinical models. Studies in several 
tumour types confirm that both CD4+ and CD8+ T cell responses to neoantigens can be successfully 
induced. In their studies for B16F10 melanoma vaccination, Sahin et al. demonstrated that they 
successfully generated immune responses to 16 of 50 prioritised neoantigens using a synthetic peptide 
vaccine platform [168]. Vaccines corresponding to two of these prioritised neoantigens were further 
tested for treatment of B16F10 tumour-bearing mice. In both cases, synthetic long peptide vaccines 
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were able to significantly inhibit tumour growth. In follow-up studies, the authors further 
demonstrated that polyepitope mRNA vaccines targeting sequence-identified neoantigens induced 
potent tumour-specific immune responses and tumour protection in three tumour-bearing mouse 
models. Of note, the tumours did not express detectable levels of MHC class II molecules, but the 
majority of immunogenic neoantigens induced CD4+ rather than CD8+ T cell responses [192]. 
2.5.5 Nanotechnology and cancer immunotherapy 
Despite the tremendous therapeutic potentials and crucial breakthroughs in harnessing our own 
immune system to combat against cancer, there are still some key challenges that limit the success of 
cancer immunotherapy, such as insufficient immunogenicity of cancer vaccines, off-target effects, 
unsatisfactory effects of adoptive T cell therapies and the tumour-induced immune suppression. Thus, 
it has been intensively investigated to improve immunotherapy efficacy by taking advantages of the 
unique physicochemical properties of nanomaterials.  
Biodegradable nanoparticles have been designed to target specific receptors expressed on antigen 
presentation cells and used to entrap and co-deliver tumour antigens as well as adjuvants to elicit 
effective activation of the immune system against tumours [201], which is suitable for vaccination 
purpose. According to Xu’s group’s study, LDH nanoparticles can serve as a very good adjuvant. 
Immunisation of mice with CpG-OVA-conjugated LDH NPs significantly inhibited the growth of 
OVA-expressing B16/F10 tumour [202]. In addition, nanoparticles with precisely adjusted 
dimensions and modified characteristics can achieve target delivery to lymphoids [203]. With the 
conjugation of specific antigens and co-stimulation ligands on the surface, nanoparticles can also 
serve as artificial antigen presentation cells that strengthen the anti-tumour effect of T cell-based 
immune responses [204]. Nanoparticle-based delivery systems can trigger immunogenic cell death 
or target immune checkpoint molecules to initiate anti-tumour immune responses and reverse immune 
suppressions. It has been demonstrated that therapeutics-loaded nanoparticles can increase the anti-
tumour efficacy of adoptive T cell therapies [205]. 
2.6 Cancer stem cells  
Over the last decade, major advances have been made in identifying the malignant cell population 
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responsible for tumour maintenance and initiation of relapse. Many names have been used to identify 
this population but the term of cancer stem cell (CSC) has received broad acceptance. Cancer stem 
cell has been defined as ‘a cell within a tumour that possesses the capacity to self-renew and cause 
the heterogeneous lineages of cancer cells that comprise the tumour’ [206].  
The biology of CSCs in solid malignancies remains largely unknown. The first solid CSCs were 
identified in breast tumour tissues in 2003 [207]. Since then CSCs have been isolated from brain 
cancers [207, 208], colon cancers [209], melanoma [210], pancreatic cancers [211], prostate cancers 
[212], ovarian cancers [213], hepatic cancers [214], lung cancers [215] and gastric cancers [216]. 
Progress, however, has been complicated by the lack of clearly defined developmental surface 
markers specific for individual tumour types. Instead, isolation of many solid CSCs has been carried 
out using several adhesion markers including CD44 and CD24, direct or indirect evidence of 
multidrug efflux proteins including ABCB5. CD133 (Prominin 1), an apical plasma membrane 
protein has been found predominantly on embryonal epithelial structures, and also used to isolate 
neural CSCs from a range of pediatric brain tumours [208]. CD133 is expressed in many different 
types of stem cells and is thought to be involved in the attachment of stem cells to their niche. CD133 
has continued to identify tumour cells with self-renewal capacity in a number of other solid 
malignancies, although there is an ongoing debate on how universal this marker is within the solid 
tumour CSC field [217].  
Although intermittent improvements are being made, tumour relapse and treatment resistance remains 
a major cause of morbidity and mortality that are proposed to be particularly due to the persistence 
of highly resistant CSC population during chemotherapy. This is true at least in the case of cancers 
following CSC model. Hence, for complete eradication of cancer cells, development of new 
therapeutic strategies considering CSCs and its relationship with tumour microenvironment are 
urgently required as the tumour milieu is believed to be the key source for cancer cell differentiation 
and bidirectional conversion [218, 219].  
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2.7 Challenges and strategies 
2.7.1 Knowledge gaps for siRNA delivery using nanoparticles 
As summarised in previous sections, there are so many nanoparticle systems examined for siRNA 
delivery that can be used for cancer immunotherapy. For each nanoparticle system, there should be 
an optimal platform for the effective delivery in vitro and in vivo in terms of the knockdown of target 
gene. In particular, LDH NPs have been extensively examined for siRNA delivery in Xu’s group. 
However, the systematic research about how siRNA is loaded onto LDH (mixing style) and how much 
siRNA is loaded (such as LDH: siRNA mass ratio) affect the siRNA silencing capability has not been 
conducted yet, which has been first addressed in this PhD research project (Chapter 4).  
As T cells are very important players in immunotherapy, there are many biological modifications to 
improve T cell’s cytotoxicity to the cancers.  T cells, such as TILs, are normally suspended during 
the standard culture and are much different from the plate-adhesive cells, thus delivery of siRNA to 
T cells via nanoparticles requires good suspension stability. Such a kind of research has not been well 
documented for siRNA delivery using LDH NPs and LCP NPs. More particularly, there is no report 
about comparing the siRNA delivery performance of two nanoparticle systems, such as LDH and 
LCP NPs to T cells and cancer cells and why some system is more efficient, although LDH and LCP 
NPs are well studied for siRNA delivery for cancer therapy separately. This knowledge gap has been 
addressed in Chapter 5. 
As described above, TIL-based and PD-1/PD-L1 antibody-based immunotherapy have shown 
prospective future for cancer therapy. However, these antibodies can only block surface molecules 
while intracellular PD-1/PD-L1 may be continuously generated, which may be responsible for part 
of failure in the antibody-blockade therapy. Similarly, PD-1+ TILs often fail to inhibit the tumour 
growth and metastasis due to the overexpression of PD-1 on the surface. How to improve the TIL-
based therapy and enhance the prognosis, silencing PD-1 in TILs as well as PD-L1 in cancer cells 
may be a good alternative approach, which is reported in Chapter 6. 
Cancer stem cells are critical for drug resistance and metastasis in solid tumours, which may be also 
related to the expression of PD-L1. Understanding the expression and regulation of immune 
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inhibitory molecular PD-L1 will inform the design of more effective and lasting cancer 
immunotherapy based on PD-1/PD-L1, while such information research has not been well 
documented. Chapter 7 thus provides some useful information about the PD-L1 expression in CSCs 
and potential mechanism that induce PD-L1 expression in CSCs.  
2.7.2 Strategy for this PhD research 
The primary purpose of this PhD project is to optimise LDH and LCP NP systems for efficient siRNA 
delivery and then develop preclinical effective TIL-based immunotherapy for breast cancers. Instead 
of using conventional antibody blocking method, this study strategically silences PD-1 gene in TILs 
and PD-L1 gene in cancer cells simultaneously utilizing the optimal nanoparticle system for siRNA 
delivery and determine if this strategy will more effectively enhance the immunity of TILs. Before 
we test our hypothetic strategy and achieve the preclinical goal, a good delivery system for RNAi 
therapy (or siRNA) is needed. Therefore, the first task of the study is to optimise 1-2 nanoparticle 
platforms for more effective delivery of siRNA to suspended T cells and plate-adhesive cancer cells.  
This hypothetical strategy is actually complementary to antibody method that blocks cell surface PD-
1/PD-L1. Since the high level of PD-1/PD-L1 expression in TILs and breast cancer cells readily 
recognises each other via PD-1/PD-L1 interactions (Fig. 14A) and helps escape from immune survey, 
which is mainly responsible for the failure in TIL-based therapy for breast cancers. Combined with 
PD-1 and PD-L1 blockade, TILs are activated, which help lyse the tumour cells (Fig. 14B) and inhibit 
the tumour growth.  Complementarily, our gene silencing strategy reduces the expression of PD-1 
in TILs and PD-L1 in cancer cells (Fig. 14C), which is expected to largely weaken the PD-1/PD-L1 
interaction sand thus enhance the TILs activity in killing cancer cells and inhibiting tumour growth.  
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Figure 14. When PD-L1 expressed on tumour cells binds to the immune checkpoint PD-1 on T cells, 
T cell function is turned off (A). Blocking PD-1 or/and PD-L1 by antibody restores T cell function (B) 
to kill tumour cells. Knockdown of PD-1/PD-L1 by RNAi activates T cells, leading to tumour killing 
(C). 
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Chapter 3  
Methodological Strategies  
Chapter 3 summarises the general methods to prepare two nanoparticles (NPs), i.e. layered double 
hydroxide (LDH) and lipid-coated calcium phosphate (LCP), and the way to load siRNA/dsDNA, 
followed by the characterisation approaches to confirm the designed physicochemical properties. 
Then the relevant cell culture and cell testing to demonstrate the NPs’ delivery performance are 
provided in general, and the corresponding bioassays are described to obtain the target biological 
effect. More details for specific experiments are given in each chapter. 
3.1 Material synthesis 
3.1.1 Synthesis of LDH and loading of siRNA/dsDNA 
In general, MgAl-Cl-LDH NPs are synthesised by combining co-precipitation and hydrothermal 
heating in an autoclave, which has been well established in our group [1, 2]. 
 
Figure 1. Schematic outline of MgAl-LDH nanoparticles and loading of siRNA/dsDNA. 
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Briefly, a mixed solution containing designed amounts of MgCl2 and AlCl3 is quickly added to NaOH 
solution within a few seconds under vigorous stirring. After stirring for 10 min, the slurry is separated 
and collected from the supernatant via centrifugation, and washed with deionised water to remove 
the soluble impurities. The washed slurry is re-dispersed in deionised water, and then transferred into 
a stainless-steel autoclave with a Teflon lining. Heating at 100℃ for 16 h normally results in a 
transparent suspension with the yield of ~60%.   
The LDH nanoparticle suspension can be then mixed with bovine serum albumin (BSA) in an 
LDH:BSA mass ratio of 1:2.5-1:5 to keep the colloidal stability of LDH nanoparticles in physiological 
solutions. The BSA-coated LDH nanoparticles can be then confirmed in PBS or culture medium for 
the colloidal stability. 
To load siRNA or dsDNA onto LDH NPs, siRNA or dsDNA solution is mixed with LDH NP 
suspension at designed LDH:siRNA or LDH:dsDNA mass ratios (from 1:1 to 160:1). In the normal 
situation, all siRNA or dsDNA will be associated with LDH NPs at the mass ratio from 10:1 to 160:1.   
3.1.2 Synthesis of LCP and loading of siRNA/dsDNA 
LCP NPs are generally prepared by a modified two-step emulsion method, as reported in the previous 
papers [3, 4]. As outlined in Figure 2, the anionic lipid (such as DOPA) coated calcium phosphate 
(CaP) cores are first synthesised by mixing two water-in-oil microemulsions, e.g. aqueous CaCl2 
solution (pH 7.0) and Na2HPO4 solution both in oil phase (cyclohexane/Igepal CO-520).  After 
breaking the emulsions using alcohol, the CaP cores are then collected via high speed centrifugation 
(20000g or higher speed). The collected CaP cores are then dispersed in chloroform containing the 
second lipid with a certain amount of cholesterol.  
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Figure 2. Schematic outline of LCP preparation and loading of siRNA. 
After evaporation of chloroform under reduce pressure, the formed thin film is hydrated in pure water 
or PBS buffer (containing 10-20% alcohol) to form bilayer lipid-coated CaP (LCP) nanoparticles 
(NPs), which are normally well dispersed under gentle ultrasound treatment.   
If siRNA or dsDNA is to be loaded, this siRNA or dsDNA can be pre-mixed with CaCl2 solution, 
followed by the same procedure used for blank LCP NP preparation, with the loading efficiency of 
about 50-60%. 
3.2 Characterisation and quantification 
3.2.1 Transmission electron microscopy (TEM) 
The transmission electron microscopy (TEM) is a microscopy technology to examine the particle 
morphology, particle size and aggregation state of nanomaterials. TEM images are recorded on a 
transmission electron microscope at an acceleration voltage of about 100 kV. The freshly made LDH 
and LCP NPs collected from suspension are dispersed in alcohol with gentle sonication, and then a 
droplet of the alcohol dispersion is dropped on a copper grid coated with carbon film. The air-dried 
sample is then imaged in a TEM to obtain their size and morphology information. 
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3.2.2 Fourier-transform infrared (FTIR) 
Fourier-transform infrared (FTIR) is applied to identify functional groups and chemical bonds in 
compounds and particles. Characteristic absorbance peaks of functional groups and chemical bonds 
are recorded at some particular vibration frequencies in the infrared spectrum. In this work, LDH NP 
powder is normally mixed with KBr powder at a mass ratio of 1:100 and made into a pellet. Then the 
FTIR spectrum of this pellet is recorded by 32 or 64 scans on an FTIR equipment in the range from 
4000-400 cm-1 with a resolution of 4 cm-1. 
3.2.3 X-ray diffraction (XRD) 
X-ray diffraction (XRD) is used to examine the structure information of crystalline particles. X-rays 
project to the atomic planes and diffract into a diffraction pattern according the crystalline structure. 
The Bragg equation (λ = 2dsinθ) is used to calculate the interplanar spacing. In the current thesis, 
XRD patterns were normally recorded in a Bruker X-ray Diffractometer operating at 40 kV/30 mA 
with Cu kα radiation (λ = 0.154178 nm) at a scanning rate of 0.02°/s in 2θ from 2° to 80°. 
The thickness of LDH nanoparticles along the c axis is then estimated according to the Scherrer’s 
equation 𝐷 = (𝐾𝜆)/(𝛽𝑐𝑜𝑠𝜃), where D stands for the mean thickness along the c-axis of LDH NPs, K 
is the shape factor and a typical value is about 0.9, λ the X-ray wavelength, β the line broadening, i.e. 
the full width at the half maximum intensity (FWHM) in radian, and θ the Bragg angle of peaks (003) 
and (006). The calculation is based on typical layered features of LDHs in the XRD patterns. 
3.2.4 Dynamic light scattering 
Dynamic light scattering (DLS) is applied to determine particle size distribution and the average 
particle size. This is done by testing the particle diffusion under Brownian motion, and the particle 
size distribution is deduced from the autocorrelation function that is generated from DLS data [5]. 
The particles are normally dispersed in deionised water, chloroform or PBS by gentle ultra-sonication 
before DLS analysis, and the measurements are normally conducted at 25 °C on a Malvern Zetasizer 
Nano-ZS with triplicates. Note that light scattering is affected by the refraction of nanomaterials, thus 
the refractive index of measured nanomaterials should be correctly estimated if it is not available.   
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3.2.5 Zeta (ζ) potential measurement 
The charge or zeta potential of particles is determined by measuring their velocity during 
electrophoresis. The surface charge of nanoparticles in solution is normally represented by the ζ-
potential. In the suspension, nanoparticles with the surface charge will attract a thin layer of 
oppositely charged ions to the surface, i.e. the electric double layer (EDL). The potential difference 
between attracted ion layer and the dispersion medium is defined as the ζ potential of nanoparticles. 
The ζ-potential can be deduced from the electrophoretic mobility of charged particles under an 
applied electric field, and the Helmholtz-Smoluchowski equation is often used for this conversion, 
where the thickness of EDL is much smaller than the particle radius:   
                             µe = r0/ 
where (μe) is the electrophoretic mobility, εr the relative permittivity or dielectric constant, 
ε0 the permittivity of vacuum, and  viscosity at experimental temperature. In this research, ζ 
potential of nanoparticles is normally measured at 25 °C on a Malvern Zetasizer Nano-ZS. The 
nanoparticles are normally dispersed in deionised water or PBS with gentle ultra-sonication treatment 
before analysis. 
3.2.6 Quantification of soluble BSA 
To determine the amount of BSA coated onto LDH NPs, the soluble BSA in the supernatant is 
quantified by measuring the absorbance at 280 nm using NanoDrop 1000 spectrophotometer and then 
estimating its concentration according to the working curve. 
3.2.7 Identification of siRNA/dsDNA using agarose gel electrophoresis 
Agarose gel electrophoresis (AGE) is a convenient method for nucleic acids separation and 
identification. The concentration of agarose is adjusted to control the pore size of gels and thus 
separate nucleic acids of different sizes. In this thesis, the identification and loading capacity of 
siRNA and dsDNA onto LDH and LCP nanoparticles were generally determined by AGE.  
The LDH-dsDNA or LDH-siRNA complexes are made by mixing LDH NP suspension and 
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dsDNA/siRNA solution at a certain mass ratio. Then the LDH-dsDNA/siRNA mixture is loaded onto 
the loading zone for AGE, followed by running AGE to determine non-binding dsDNA or siRNA, 
which will show approximately how much siRNA/dsDNA is bound to LDH NPs. 
The LCP-dsDNA/siRNA NPs are normally lysed in a lysis buffer (2 mM EDTA and 0.05% Triton X-
100 in pH 7.8 Tris buffer) by incubating at 50ºC for 10 min. The released dsDNA/siRNA can be then 
detected by agarose gel through electrophoresis. 
 
3.2.8 Quantification of siRNA/dsDNA loaded in LDH and LCP NPs 
To quantify the loading amount of dsDNA/siRNA in LDH or LCP NPs, a siRNA-mimicking Cy3-
dsDNA is often used and quantified by measuring the fluorescence intensity. In the case of LDH/Cy3-
dsDNA complexes, the supernatant of mixed LDH/Cy3-dsDNA suspension is collected via the high-
speed centrifugation and the non-binding Cy3-dsDNA in the supernatant is then quantified by the 
fluorescence intensity, so that the loading amount can be calculated. Reversely, LCP-Cy3-dsDNA 
NPs are lysed to release the loaded Cy3-dsDNA, and the amount of Cy3-dsDNA in lysed solution 
can be then quantified by measuring the Cy3 fluorescence intensity [6, 7]. 
3.3 Cell culture, transfection and cytotoxicity 
3.3.1 Cancer cell culture 
In this thesis, breast cancer cell line MCF-7 and colon cancer cell lines HCT-116 and HT-29 were 
purchased from ATCC for the relevant tests [11] and maintained in Dulbecco’s Modified Eagles 
Medium (DMEM, Invitrogen, Australia) supplemented with 10% fetal calf serum, 1% penicillin, and 
1% streptomycin in 75 ml flasks at 37ºC and 5% CO2 
3.3.2 Cancer stem cell culture and identification 
Sphere culture method is used, as previously reported [12]. In general, 4,000 cells in one milliliter are 
suspended in sphere cultural media (Dulbecco's Modified Eagle's Medium F-12, 0.4% BSA, 0.2% 
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epidermal growth factor and 0.2% insulin) in upright T25 flasks. The sphere culture is normally 
maintained in a humidified incubator at 37 ⁰C. The spherical cells obtained from sphere culture of 
MCF-7, HT116, HT-29 cells are firstly verified by their surface markers. After isolation, 1 x 105 cells 
are stained with rabbit anti-human CD133 (prominin-1) antibody (Sigma-Aldrich); mouse anti-
human CD44 conjugated with FITC (Invitrogen, Australia); and mouse anti-human CD24 antibody 
conjugated with RPE (Invitrogen, Australia). For CD133 staining, mouse anti-rabbit IgG-FITC 
(Sigma-Aldrich) is used as the secondary antibody. After 3 washes with 2% FCS/PBS, the cells are 
fixed in 2% paraformaldehyde/PBS and analysed by flow-cytometry (Accuri, BD) and CFlow 
Sampler software.  
3.3.3 Tumour infiltrating lymphocyte (TIL) culture 
TILs are normally isolated from breast cancer biopsy specimens by mincing the tissue into small 
pieces and digesting them with collagenase type IV (0.1 mg/mL) (Sigma-Aldrich) for 2 h, followed 
by culture in X-VIVO-15 medium (Lonza) containing 5% human AB serum and recombinant human 
IL-2 (150 IU/mL) in 24-well plates, as shown in Figure 3. Afterwards TILs are expanded in number 
using a rapid expansion protocol (REP) [13, 14]. Once a sufficient number of TILs (>1×107) is 
generated, they are cryopreserved for later expansion. A REP for “young TILs” previously used in 
melanoma patients is then followed. Cryopreserved and pre-REP TILs from patients are thawed and 
further expanded to treatment levels using an anti-CD3 antibody (OKT-3, 30 ng/mL, R&D Systems), 
rhIL-2 (BD PharMingen) and irradiated feeder cells, as previously described [14]. These TILs are 
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normally re-infused into the patient as TIL-based immunotherapy. In this research, TILs are further 
treated with LDH or LCP NPs to knockdown the PD-1 expression for enhanced cytotoxicity to cancer 
cells. 
 
 
 
 
 
 
Figure 3. Schematic presentation of TILs collection, culture and expansion. 
3.3.4 Determining the portion of CD4+ and CD8+ T cells in TILs 
TILs are collected and stained with the following antibodies: anti-CD3 (Pcy5), anti-CD4 (PE), anti-
CD8 (ECD), and anti-CD56 (APC) (Biolegend, CA). CD27 and CD28 surface expression is further 
tested after incubating TIL in complete medium without rhIL-2 for 48 hours. Isotype-matching 
antibodies are used as controls. After incubation at 4°C for 30 min with the above coupled antibodies 
and being washed with PBS, TILs are fixed with 4% paraformaldehyde and subject to FACS analysis 
to determine the portions of CD4+ and CD8+ T cells in TILs. 
3.3.5 Cell transfection and gene silence with LDH and LCP 
For transfection experiments, the cells are seeded or pre-cultured in a well of 6-well plate. Then the 
cells are treated in culture media containing LDH-Cy3-dsDNA or LCP-Cy3-dsDNA at 37 ºC in 5% 
CO2 atmosphere for a period. As-cultured cells are collected by centrifugation. After 3 washes with 
2% FCS/PBS, the cells are fixed in 2% paraformaldehyde/PBS, and subject to FACS analysis to 
quantify the amount of Cy3-dsDNA taken up by cells via NPs. 
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To determine the knockdown of target gene expression, the cells are seeded or pre-cultured in a well 
of 6-well plate. Then the cells are treated in culture media containing LDH-siRNA or LCP-siRNA at 
37 ºC in 5% CO2 atmosphere for 4 h. Then culture medium is replaced with the fresh medium and 
transfected cells are cultured for another 72 h at 37 oC, 5% CO2. Afterwards, the cells are collected, 
and the mRNA and protein expression level can be determined by RT-PCR and ELISA assay. The 
protein on the cell surface can be also stained with antibodies and quantified by FACS, such as surface 
PD-1 on the TILs.  
3.3.6 Cytotoxicity of LDH and LCP NPs 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) cell proliferation assay is 
used to detect cell proliferation and viability. The cytotoxicity of blank LDH or LCP NPs to cancer 
cells is briefly conducted as follows. Cells are incubated in 200 µL of medium in a 96-well plate 
overnight, and fresh media containing a range of concentrations of blank LDH or LCP NPs (0–160 
μg/mL). After treatment for 48 h, DMEM is supplemented with 20 μL of MTT reagent to each well 
and incubated for 3 h at 37°C. Then MTT solution is removed and added with 100 μL of DMSO and 
incubated for 10 min at 37°C to dissolve the formazan crystals. Absorbance readings at 570 nm are 
recorded to estimate the cell viability with reference to that at 650 nm using the plate reader. 
 
3.3.7 Cytotoxicity induced by LDH-siRNA and LCP-siRNA 
To determine the condition of viable cells in culture media with a range of concentration of LCP-CD-
siRNA or LDH-CD siRNA NPs, the cells are plated in a 96-well plate overnight. Then, the cells are 
treated with fresh culture media containing various concentrations of LCP-CD siRNA or LDH-CD 
siRNA NPs for 48 h. Cells are washed 3 times with PBS and then stained with 0.4% trypan blue 
(Sigma, USA) for 3 min to show the cell viability. After staining, the samples are imaged in bright 
field (Olympus, Japan). Similarly, the cell viability after treatment with various concentrations of 
LCP-CD siRNA or LDH-CD siRNA NPs for 48 h can be determined in the way described in section 
3.3.6. 
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3.3.8 TIL cytotoxicity to MCF-7 
The killing efficacy of TILs to MCF-7 is determined by the cytotoxic T lymphocyte (CTL) assay. 
Firstly, MCF-7 cells are seeded at a density of 1 × 104 cells/well in U-bottomed 96-well microplates 
and cultured for 18 h. Then the medium is replaced by 50 μl of fresh phenol red-free RPMI 1640 
medium (Gibco-BRL) containing 5% FCS. Similarly, TILs are incubated for 24 h in CNE2-CM, and 
then collected and resuspended in phenol red-free RPMI 1640 containing 5% FCS. Fifty microliters 
of TILs suspension are then added to each well at the T cell/cancer cell ratio of 10:1, 30:1, or 100:1. 
After 4 h incubation, the plates are centrifuged and 50 μl of the supernatant transferred to new 96-
well flat-bottomed plates. Then the cytotoxic activity of TILs is evaluated with the lactate 
dehydrogenase release assay using CytoTox 96® non-radioactive cytotoxicity assay (Promega, WI), 
following the manufacturer’s instructions.  
3.4 Biological assays 
3.4.1 Flow cytometry (FACS) 
Flow cytometry (FACA) is a biophysical technology applied in cell counting, cell sorting, protein 
engineering and biomarker detection [8]. FACS analysis is normally performed in a BD Accuri™ C6 
(San Jose, CA, USA) flow cytometer with CFlow Sampler software (Becton Dickinson, Mountain 
View, USA). In this thesis, the immunophenotypes and the PD-1 expression level of TILs were 
determined via fluorescence-activated cell sorting (FACS), as reported previously [9]. The PD-L1 
expression levels in cancer cells and cancer stem cells are also analysed by FACS [10].  
3.4.2 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a plate-based assay using antibodies and color change to identify biomolecule and measure 
their concentration. Taking IFN-γ as an example, a 96-well plate coated with human IFN-γ specific 
mouse monoclonal antibody is prepared. Standard solutions and samples are then added to wells, and 
IFN-γ is immobilised by capture antibody. Then, a detection antibody (biotinylated mouse 
monoclonal anti-human IFN-γ) is added, and this produces an antibody-antigen-antibody “sandwich”. 
Afterwards, an avidin-horseradish peroxidase is subsequently added. Adding TMB substrate solution 
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produces a blue color in proportion to the concentration of IFN-γ present in samples. Finally, the stop 
solution is added to change the reaction color from blue to yellow. The fluorescence intensity is read 
at 450 nm with a microplate reader to estimate the IFN-γ concentration. In this thesis, cytokines such 
as IFN-γ, TNF-α, IL-17 and IL-10 secreted from T cells were determined utilizing the relevant ELISA 
kits according to the supplier’s protocols. 
3.4.3 Real-time PCR 
Real-time PCR assay is used to quantify the expression of mRNA in cells. In brief, trizol/chloroform 
(1:5, v/v) is first added to lyse cells and the supernatant is collected by centrifugation (12,500 rpm, 
15 min). Then, isopropanol is added, and the supernatant centrifuged for another 15 min at 12,500 
rpm. The collected pellet is then washed with 70% ethanol. After drying the pellet, H2O is added to 
resuspend the total RNA. Reverse transcription reactions are then performed following the 
manufacturer’s instruction and cDNA is diluted with H2O. For each well, cDNA solution is mixed 
with PCR Master-Mixture. After centrifugation, real-time PCR is conducted (Real-time PCR, iCycler 
iQTM, Bio-Rad, USA).  
3.4.4 Western blotting (WB) 
The western blotting is a protein detection method that measures the target protein expression in cells. 
For example, the relative PD-L1 concentration in cell lysates is estimated using the Pierce™ BCA 
Protein Assay Kit (Thermo Scientific). Samples are normally mixed with protein-loading buffer (Bio-
Rad) containing 2-mercaptoethanol. After denaturation by 5-min boiling, the samples are loaded on 
4-15% Mini-PROTEAN® TGX™ Precast Gels SDS polyacrylamide gel (Bio-Rad). Gels are then 
blotted onto PVDF membranes for 90 min @ 80 V, proteins are thus transferred onto PVDF 
membranes and blocked for non-specific binding with TBST (0.05% (v/v) Tween-20 in TBS pH 7.4) 
plus 5% BSA for 1 h at room temperature. PD-L1 RabMab antibodies (ab205921) (abcam, USA; at 
dilution of 1:800-1000) is then applied overnight at 4 ℃. The membrane is washed with TBST, then 
incubated with HRP-conjugated secondary antibodies (Goat anti-rabbit IgG H&L (HRP), ab97051) 
(abcam, USA; at dilution 1: 5000) for 2 h. After washing, protein bands are finally visualised using 
Clarity™ Western ECL Substrate (Bio-Rad), and analysed using ImageJ v1.40 software.  In this 
thesis, the western blot was mainly applied in detection of PD-1 and PD-L1 expression levels. 
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3.5 Statistics 
Statistics is applied to analyse the collected data. All the data are represented as means ± SEM. Data 
are normally analysed by one-way analysis of variance (ANOVA), followed by multiple comparisons 
using Tukey's test within GraphPad Prism 6 software. A p-value < 0.05 is considered significant. *, p 
< 0.05; **, p < 0.01; ***, p < 0.001. In current thesis, all experiments were repeated for three or more 
times. 
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Chapter 4 
Optimisation of Formulations Consisting of Layered Double Hydroxide 
Nanoparticles and Small Interfering RNA for Efficient Knockdown of 
the Target Gene 
The relevant results were already published in ACS Omega 2018, 3: 4871−4877. The figure sequence 
and the reference format are kept the same as in the published paper. 
Description of this research: 
In this research, the operational parameters for formulating layered double hydroxide (LDH)-siRNA 
hybrid system, including the mixing method of siRNA and LDH nanoparticles, and more importantly 
the LDH:siRNA mass ratio, has been optimised in terms of the delivery efficacy and the target gene 
silencing capability. The optimisation for LDH-siRNA delivery system resulted in based on this 
research thus provides the basic guidance for more efficient in vitro and in vivo siRNA delivery using 
LDH nanoparticles, which has been compared in the research conducted in Chapter 5.   
  
 61 
 
Graphic Abstract 
 
Layered double hydroxide (LDH) nanoparticle (NP) is a safe and effective vector for siRNA delivery, 
and the siRNA delivery efficiency is mainly determined by the LDH:siRNA mass ratio as well as the 
mixing style, which has been well optimised in this research. 
Abstract: Layered double hydroxide (LDH) nanoparticle (NP) is a safe and effective vector for 
siRNA delivery. However, it is unclear whether there are the optimal parameters for efficient delivery 
of functional siRNA using LDH NPs. In this research, we comprehensively examined the effect of 
parameters, such as the mixing method and LDH:siRNA mass ratio on siRNA silencing capability. 
We first noted that the best loading way for gene segments (25 bp dsDNA and siRNA) is to add gene 
molecules to 100-nm LDH and then dilute in DMEM. Very interestingly, the optimal LDH:gene mass 
ratio is around 20:1 in terms of cellular uptake amount of gene segments, while this ratio is shifted to 
around 5:1 in terms of target gene silencing efficacy, which has been reasonably explained. The 
optimisation for LDH NP based gene delivery system may provide the guidance for more efficient in 
vitro and in vivo siRNA delivery using the optimal parameters.  
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4.1 Introduction 
Layered double hydroxide (LDH) is a group of anionic clay materials that have attracted increasing 
attention in recent years for biomedical applications, such as gene delivery, vaccine delivery and drug 
delivery [1-3]. LDH materials have several unique features, including anionic exchange capacity [4], 
and the ability to capture organic and inorganic anions [5-7]. MgAl-LDH nanoparticles (NPs) have 
been extensively investigated as vehicles for delivery of genes and drugs to cells [8-11], which are 
biocompatible, have a high loading capacity, facilitate cellular uptake, and release target biomolecules 
in a pH-dependent manner [12]. Moreover, the inherent surface positive charge and anion exchange 
property enable MgAl-LDH NPs to carry and deliver anionic biomolecules and pharmaceutical drugs 
such as oligonucleotides [13], DNAs [14, 15], RNAs [10, 14], methotrexate [16], 5-fluorouracil [13] 
and anti-inflammatory drugs (diclofenac, gemfibrozil, ibuprofen, naproxen) [11]. Recent studies have 
demonstrated the capacity of LDH NPs to target specific cells [15] or subcellular compartments [1]. 
More advantages of LDH NPs as delivery vehicles include the low toxicity, protection of payloads 
and high cellular delivery efficacy [17, 18]. These properties indicate that LDH NPs are a good 
cellular delivery system for biomolecules like DNAs or RNAs.  
RNA interference (RNAi) is a biological mechanism, in which small interfering RNA (siRNA) or 
microRNA (miRNA) destroys targeted messenger RNA (mRNA) to suppress specific gene 
expression [19-21]. Due its preciseness and effectiveness, RNAi has proven to be a promising 
measure for the treatment of cancer [22-25]. However, some impediments hinder its further clinical 
use, such as low cellular uptake and instability of RNA molecules under physiological conditions. 
Thus, it is necessary to devise an efficient gene delivery system for RNAi molecules to enter tumour 
cells in order to elicit gene modification effects [26-29].  
Mg2Al-Cl-LDH nanomaterials have shown great potential to be an efficient delivery system for RNA 
molecules in RNAi-based treatment of cancers, as reported elsewhere [13, 14, 30, 31]. In particular, 
50-100 nm LDH NPs were found to have the highest cellular uptake than 100-200 nm and 350 nm 
ones and more accumulation at the tumour tissue [31]. However, it is not clear whether the parameters 
applied to formulate the LDH-siRNA hybrid system are optimal as there is no such a report about the 
parameters’ optimisation for this system.x` 
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Therefore, the objectives of this research were to: (1) examine the effect of LDH NPs:siRNA mixing 
method on the siRNA uptake by MCF-7 cells; (2) investigate the effects of the LDH NPs:siRNA mass 
ratio on the cellular uptake and the target gene knockdown efficacy, respectively; and (3) confirm the 
delivery efficacy of siRNA in terms of target mRNA silence and target protein expression reduction 
using the optimised parameters. Our findings in this research suggest a set of optimal parameters for 
efficient siRNA delivery using LDH NPs.   
4.2 Results and discussion 
4.2.1 Physicochemical features of LDH nanoparticles 
Analysis of homogeneously dispersed Mg2Al-Cl-LDH suspension gave a narrow particle size 
distribution (Figure 1A). The equivalent mean hydrodynamic diameter was 110 nm with the 
polydispersity index (PDI) of 0.099, most particles were distributed within a range of 50~200 nm, 
and the suspension was transparent. Consistent with previous reports [32-34], Mg2Al-Cl-LDH 
nanoparticles (NPs) had an average zeta potential of ~40 mV in suspension. The TEM image (Figure 
1B) shows that LDH crystallites were well crystallised with a typical hexagonally-shaped 
morphology, as reported previously [32, 34]. The lateral length of the crystallites was in the range of 
40~160 nm, well corresponding to the hydrodynamic diameter distribution measured in PCS if the 
hydration layer is accounted for, indicating that LDH NPs were individually dispersed in aqueous 
solution. 
The layered structure of as-prepared LDH NPs is confirmed by the XRD pattern (Figure 1C) and 
FTIR spectrum (Figure 1D). FTIR spectrum is typical of Mg2Al-Cl-LDH material, as featured by a 
broad band at 3473 cm-1 (νOH), a peak at 1629 cm-1 (δH2O) and a broad band at 627 and 415 cm-1 (due 
to M-O vibrations and M-O-H bending). According to the XRD pattern of Mg2Al-Cl-LDH NPs, this 
LDH had a basal spacing of 0.781 nm. Taking into account that the thickness of LDH hydroxide layer 
is 0.48 nm, the interlayer spacing is 0.31 nm, similar with the size of chloride ion [32]. These data 
indicate LDH nanoparticles used in this study possess the typical physicochemical properties of LDH 
NPs, as reported previously [8, 35, 36].  
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Figure 1. Characterisation of LDH NPs. (A) Particle size distribution of Mg2Al-Cl-LDH NPs in 
suspension; (B) TEM image; (C) FTIR spectrum; and (D) XRD pattern of Mg2Al-Cl-LDH NPs. 
4.2.2 Optimisation of the mixing method and the culture time 
Three mixing methods were designed to load siRNA/dsDNA onto LDH NPs. siRNA was mimicked 
by dsDNA-Cy3 and the loading efficiency of each mixing method was quantified by the cellular 
uptake amount of dsDNA-Cy3 loaded LDH NPs, which was measured in terms of the average cell 
fluorescence intensity by FACS. After LDH-dsDNA hybrids were obtained in one mixing method, 
they were added in culture medium for MCF-7 cells to take up for 4 h. Cells were then harvested and 
fixed for FACS analysis. In each test, the fluorescence intensity of cells from group MM 3 (mixing 
method 3) was adjusted as 100% and compared with that from the other two groups, as shown in 
Figure 2. The conclusion is that MM3 exhibits the highest uptake efficiency for the siRNA/dsDNA 
delivery to MCF-7 cells. This optimal mixing method was employed in following experiments.  
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The mixing method affects the LDH-dsDNA delivery efficacy probably through changing the 
aggregation of LDH NPs when mixing with complete cell culture medium. As reported previously, 
the aggregation is concentration- and size-dependent [35], happening through shortening the van del 
Wall’s thickness of electron double layers on the LDH NP surface and serum-protein bridging effect 
[37]. When LDH is premixed with medium (MM1 and MM2), the surface of LDH NPs is partly 
occupied with serum proteins and the electron double layer thickness on the LDH NP surface is 
decreased by the salt ions, which may induce aggregation of LDH NPs [37]. Further, phosphate 
anions in medium are also adsorbed on the LDH NP surface, which may significantly reduce the 
dsDNA loading onto LDH NPs via anion exchange. Both aggregation and less exchange liability may 
result in some free dsDNA, and thus less cellular uptake. When dsDNA is first loaded onto LDH NPs 
via surface adsorption and interlayer intercalation of dsDNA [38], dsDNA is all adsorbed onto LDH 
particle surface. The surface loading normally results in LDH-dsDNA aggregates [37], which may be 
then better dispersed in culture medium, leading to an increased cellular uptake.  
 
Figure 2. Optimisation of the mixing method. dsDNA was loaded to LDH NPs in MM 1, 2 and 3, at 
LDH:dsDNA mass ratio = 20:1. Then the mixture was added into the medium for MCF-7 uptake. The 
uptake amount was measured in terms of the mean fluorescence intensity (MFI) in FACS. Data 
presented as the mean ± SE from 3 independent experiments. 
To optimise the cellular uptake time, MCF-7 cells were treated with LDH-dsDNA-Cy3 (mixing 
method 3, LDH:dsDNA = 20:1) and harvested for FACS analysis at different time points to assess 
the Cy3-positive cell percentage. A robust uptake of LDH-dsDNA hybrids was observed during the 
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first hour. After LDH-dsDNA treatment for 4 h, vast majority of MCF-7 cells (>80%) were positive. 
Extending the culture time to 8 h seemed not to obviously increase the positive cell percentage, as 
reported previously [35]. Thus 4 h appears to be the optimal culture time. 
 
Figure 3. Cellular uptake profile of LDH-dsDNA hybrids represented by the positive cell percentage 
vs. culture time. LDH:dsDNA = 20:1, [LDH] = 20.8 µg/mL, and [dsDNA-Cy3] = 80 nM. 
4.2.3 Optimisation of the LDH:dsDNA mass ratio for cellular uptake 
For the optimisation of LDH:dsDNA mass ratio for gene delivery, dsDNA (25 bp) was immobilised 
with LDH NPs at different mass ratios. From the imaging, dsDNA was completely immobilised by 
LDH NPs when LDH:dsDNA was 20:1 or 40:1 (Figure 4A). at 10:1, most dsDNA was loaded onto 
LDH, while considerable dsDNA was free at 5:1 to 1:1. For comparison, the mean fluorescence 
intensity (MFI) of cells treated with LDH-dsDNA hybrids at the mass ratio of 20:1 was set at 100%. 
The MFI from other groups was then compared to give a relative MFI. Clearly, MCF-7 cells took up 
the most dsDNA via LDH NPs at the mass ratio between 15:1 to 25:1 (Figure 4B).  
 67 
 
 
Figure 4. (A) Agarose gel electrophoresis (AGE) for examining the immobilisation of dsDNA by LDH 
NPs at the mass ratio from 40:1 to 1:1. (B) Relative cellular uptake amount of dsDNA represented 
by the relative mean fluorescence intensity (MFI) of MCF-7 cells vs. LDH:dsDNA mass ratio at 
[dsRNA-Cy3] = 80 nM = 1.04 µg/mL. 
The relationship between the mass ratio and cellular uptake rate probably results from the trade-off 
between the dsDNA amount per LDH NP and the concentration of LDH NP number. Since almost 
all dsDNA-Cy3 is loaded onto LDH NPs at the mass ratio of 15:1 and above (Figure 4A), dsDNA-
Cy3 is all adsorbed onto LDH NPs in the mass ratio range indicated in Figures 5B and 5C, and the 
dsDNA amount per LDH NP is linearly dependent on the LDH:dsDNA mass ratio. In the mass ratio 
range in Figure 5A, the maximum dsDNA amount per LDH NP may be achieved at the mass ratio of 
10:1 to 2:1 and may be nearly constant, so there is an essential amount of free dsDNA-Cy3 at the 
mass ratio 5:1 to 2:1. As also pointed out in previous studies [35, 39, 40], the cellular uptake efficiency 
of LDH NPs is almost linearly dependent on the LDH concentration under 20 μg/mL 
(~1.0 × 1010 number/mL) and reached a plateau beyond this critical concentration. In the current 
research, the critical concentration occurs at the LDH:dsDNA mass ratio of around 20:1. Therefore, 
the dsDNA cellular uptake is monotonically reduced with the mass ratio from 20:1 to 80:1 (Figure 
4B) where the LDH NP number taken up by the cells is similar but the dsDNA amount per LDH NP 
is decreased with the mass ratio from 20:1 to 80:1. With the mass ratio changing from 20:1 to 10:1, 
the LDH NP number taken up by the cells is decreased but the dsDNA amount per LDH NP is 
increased. It seems that the former is predominant over the latter, so that the dsDNA uptake is overall 
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decreased (Figure 4B). Obviously, the dsDNA amount per LDH NP is maximised in the mass ratio 
of 10:1 to 2:1 while the LDH NP number concentration is decreased linearly, thus the cellular uptake 
of dsDNA is reduced accordingly (Figure 4B). It should be mentioned that the aggregation state of 
LDH-dsDNA hybrids may be slightly varied at different mass ratios, which is supposed not to 
significantly affect the dsDNA transfection to MCF-7 cells. 
 
Figure 5. Scheme illustration of the dsRNA loading amount per LDH NPs and the relative LDH NP 
number at the varied LDH:dsDNA mass ratios. (A) At 2:1 to 10:1, LDH NPs have the maximum 
dsDNA loading with some free dsDNA; (B) At 15:1 to 30:1, LDH NPs have the maximum dsDNA 
loading without free dsDNA; (C) At 40:1 to 160:1, each LDH NP loads fewer dsDNA molecules 
without free dsDNA.   
Therefore, it appears that the optimal LDH:dsDNA mass ratio is around 20:1 in terms of the cellular 
uptake amount of dsDNA-Cy3 at the dsDNA concentration of 80 nM in culture medium.  
 
 
 69 
 
4.2.4 Optimised functional siRNA delivery to MCF-7 
To verify the feasibility of optimised siRNA delivery system, MCF-7 cells were transfected with CD-
siRNA at different LDH:siRNA mass ratios ranging from 1:1 to 40:1. MCF-7 cells were incubated 
with LDH-CD-siRNA for 4 h and followed by incubation for 72 h in the standard culture medium. 
As shown in Figure 6, the MCF-7 cell viability was decreased by approximately 45%-60% at a mass 
ratio of 5:1 with the CD-siRNA concentration from 40-160 nM. This decrease of cell viability is 
much more than that at the mass ratio of 20:1 (5%-12%), 10:1 (8%-17%), 2:1 (32%-42%) and 1:1 
(22%-33%) under the same conditions, respectively. This observation indicates that the optimal 
LDH:siRNA mass ratio is around 5:1 in terms of CD siRNA inhibition efficacy of cancer cells, which 
is much different from that (20:1) in terms of just cellular uptake by or delivery to MCF-7 cells 
(Figure 4B). 
 
 
 
 
 
 
 
Figure 6. Cell viability of MCF-7 transfected with CD-siRNA delivered by LDH NPs under various 
conditions. Data presented as the mean ± SE from 3 independent experiments. 
The shift of the optimal mass ratio from 20:1 for just cellular uptake to 5:1 for functional siRNA to 
take effect may be further related to the siRNA release from LDH-siRNA hybrids to the cytosol so 
as to target and dice specific mRNA. The siRNA release from LDH-siRNA hybrids may occur via 
two processes, i.e. dissolution of LDH NPs and anion exchange. As revealed previously [35, 41], 
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cellular internalisation of LDH NPs is basically driven by clathrin-mediated endocytosis. During 
endocytosis, a certain amount of LDH NPs is acidified in endosome (pH 5-6) to be dissolved and 
release siRNA molecules, which may also occur in the cytosol (pH 7.4) at a much lower pace after 
LDH-siRNA hybrids escape from endosome. As the dissolved LDH NP amount would be very similar 
for each cell in a similar time scale, thus LDH NP with the maximum siRNA loading would free the 
most siRNA molecules for complexing with RISC and dicing the target mRNA. In comparison, 
double amount of LDH NPs would be taken up by MCF-7 cells at 10:1 as at 5:1, thus only half amount 
of free siRNA would be released to the MCF-7 cytosol at 10:1 as at 5:1, and would result in lower 
inhibition on cell viability. At the mass ratio of 20:1 to 80:1, the release of siRNA is even more 
difficult, resulting in much lower inhibition of tumour cell growth (Figure 6). In contrast, less than 
half amount of LDH NPs would be taken up by MCF-7 cells at 2:1 as at 5:1 (LDH NP number at 2:1 
was about 40% at 5:1 when siRNA was fixed at 40, 80 or 160 nM), thus less than half amount of 
siRNA may be released to MCF-7 cytosol at 2:1 as at 5:1 (supposed the siRNA loading per LDH NP 
is maximum and the same), resulting in much lower cell growth inhibition. In addition, few siRNA 
molecules on the LDH surface would be exchanged with cytosol anions (Cl- and phosphates) and 
become free, but this would contribute limitedly to the cell viability.   
 
Figure 7. Down-regulation of PD-L1 in MCF-7. (A) Real-time PCR data for the knockdown of PD-
L1 mRNAs; and (B) Western-blot showing reduction of PD-L1 expression in MCF-7 treated with 
LDH-PD-L1-siRNA at the concentration from 40 to 160 nM. 
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Therefore, the optimal LDH:siRNA mass ratio seems to be 5:1 for functional siRNA delivery as the 
result of trading-off of these several processes. Comparatively, we used an LDH:siRNA mass ratio 
of 1:1 for siRNA delivery to neuron and NIH3T3 cells in our previous researches [10, 42], which 
may underlie the delivery capacity of LDH NPs. On the other hand, using the mass ratio of 40:1 for 
cellular uptake of siRNA [35] is not optimal either. Similarly, varied mass ratios (10:1 to 40:1) were 
used to deliver CD-siRNA to kill cancer cells in combination with 5-FU [13], which may not 
maximise the biological function of CD-siRNA in killing cancer cells.     
As a feasibility test, the optimised parameters for functional siRNA delivery were used to formulate 
LDH-PD-L1-siRNA at the concentration of 40, 80, and 160 with the LDH:siRNA mass ratio of 5:1, 
which was used to treat MCF-7 for target gene silence. As shown in Figure 7, the delivered PD-L1 
siRNA efficiently silenced PD-L1 mRNA expression (20-80%) and PD-L1 expression (30-75%).  
Therefore, this research has optimised and confirmed the LDH NP system for efficient in vitro 
delivery of genes to cancer cells, which is believed to be also applicable for the in vivo delivery for 
cancer gene-therapy [43, 44].  
4.3 Conclusions 
In this work, the mixing method, cellular uptake time and LDH:siRNA mass ratio were optimised for 
functional siRNA delivery to cancer cells. We found that the optimal mixing method was to directly 
add siRNA into LDH suspension, followed by a dilution with culture medium and the optimal cellular 
uptake time was 4 h, with >80% cells being transfected. In the mass ratio optimisation, MCF-7 cells 
seem to take up the greatest number of dsDNA or siRNA at the LDH/gene mass ratio of 20:1. 
However, most functional CD-siRNA and PD-L1 siRNA seem to avail and work the best at the mass 
ratio of around 5:1. Therefore, this research has thus optimised the LDH-based platform for gene 
delivery in vitro as well as in vivo.   
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4.4 Materials and methods 
4.4.1 Chemicals and reagents 
All samples were prepared under sterile conditions. Sodium hydroxide pellets, magnesium chloride 
hexahydrate (MgCl2·6H2O), aluminum chloride hexahydrated (AlCl3·6H2O), were purchased from 
Ajax Finechem, Chem-Supply, Scharlau and Sigma-Aldrich Pty Ltd, Invivogen, respectively. 
DsDNA-Cy3 was purchased from GeneWorks. Cell Death siRNA (CD-siRNA) were purchased from 
QIAGEN Pty. Ltd. PD-L1 siRNA (sense: 5'-AGAcGuAAGcAGuGuuGAAdTsdT-3' and antisense: 
5’-UUcAAcACUGCUuACGUCUdTsdT-3’), and other chemicals and reagents were purchased from 
Sigma-Aldrich if not illustrated specifically. Water used in experiments was deionised Milli-Q water. 
4.4.2 LDH preparation 
 Mg2Al-Cl-LDH NPs were synthesised by co-precipitation-hydrothermal method, which had been 
well established in our group [8]. Briefly, a mixture of MgCl2 (0.70 M) and AlCl3 (0.30 M) with a 
total volume of 10 mL was quickly added to 40 mL of NaOH solution (0.45 M) within 5 s, under 
vigorous stirring. After 10 min stirring, the slurry was separated via centrifugation and re-dispersed 
in 40 mL of deionised water. The resultant suspension was moved into a stainless-steel autoclave 
with a Teflon lining and heated at 100 oC for 16 h. The final mass concentration of LDH was 
approximately 10 mg/mL, with the yield of ~60%. 
BSA were added as reported before [45]. Two milliliters of 4 mg/ml LDH suspension was added into 
2ml of 10 mg/ml BSA solution (dissolved in deionised Milli-Q water) drop by drop under vigorously 
magnetic stirring for 30 min to ensure saturated absorption. 
4.4.3 Characterisation of LDH 
The particle size distribution of as-prepared LDH NPs was determined by photon correlation 
spectroscopy (PCS, Nanosizer Nano ZS, MALVERN Instruments) using Non-Invasive Backscatter 
optics (NIBS). For Transmission electron microscope (TEM) imaging, LDH solution was air-dried 
on a copper grid. Images were obtained on a JEOL 1010A transmission electron microscope at an 
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acceleration voltage of 200 kV. Fourier transform infrared (FTIR, Perkin-Elmer 1760X FTIR) 
spectroscopy and X-Ray Diffraction (XRD, Siemens F-series Diffractrometer with Cu Kα 
radiation, λ = 0.15418 nm) pattern were collected to confirm layered structure of LDH NPs.  
4.4.4 Cell culture 
MCF-7, a widely studied epithelial cancer cell line derived from breast adenocarcinoma, was used as 
the cancer cell model in this study. Normally, MCF-7 cells were cultured in DMEM supplemented 
by 10% (vol/vol) FBS at 37 oC in 5% CO2 atmosphere.  
4.4.5 Optimisation of the siRNA delivery with LDH NPs 
LDH NPs were used to load siRNA-mimicking dsDNA-Cy3 with different parameters. The delivery 
efficiency was evaluated by FACS, which was used to decide the optimal parameters. 
For mixing method optimisation, we designed three different methods. In mixing method 1 (MM1), 
both dsDNA and LDH suspension (LDH:dsDNA mass ratio was 20:1) were diluted with DMEM 
medium containing 10% FBS. After 15 min incubation at room temperature, diluted dsDNA was 
added to diluted LDH suspension and the mixture was left at room temperature for another 15 min. 
In mixing method 2 (MM2), only LDH suspension was diluted in medium before mixing with dsDNA. 
While in mixing method 3 (MM3), dsDNA was directly added into LDH suspension, and then the 
mixture was diluted to the designed volume. The obtained mixture (at the nominal dsDNA-Cy3 
concentration of 80 nM) was added to MCF-7 cells seeded for 24 h (1×105 cells per well) and then 
kept for 4 h. Cells were harvested and fixed for FACS analysis afterwards. 
To define the optimal LDH:siRNA mass ratio for transfection, an appropriate dose of dsDNA was 
mixed with different amounts of LDH in suspension with LDH/dsDNA mass ratios ranging from 2:1 
to 160:1, using mixing method 3 (MM3) as mentioned above. After adding the mixture, the cells were 
incubated at 37 oC with 5% CO2 for 4 h and then collected for FACS analysis. 
To determine the proper culture time, MCF-7 cells treated with LDH-dsDNA-Cy3 were placed in an 
atmosphere of 37 oC with 5% CO2. At different time points (0.25, 0.5, 1, 2, 4, 8 h), cells were collected 
for FACS analysis. 
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4.4.6 FACS analysis 
FACS analysis was performed in a BD Accuri™ C6 (San Jose, CA, USA) flow cytometer with CFlow 
Sampler software (Becton Dickinson, Mountain View, USA).  
4.4.7 Cell viability assay 
Cell viability was assessed by a colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). Briefly, MCF-7 cells were cultured in the 96-well plates (2.5 
×103 cells per well) and treated with the LDH-CD-siRNA at the concentration ranging from 40 to 160 
nM. After 24 h, DMEM was supplemented with 20 μL of MTT reagent (0.5 mg/mL) to each well and 
incubated for 3 h at 37°C. Thereafter MTT solution was removed. After addition of 100 μL 
of DMSO, the plates were incubated for 10 min at 37°C to dissolve the formazan crystals. 
Absorbance readings of DMSO extracts were performed at 570 nm with reference of that at 650 nm 
using the plate reader. 
4.4.8 Knockdown of PD-L1 gene in MCF-7 with siRNA 
PD-L1 siRNA (sense ： 5'-AGAcGuAAGcAGuGuuGAAdTsdT-3' and antisense ： 5’-
UUcAAcACUGCUuACGUCUdTsdT-3') were used in this study. For MCF-7 cells, 1×105 cells/well 
were seeded in a 6-well plate and cultured at 37 oC for 4 h in the presence of LDH-PD-L1 siRNA that 
was formulated using optimal parameters. The culture medium was the replaced with the fresh 
medium, and transfected MCF-7 cells were cultured for another 72 h at 37 oC, 5% CO2. PD-L1 mRNA 
and protein level were examined by Real-time PCR and Western-blotting, respectively. 
4.4.9 Real-time PCR 
Real-time PCR assays were carried out according to the manufacturer’s instructions. Briefly, 1.2 mL 
of trizol/chloroform (1:5, v/v) was mixed with lyse cells and the supernatant was collected by 
centrifugation (12,500 rpm, 15 min). Subsequently, 2.4 mL of isopropanol was added, followed by 
the centrifugation of the supernatant for another 15 min at 12,500 rpm. Pellet was collected and 
washed by 70% ethanol once. The pellet was resuspended in 50 µL of H2O after drying and diluted 
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with 80 µL of H2O. For each well, 3.5 µL of pellet solution was mixed with 8.5 µL of PCR Master 
Mixture solution. Real-time PCR was conducted after centrifugation. 
4.4.10 Western blotting 
The relative PD-L1 concentration in cell lysates was estimated using the Pierce™ BCA Protein Assay 
Kit (Thermo Scientific). Samples (roughly 10 µg total protein per well) were mixed with protein-
loading buffer (Bio-Rad) containing 2-mercaptoethanol. After denaturation by 5-min boiling, samples 
were loaded on 4-15% Mini-PROTEAN® TGX™ Precast Gels SDS polyacrylamide gel (Bio-Rad). 
Gels were blotted onto PVDF membranes for 90 min @ 80 V, proteins were transferred onto PVDF 
membranes and blocked for non-specific binding with TBST (0.05% (v/v) Tween-20 in TBS pH 7.4) 
plus 5% BSA for 1 h at RT. PD-L1 RabMab antibodies (ab205921) (abcam, USA; at dilution of 
1:800-1000) was applied overnight at 4 ℃. The membrane was washed with TBST, then incubated 
with HRP-conjugated secondary antibodies (Goat anti-rabbit IgG H&L (HRP), ab97051) (abcam, 
USA; at dilution 1: 5000) for 2 h. After washing, protein bands were visualised using Clarity™ 
Western ECL Substrate (Bio-Rad), and analysed using ImageJ v1.40 software. 
4.4.11 Statistical analysis  
All experiments were repeated for three or more times. All the data are represented as means ± SEM. 
Data were analyzed by one-way analysis of variance (ANOVA), followed by multiple comparisons 
using Tukey's test within GraphPad Prism 6 software. A p value <0.05 was considered to be 
significant. 
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Chapter 5 
Enhancing PD-1 Gene Silence in T Lymphocytes by Comparing the 
Delivery Performance of Two Inorganic Nanoparticle Platforms 
The relevant results were already published in Nanomaterials 2019, 9:159. The figure sequence and 
the reference format are kept the same as in the published paper. 
Description of this research: 
Following the discovery of optimal layered double hydroxide (LDH)-siRNA hybrid system found in 
Chapter 4, this research has for the first time compared the siRNA delivery efficacy of two commonly 
used inorganic nanoparticle systems, i.e. layered double hydroxide (LDH) and lipid-coated calcium 
phosphate (LCP) nanoparticles, to the T cells. The delivery data clearly show that LCP nanoparticles 
are a more efficient delivery platform to transfer siRNA to suspended mouse T cell lines (EL4) and 
human ex vivo tumour infiltrating lymphocytes (TILs) for the target gene silencing. Such results thus 
underpin the subsequent research in Chapter 6 that simultaneously knockdowns the expression of PD-
1 in TILs and PD-L1 in breast cancer cells (MCF 7) for enhanced cancer growth inhibition. 
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Graphic Abstract 
 
Both LDH and LCP nanoparticles are able to quickly deliver gene segment to mouse T cell lines 
(EL4), while the LCP nanoparticles exhibited much more cellular uptake and higher PD-1 gene 
silence efficiency in EL4 and human tumour infiltrating lymphocytes (TILs). 
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Abstract: Suitable carriers are crucial to RNAi applications for cancer genotherapy and T-cell 
immunotherapy. In this research, we selected two extensively-investigated biocompatible inorganic 
nanoparticle carriers, i.e., layered double hydroxide (LDH) and lipid-coated calcium phosphate (LCP) 
and then compared their efficacy for siRNA delivery in T cells, in order to understand which carrier 
is more efficient in delivering functional programmed cell death protein 1 siRNA (PD-1 siRNA) to 
suspended T lymphocytes. Both LDH and LCP nanoparticles quickly delivered gene segment to 
mouse T cell lines (EL4), while the LCP nanoparticles exhibited more cellular uptake and higher PD-
1 gene silence efficiency. We further demonstrated that LCP nanoparticles successfully reduced the 
expression of PD-1 in human ex vivo tumour infiltrating lymphocytes (TILs). Thus, LCP 
nanoparticles can be used as a better nano-carrier for gene therapy in lymphocytes, especially in 
regard to TIL-related cancer immunotherapy. 
Keywords: layered double hydroxide (LDH) nanoparticle; lipid-coated calcium phosphate (LCP) 
nanoparticle; programmed cell death protien-1 (PD-1); human tumour infiltrating lymphocytes (TILs); 
PD-1 gene silencing; EL4 cells 
5.1 Introduction 
RNAi technology has been now examined for enhanced cancer immunotherapy in combination with 
other therapies [1–4]. For example, silencing programmed death ligand 1 (PD-L1) on the surface of 
cancer cells is able to induce higher T-cell immunity and enhance the therapeutic efficacy in 
combination with photodynamic therapy [4]. To this end, many research inquiries have been 
conducted to knockdown PD-L1 expression on tumour cells, while silencing programmed death 1 
(PD-1) on the surface of T cells is rarely investigated. An efficient siRNA delivery vehicle is 
necessary to knockdown the expression of PD-L1 on tumour cells or PD-1 on the T cells. For gene 
delivery, many types of nanoparticles (NPs), such as polyeric NPs (PEI), biomolecular NPs (PLGA 
and BSA), and inorganic NPs (Au, carbon, and SiO2) are extensively investigated [5], while two 
inorganic nanoparticles (NPs), i.e., layered double hydroxide (LDH) [6–10] and lipid-coated calcium 
phosphate (LCP) [11–15], both with many suitable properties, appear as efficient delivery vehicles 
for the functional siRNA. 
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LDH is a group of anionic clay materials that have attracted increasing attention in recent years for 
biomedical applications, such as gene delivery, vaccine delivery, and drug delivery [6–10,16,17]. In 
particular, MgAl-LDH nanoparticles (NPs) have been demonstrated as efficient vehicles for the 
delivery of genes and drugs to cells [6–10,16], which are biocompatible, have a high loading capacity, 
and release target biomolecules in a pH-dependent manner [17,18]. More advantages of LDH NPs as 
delivery vehicles include the low toxicity, protection of payloads, and their high cellular delivery 
efficacy [7,10,17,19]. These properties enable LDH NPs to become a good option for the cellular 
delivery of DNAs or RNAs. Furthermore, to overcome poor colloidal stability due to aggregation in 
biological media for in vivo applications, we recently developed an approach to coating bovine serum 
albumin (BSA) on LDH nanoparticles (BSA-LDH), which colloidally stabilises the LDH NPs in 
various electrolyte solutions and media [20,21]. 
On the other hand, calcium phosphate (CaP), which is the main inorganic component in bones, has 
excellent properties as a nanocarrier of DNA and siRNA for gene therapy in the nanomaterial form, 
as reported elsewhere in the last decades [5,22]. Recently, by stabilizing the CaP NPs with a lipid 
bilayer, Huang et al. developed LCP NPs that naturally possess a colloidal stability in electrolyte 
solutions and biological media. LCP NPs have been demonstrated to significantly improve siRNA 
delivery when compared with their lipid/protamine/DNA (LPD) formulation [13,23]. We have 
recently shown that LCP NPs improved the cellular uptake of siRNA and they significantly inhibited 
the growth of human breast cancer cells in vitro with our optimised LCP NPs [14,15,24]. 
Both LDH and LCP NPs appear as good siRNA delivery systems. However, which one is more 
efficient has not been investigated and reported yet. Therefore, in this study, we compared the 
capability of LDH and LCP NPs in delivering murine PD-1 siRNA into EL4 T cells. EL4 T cells are 
cancerous lymphocytes, with high PD-1 expression, which are a suitable model for comparing the 
delivery systems in terms of the silence efficacy of target gene PD-1. Thus, the objectives of this 
research were to: (1) reveal the time-dependent and dosage-dependent cellular uptake of LDH NPs, 
BSA-LDH NPs, and LCP NPs by EL4 cells; (2) understand the factors that affect the siRNA delivery 
efficacy in terms of target PD-1 mRNA silence and protein expression reduction in EL4; and, (3) 
confirm that the selected better system works on a human T cell, i.e., tumour infiltrating lymphocyte 
(TIL). Here, TILs were isolated from breast cancer patients with high PD-1 expression and then 
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transfected with the selected system to confirm the efficient knockdown of PD-1 gene expression. 
Our findings in this research suggest a set of optimal parameters and a better delivery system for PD-
1 silence on TILs as well as other cancer cells and lymphocytes. 
5.2 Materials and methods 
5.2.1 Chemicals and reagents 
All the samples were prepared under sterile conditions. Sodium hydroxide pellets, magnesium 
chloride hexahydrate (MgCl2·6H2O), and aluminum chloride hexahydrated (AlCl3·6H2O) were 
purchased from Ajax Finechem (Taren Point, NSW, Australia), and Sigma-Aldrich (Castle Hill, NSW, 
Australia), respectively. dsDNA-Cy5 was purchased from GeneWorks (San Diego, CA, USA). PD-1 
siRNA (sense: 5′-AGAcGuAAGcAGuGuuGAAdTsdT-3′ and antisense: 5′-
UUcAAcACUGCUuACGUCUdTsdT-3′ for EL4, and sense 5′-AGAccuuGAuAcuuucAAAd-TsdT-
3′ and antisense 5′-UUUGAAAGuAUcAAGGUCUdTsdT-3′ for human TILs), and other chemicals 
and reagents were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia) if not illustrated 
specifically. Water used in experiments was deionised Milli-Q water. 
5.2.2 LDH NP preparation 
Mg2Al-Cl-LDH NPs were synthesised by the co-precipitation-hydrothermal method, which had been 
well established in our group [25,26]. Briefly, a mixture of MgCl2 (0.70 M) and AlCl3 (0.30 M) with 
a total volume of 10 mL was quickly added to 40 mL of NaOH solution (0.45 M) within 5 s, under 
vigorous stirring. After 10 min stirring, the slurry was separated via centrifugation and then re-
dispersed in 40 mL of deionised water. The resultant suspension was moved into a stainless steel 
autoclave with a Teflon lining and then heated at 100 °C for 16 h. The final mass concentration of 
LDH was approximately 10 mg/mL, with the yield of ~60%. 
BSA were added to stabilise LDH particles in medium, as reported previously [21]. Two milliliters 
of 4 mg/mL LDH suspension was added into 2 mL of 10 mg/mL BSA solution (dissolved in deionised 
Milli-Q water) drop by drop under vigorously magnetic stirring for 30 min to ensure saturated 
absorption. 
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Specifically, Cy5-dsDNA/siRNA was loaded directly onto LDH NPs by adding to the LDH 
suspension at the LDH/dsDNA or siRNA mass ratio of 10:1, which was then diluted to the designed 
volume for cellular uptake or cell transfection after 15 min incubation at room temperature. 
5.2.3 LCP NP preparation 
LCP NPs were prepared by a modified two-step method that was based on the previous reports [13,24]. 
The anionic lipid coated calcium phosphate (CaP) core was synthesised by a water-in-oil 
microemulsion method and then the CaP core was coated with a second lipid layer to form the bilayer 
lipid-coated CaP (LCP) nanoparticles (NPs) by the film-rehydration method. Briefly, the first 
microemulsion (solution 1a) was prepared by mixing 75 µL of 5 M CaCl2 and 50 µL of H2O with 5 
mL of premixed cyclohexane/Igepal CO-520 (70/30, v/v). The second microemulsion (solution 1b) 
containing sodium phosphate was prepared by adding 75 µL of 50 mM Na2HPO4 and 50 µL of H2O 
into another 5 mL of oil phase. Subsequently, the second microemulsion was added with 50 µL of 20 
mM DOPA in chloroform and then with the first microemulsion drop by drop, which was followed 
by stirring for another 15 min. The CaP-DOPA cores were harvested by adding 10 mL of absolute 
ethanol and centrifuging at 10,000× g for 20 min, and then being washed with 10 mL ethanol three 
times. The collected CaP core particles were then dispersed in 1 mL of CHCl3 and mixed with 
DOTAP/DOPC/cholesterol (2:1:3). After evaporation under reduced pressure, the lipid film was then 
hydrated in PBS buffer (pH = 7.4) to obtain LCP NPs, which were normally well dispersed under 
gentle ultrasound treatment. Similarly, Cy5-dsDNA or siRNA was loaded in LCP NPs by adding the 
same amount of Cy3-dsDNA or siRNA (15 µL, 100 µM) in both CaCl2 and Na2HPO4 solutions (75 
µL), followed by the same preparation procedures. The dsDNA/siRNA loading capacity was 
approximately 58 µg/mg (LCP), as reported previously [24]. 
5.2.4 Characterisation of LDH, BSA-LDH and LCP NPs 
The particle size distribution and zeta potential of as-prepared LDH, BSA-LDH, and LCP NPs was 
determined by photon correlation spectroscopy (PCS, Zetasizer Nano ZS, MALVERN Instruments, 
Malvern, UK) using Non-Invasive Backscatter optics (NIBS). For Transmission electron microscope 
(TEM) imaging, LDH, BSA-LDH, and LCP solution was air-dried on a copper grid. The images were 
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obtained on a JEOL 1010A transmission electron microscope (Tokyo, Japan) at an acceleration 
voltage of 200 kV. 
5.2.5 Cell culture and FACS analysis 
EL4 cells, which constitutively produce PD-1, a widely studied Mouse lymphoma cell line, was used 
as the cancer cell model in this study. Normally, EL4 cells were cultured in DMEM that was 
supplemented by 10% (v/v) FBS at 37 °C in 5% CO2 atmosphere. 
As-cultured EL4 cells were collected by centrifugation. After three washes with 2% FCS/PBS, the 
cells were fixed in 2% paraformaldehyde/PBS. For FACS analysis of PD-1 expression, the cells were 
then stained with PD-1 antibody (Cell Signal Technology, 1:500 dilution), and then analysed in a BD 
Accuri™ C6 (San Jose, CA, USA) flow cytometer with CFlow Sampler software (Becton Dickinson, 
Mountain View, CA, USA). 
5.2.6 Tumour infiltrating lymphocyte isolation and characterisation 
Tumour infiltrating lymphocytes (TILs) were isolated from breast cancer biopsy specimens by 
mincing the tissue into small pieces and then digesting them with collagenase type IV (0.1 mg/mL) 
(Sigma-Aldrich, Castle Hill, NSW, Australia) for 2 h, followed by culture in X-VIVO-15 medium 
(Lonza, Basel, Switzerland) containing 5% human AB serum and recombinant human IL-2 (150 
IU/mL) in 24-well plates, followed by an expansion using a rapid expansion protocol (REP) [27,28]. 
Once a sufficient number of T cells (>1 × 107) was generated, they were cryopreserved for later 
expansion. A REP for “young TILs” that was previously used in melanoma patients was followed. 
Cryopreserved, pre-REP TILs from patients were thawed and then further expanded to treatment 
levels using an anti-CD3 antibody (OKT-3, 30 ng/mL, R&D Systems, Minneapolis, MN, USA), rhIL-
2 (BD PharMingen, San Jose, CA, US), and irradiated feeder cells, as previously described [28]. The 
expanded TILs were fixed and then labelled with human CD4 and CD8 antibody conjugates, followed 
by labelling human PD-1 antibody conjugate and being subjected to FACS analysis. 
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5.2.7 Delivery of dsDNA and siRNA to EL4 and TILs 
About 1 × 106 cells EL4 cells or TILs were seeded in the wells of six-well plates and then mixed with 
LDH-PD-1-siRNA/Cy5-dsDNA or LCP-PD-1-siRNA/Cy5-dsDNA at 37 °C for a period of time (0–
8 h) at 20–80 nM of siRNA or dsDNA. The culture medium was then replaced with the fresh medium 
and transfected EL4 or TILs were cultured for another 72 h at 37 °C, 5% CO2. After transfection, the 
cells were collected, and the PD-1 expression level was determined by RT-PCR, ELISA assay, and 
FACS, respectively. 
5.2.8 Western blotting 
The relative PD-1 concentration in cell lysates was estimated using the Pierce™ BCA Protein Assay 
Kit (Thermo Fisher Scientific, Waltham, MA, US). The samples (roughly 10 µg total protein per well) 
were mixed with protein-loading buffer (Bio-Rad, Hercules, CA, US) containing 2-mercaptoethanol. 
After denaturation by 5-min boiling, the samples were loaded on 4–15% Mini-PROTEAN® TGX™ 
Precast Gels SDS polyacrylamide gel (Bio-Rad). Gels were blotted onto polyvinylidene difluoride 
(PVDF) membranes for 90 min at 80 V, the proteins were transferred onto PVDF membranes and 
then blocked for non-specific binding with TBST (0.05% (v/v) Tween-20 in TBS pH 7.4) plus 5% 
BSA for 1 h at RT. PD-1 RabMab antibodies (ab205921) (Abcam, Cambridge, UK; at dilution of 
1:800–1000) was applied overnight at 4 °C. The membrane was washed with TBST and then 
incubated with HRP-conjugated secondary antibodies (Goat anti-rabbit IgG H&L (HRP), ab97051) 
(Abcam, Cambridge, UK; at dilution 1:5000) for 2 h. After washing, the protein bands were visualised 
using Clarity™ Western ECL Substrate (Bio-Rad) and then analysed using ImageJ v1.40 software 
(Hercules, CA, US). 
5.2.9 Real-Time PCR 
All real-time PCR assays were conducted according to the manufacturer’s instructions. In brief, 1.2 
mL of trizol/chloroform (1:5, v/v) was added to lyse cells and the supernatant was then collected by 
centrifugation (12,500 rpm, 15 min). Subsequently, 2.4 mL of isopropanol was added, and the 
supernatant was centrifuged for another 15 min at 12,500 rpm. The collected pellet was washed with 
70% ethanol. After drying the pellet, 50 µL of H2O was added to resuspend the total RNA. Reverse 
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transcription reactions were performed in 20 µL as the manufacturer instructed and the cDNA was 
diluted with 80 µL of H2O. For each well, 3.5 µL of cDNA solution that was mixed with 8.5 µL of 
PCR Master-Mixture. After centrifugation, real-time PCR was conducted (Real-time PCR, iCycler 
iQTM, Bio-Rad, Hercules, CA, US). 
5.2.10 Statistical analysis 
Data are presented as the mean ± SEM or the mean ± SE and analysed by two-way ANOVA using 
GraphPad Prism software. All the cell tests were done in triplicate. A p-value < 0.05 was considered 
to be significant. * p < 0.05; ** p < 0.01; *** p < 0.001. 
5.3 Results 
5.3.1 Physicochemical properties of LDH and LCP NPs 
Homogeneously dispersed Mg2Al-Cl-LDH NPs had a narrow particle size distribution (Figure 1A, 
D), with the equivalent mean hydrodynamic diameter of 110 nm and the polydispersity index (PDI) 
of 0.099. The LDH NP suspension was transparent, with a zeta potential of 35 mV. The TEM image 
(Figure 1A) shows that LDH crystallites were well crystallised, with a typical hexagonally shaped 
morphology. These observations are consistent with previous reports [25,26]. As also shown in Figure 
1B, E, bovine serum albumin (BSA) coated LDH (BSA-LDH with the BSA/LDH mass ratio of 5:2 
and the LDH concentration of 2.0 mg/mL) had an average size of 176 nm with a PDI of 0.229 and a 
zeta potential of about −20 mV. These data mean that LDH NPs were well coated with BSA and then 
colloidally stabilised with BSA, which is consistent with previous reports [20,21]. The TEM image 
in Figure 1B clearly shows that BSA-LDH (5:2) nanocomplexes were nearly mono-dispersed in PBS. 
The size increase suggests that LDH-BSA NPs were slightly aggregated via the BSA bridging effect 
[20]. 
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Figure 1. Particle morphology and particle size distribution. The upper penal shows the morphology 
of the nanoparticles used in this study (A) Mg2Al-Cl-LDH; (B) bovine serum albumin (BSA) on 
layered double hydroxide nanoparticles (BSA-LDH) in PBS; and, (C) lipid-coated calcium phosphate 
(LCP). The lower panel shows the size distributions of the corresponding nanoparticles (NPs) in the 
upper panel (i.e., (A, D); (B, E); and, (C, F)). 
The average size of LCP NPs was about 40 nm after the CaP cores were coated with the lipid bilayer 
(Figure 1C, F), with a zeta potential of 18 mV [24]. The LCP NPs were well dispersed and sphere-
like particles, as observed by TEM (Figure 1C). The TEM image confirmed the typical structure of 
LCPs, containing a CaP core and a coating lipid membrane [23,24]. When the dsDNA or siRNA was 
loaded (58 µg/mg CaP), the average particle size was similar, while the zeta potential was reduced to 
about 14 mV [24]. 
These data indicate that the LDH, BSA-LDH, and LCP nanoparticles that were used in this study 
possess the typical physicochemical properties of LDH and LCP NPs, as reported previously [20,24]. 
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5.3.2 Cellular uptake of LDH, BSA-LDH and LCP NPs 
Cy5-dsDNA was bound to LDH or encapsulated within LCP NPs and used as the dye tag to quantify 
the cellular uptake. As shown in Figure 2A, different uptake behaviors by EL4 were observed. For 
LDH and BSA-LDH, the peak of uptake percentage was achieved at 2–4 h (~50% and ~40%, 
respectively), with the uptake amount then being slightly decreased. Although EL4 cells were 
suspended, more LDH-dsDNA was taken up by EL4 than LDH-BSA-dsDNA, which is probably due 
to the positive zeta potential of LDH-dsDNA (10:1, 20–30 mV) [29], in comparison with that of 
LDH-BSA-dsDNA (more negative than −20 mV after dsDNA was loaded onto LDH-BSA). The 
amount decreased after 4 h might be due to the metabolisation of Cy5-dsDNA released into the 
cytosol after endocytosis of LDH-Cy5-DNA. 
  
Figure 2. Cellular uptake profile of LDH and LCP NPs. (A) The fluorescence-activated cell sorting 
(FACS) results show the positive cell percentage vs. the time course (culture time) for EL4 cells 
treated with LDH-dsDNA, BSA-LDH-dsDNA and LCP-dsDNA hybrids at 40 nM of Cy-dsDNA. (B) 
The FACS results show the positive cell percentage vs. the treatment dose for EL4 cells treated with 
LDH-dsDNA, BSA-LDH-dsDNA and LCP-dsDNA hybrids for 4 h. All the tests were done in triplicate. 
For LCP NPs, the cellular uptake reached the saturation at 4 h (68%) and was maintained for another 
4 h. When compared with LDH and BSA-LDH, LCP NPs have a 20–30% higher uptake amount. This 
increase is largely attributed to the monodispersed stability of LCPs in medium and the positive 
surface charges, which provides more chances for the NP attachment to the negatively-charged 
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membrane of suspended EL4 cells, leading to a higher cellular uptake. As shown in Figure 2B, LCP 
NPs also showed a consistently higher cellular uptake at three Cy5-dsDNA doses (20, 40, and 80 nM). 
The positive cell percentage in the BSA-LDH NPs treated group was 20%, 55%, and 71%, which 
was then increased to 24%, 61%, and 79% for the LDH NPs treated group, and 35%, 75%, and 91% 
for the LCP NPs treated group, respectively. Based on these data, we therefore conclude that LCP 
NPs are more effective in delivering dsDNA into EL4 cells. 
5.3.3 PD-1 expression and gene silence in EL4 cells 
To examine the delivery efficacy of LCP and LDH NPs for gene silence in EL4, we firstly analysed 
PD-1 expression level in EL4 cells. EL4 cells were labelled with mouse CD4 and CD8 antibody 
conjugates, followed by labelling murine PD-1 antibody conjugate. The FACS data shows that 57.4% 
CD4+ EL4 cells and 32.0% CD8+ EL4 cells were PD-1 positive cells (Figure 3A). Overall, EL4 cells 
had a relatively high percentage of cells that were PD-1 positive. 
EL4 cells were then treated with LDH-, BSA-LDH- and LCP-siRNA-PD-1 at 80 nM of siRNA-PD-
1. As displayed in Figure 3B, the PD-1 mRNA expression in EL4 was decreased by 13% and 29% 
using BSA-LDH-siRNA-PD-1 and LDH-siRNA-PD-1, respectively. In sharp contrast, 72% PD-1 
mRNA expression was reduced in EL4 cells using LCP-siRNA-PD-1. Consistently, the PD-1 protein 
expression level was downregulated to 80%, 78%, and 22% while using BSA-LDH-siRNA-PD-1, 
LDH-siRNA-PD-1, and LCP-siRNA-PD-1 nanohybrids (Figure 3C), respectively. The PD-1 gene 
silence, both in terms of mRNA and protein expressions, is actually consistent with the cellular uptake 
of these LDH and LCP NPs by EL4 cells (Figure 2), which all suggest that LCP NPs are a more 
effective delivery system for EL4 cell uptake and gene silence. Note that the scramble siRNA that 
was delivered by LCP did not cause the knockdown of the target PD-1 gene (data not shown). 
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Figure 3. PD-1 expression and down-regulation of PD-1 in EL4. (A) PD-1 expression in gated CD4 
and CD8 positive T cells (32.0%). (B) Real-time PCR data for the knockdown efficiency of PD-1 
mRNA in EL4 treated with BSA-LDH-siRNA-PD-1; LDH-siRNA-PD-1; LCP-siRNA-PD-1 at the 
concentration of 80 nM for 4 h; and, (C) Western-blot showing the reduction of PD-1 expression in 
EL4 cells treated similarly. All tests were done in triplicate, with the SEM being listed in the 
parenthesis. 
5.3.4 PD-1 expression and gene silence in human TILs 
Human TILs from breast cancer patients were isolated and then expanded in vitro. The cells were 
labelled with anti-human CD4 and CD8 antibody conjugates and PD-1 expression was also labelled 
with a specific fluorescence antibody. The CD4+ and CD8+ T cells were gated for PD-1 expression. 
The FACS data shows that CD4 and CD8 positive cells had a similar PD-1 positive cell percentage 
(71.3% vs. 68.0%) (Figure 4). 
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Figure 4. PD-1 expression in human tumour infiltrating lymphocytes (TILs). FACS results show the 
PD-1 positive cells in CD4+ and CD8+ cell populations from TILs. 
The expanded TILs were then treated with LCP-siRNA-PD-1 NPs to downregulate the expression of 
PD-1 mRNA and the PD-1 protein. As shown in Figure 5A, the PD-1 mRNA percentage was 
significantly decreased from 73% to 33% when the siRNA-PD-1 concentration was increased from 
20 to 80 nM. As shown in Figure 5B, the PD-1 protein expression level was obviously reduced at the 
siRNA-PD-1 of 40 nM (by 32%), and even more at 80 nM (by 62%). The efficient silence of PD-1 
gene can be largely attributed to the high delivery efficacy of LCP NPs for siRNA to T cells, as 
discussed previously [24]. 
 
Figure 5. Down-regulation of PD-1 in TILs using LCP NPs. (A) Real-time PCR data for the 
knockdown efficiency of PD-1 mRNA in TILs treated with LCP+si-PD-1 at the concentration from 
20 to 80 nM for 4 h; (B) Western-blot showing reduction of PD-1 expression in TILs treated similarly. 
The tests were done in triplicate, with the SEM listed in the parenthesis. (C) Flow cytometry of TILs 
before and after treatment with LCP-si-PD-1 at 40 nM. All the tests were done in triplicate. 
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TILs that were treated with LCP-siRNA-PD-1 at 80 nM of siRNA-PD-1 also showed a significant 
reduction of the PD-1 protein expressed on the TIL cell surface. As displayed in Figure 5C, the peak 
shifted from 2480 to 960 in terms of the mean florescent intensity, in consistence with 60% reduction 
of the PD-1 protein expression under similar conditions (Figure 5B). All the data indicate that siRNA 
delivered by LCP NPs in this study can effectively downregulate PD-1 expression by T cells, such as 
EL4 and TILs. 
5.4 Discussion 
RNAi therapy always requires the efficient delivery to target cells. As demonstrated previously, both 
LDH and LCP NPs have high biocompatibility, good biodegradability, and low toxicity. As reported, 
the cell viability is >90% at the concentration of >200 µg/mL [24,30]. Thus, both can be effective 
and safe siRNA carriers for PD-1/PD-L1-based immunotherapy. In this work, both LDH and LCP 
NPs were further demonstrated to facilitate the delivery of dsDNA and siRNA to EL4 cells (Figure 
2), cancerous lymphocytes that are homogeneously suspended in culture medium. The cellular uptake 
of various nanoparticles usually undergoes the clathrin-mediated endocytosis. Different from 
polymeric (such as polyethyleneimide) and biomolecular (such as BSA) NPs, which escape from the 
lysosomal pathway during endocytosis [31], LDH and LCP NPs escape from the endosomal pathway 
[9,12,17,32], which ensure the intactness of carried siRNA and drug molecules and their quick 
delivery to the cytosol. This is due to the anti-acidification of LDH (simplified as 
Mg2Al(OH)6Cl·1.5H2O, MW 240) and LCP (CaHPO4·0.5H2O, MW 145) materials when the 
endosome is acidified to later endosome, but before it is fused with the lysosome, because both NPs 
may dissolve, and buffer the acidity within the endosome in the following ways: 
Mg2Al(OH)6Cl·1.5H2O + 6H
+ → 2Mg2+ + Al3+ + Cl− + 7.5H2O (1) 
CaHPO4·0.5H2O + H
+ → Ca2+ + H2PO4− (2) 
The dissolution of LDH and LCP NPs leads to the increase of dissolved salt concentration, which 
causes the influx of water into the endosome due to the osmotic pressure. The continuous influx of 
water increases the volume and finally bursts the endosome, quickly delivering NPs into the cytosol 
and avoiding the enzymatic degradation in lysosome. As reflected in Figure 2, both LDH-Cy5-
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dsDNA and LCP-Cy5-dsDNA NPs were quickly taken up by EL4 cells in the first 2–3 h, and the 
maximum uptake was achieved at around 3 h. 
Relatively, the LCP NPs delivered more Cy5-dsDNA into EL4 cells than LDH NPs (70% vs. 40–50% 
positive cell population, Figure 2), which could be attributed to their smaller size (40 vs. 110–170 
nm, Figure 1). As reported elsewhere, cells take up NPs with the size of 50 nm much more quickly 
than that of 100–200 nm [16,33]. Moreover, the anti-acidification in Equation (A2) generates stronger 
ionic strength than in Equation (A1) per unit H+ number (e.g., 1 mmol) (Appendix A), which leads to 
more water influx and thus quicker escape from the endosome. The endosome escape is superior to 
the lysosome escape in protection and sustainable release of the payload. In the lysosomal pathway, 
most of the NP-siRNA hybrids are digested in lysosome, and a considerable amount of siRNA is 
destroyed, while in the endosome pathway, most of the siRNAs are still associated with NPs and then 
protected when they escape from the endosome. These associated siRNAs can be sustainably released 
in the cytosol for the continuous silencing of target gene, while there is less siRNA available for the 
release from polymer-siRNA hybrids after the lysosomal escape. 
As LDH NPs are sheet-like while LCP NPs are spherical, their shape may further affect the cellular 
uptake. Sheet-like LDH NPs may be readily attaching onto the cell membrane by laying down, but 
they may not be easily engulfed as an endosome for internalization since this engulfing requires more 
distortion of the cell membrane. On the other hand, spherical LCP NPs may be more smoothly 
engulfed and taken up by cells, which may contribute to the higher cellular uptake of LCP NPs. 
More interestingly, LCP-siRNA NPs more efficiently silenced the PD-1 gene expression in EL4 cells, 
in comparison with LDH NPs (Figure 3). Apart from the quick uptake by EL4 cells, there may be 
two other reasons. The main reason is that a unit H+ number releases more siRNA in the LCP NP 
form than in the LDH NP form. As explained in the Appendix A, 1 mmol of H+ is able to dissolve 
145 mg of LCP and thus release 8.4 mg of siRNA for silence, while this amount of H+ can only 
dissolve 40 mg of LDH and thus release 4.0 mg of siRNA in the current experimental conditions. 
This estimation suggests that the functional siRNA released from LCP-siRNA hybrids is two times 
as that from LDH-siRNA hybrids during the endosome escape. On the other hand, the solubility of 
CaHPO4 is ca. 200 mg/L, while that of LDH is 50–100 mg/L [16] at the neutral pH, so more 
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functional siRNA can be released from LCP-siRNA hybrids (11.6 mg/L siRNA) than from LDH-
siRNA hybrids (5–10 mg/L siRNA) after they are delivered to the cytosol with the nearly neutral pH. 
Thus, these two factors, together with the quicker cellular uptake, enable LCP-siRNA hybrids to more 
efficiently release functional siRNA in the cytosol and knockdown the target PD-1 gene expression 
(Figure 3), seemingly being 3–4 times higher at the siRNA dose of 80 nM. When compared with 
optimised functional LDH-siRNA formulations (LDH:siRNA mass ratio = 5:1) reported previously 
[34], the current LCP NPs appear as more cost-effective siRNA carriers and vehicles for cellular 
delivery. As an example for confirmation, LCP NPs were further used to deliver the functional siRNA 
to human TILs and effectively knockdown the PD-1 gene expression (Figure 5). 
In summary, the current research has demonstrated that LCP NPs are more efficient siRNA delivery 
vehicles than LDH in terms of cellular delivery efficacy and the knockdown efficiency of target gene 
expression. 
5.5 Conclusions 
In conclusion, we compared two inorganic nanoparticles, i.e. layered double hydroxide (LDH) and 
lipid-coated calcium phosphate (LCP), which are both safe and effective vectors for siRNA delivery 
in many cell types regarding the delivery efficacy of functional siRNA (PD-1 siRNA) into suspended 
T lymphocytes (EL4) and silencing the target gene. We found that LCP NPs showed a more cellular 
uptake and higher PD-1 gene silence efficiency in mouse T cell line EL4 than LDH and BSA-LDH 
NPs. We further found that LCP NPs significantly reduced the expression of PD-1 in human ex vivo 
TILs, indicating the feasibility of using LCP NPs for gene therapy in lymphocytes, especially for 
TIL-related cancer immunotherapy. 
5.6 Appendix A 
The estimated release amount of siRNA per unit H+ mmol: 
Mg2Al(OH)6Cl·1.5H2O + 6H
+ → 2Mg2+ + Al3+ + Cl− + 7.5H2O (A1) 
CaHPO4·0.5H2O + H
+ → Ca2+ + H2PO4− (A2) 
 95 
 
Based on these two Equations, 1 mmol H+ can dissolve 1/6 mmol of Mg2Al(OH)6Cl·1.5H2O (MW = 
240) or 1 mmol of CaHPO4·0.5H2O (MW = 145), which leads to an ionic strength of 5 for 
CaHPO4·0.5H2O, but only 3 for Mg2Al(OH)6Cl·1.5H2O if this dissolution occurs in 1 mL water. 
As siRNA was loaded at LDH/siRNA mass ratio of 10:1 in the experiment, so 1 mmol of H+ would 
be able to dissolve 40 mg of LDH and thus release 4.0 mg of siRNA. 
Since siRNA was about 5.8 wt.% in LCP, so 1 mmol of H+ could dissolve 145 mg of LCP and release 
nearly 8.4 mg of siRNA. 
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Chapter 6 
Silencing PD-1 and PD-L1 with Nanoparticle-delivered Small 
Interfering RNA Increases Cytotoxicity of Tumour Infiltrating 
Lymphocytes 
This work has been published in Nanomedicine 2019, 14:955-967. The figure sequence and the 
reference format are kept the same as in the published paper. 
Description of this research: 
Following the finding in Chapter 5 that lipid-coated calcium phosphate (LCP) nanoparticles (NPs) 
are more efficiently delivering siRNA to EL4 cells and tumour-infiltrating lymphocytes (TILs) and 
silencing more target gene (e.g. PD-L1), this research has then delivered functional PD-L1-siRNA 
and PD-1-siRNA to reduce the expressions of PD-L1 in human breast cancer (MCF-7) and PD-1 in 
human TILs. Simultaneously or individually silencing PD-1 on TILs and its ligand-1 (PD-L1) on 
cancer cells (MCF-7) significantly enhances the cytotoxicity of TILs against the cancer cells. Thus, 
these findings have suggested a possible more efficient T-cell therapy for PD-1 positive patients by 
ex vivo silencing the PD-1 in TILs before infusion back into the cancer patients. 
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Abstract: 
Aim: To determine if silencing PD-1 on tumour-infiltrating lymphocytes (TILs) and its ligand-1 (PD-
L1) on cancer cells will enhance the cytotoxicity of TILs. Materials and Methods: Lipid-coated 
calcium phosphate (LCP) nanoparticles (NPs) were synthesised to deliver siRNAs against PD-1 and 
PD-L1 to TILs and breast cancer MCF-7 cells. The down-regulation of PD-1/PD-L1 expressions were 
determined by real-time RT-PCR and Western blotting assays. The killing efficacy of TILs to MCF-
7 cells were determined by cytotoxic T lymphocyte (CTL) assay. Results: LCP-NPs effectively 
delivered siRNAs and silenced PD-1 and PD-L1 expression. The knockdown of either gene or both 
greatly improved the cytotoxicity of TILs. Conclusion: Silencing PD-1 and PD-L1 is an effective 
approach to increase TIL cytotoxicity to cancer cells.  
Keywords: Breast cancer, PD-L1, PD-1, TILs, siRNA, MCF-7, nanoparticles delivery, cytokines.  
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6.1 Introduction 
Over the past decades, the rapid advancement in cancer therapy provides life-saving options for 
cancer patients. Cancer immunotherapy is one of the most promising approaches in current cancer 
treatment. As one significant part of immunotherapy, adoptive cell transfer (ACT) is making great 
breakthroughs in cancer treatment, which was initially reported in the 1980s [1]. ACT relies on 
immune cell populations that mediate direct tumouricidal effects, including conventional cytotoxic 
CD8+ T lymphocytes (CTLs), given alone or together with helper CD4+ T cells, natural killer (NK) 
cells, ‘cytokine-induced killer’ (CIK) cells and Chimeric Antigen Receptor T-Cell (CAR-T) [2, 3]. 
CAR-T therapy has been successful in treating patients with hematologic malignancies, but it has 
been less effective in treating solid tumours [4]. For NK and CIK cells and CTLs based therapies, 
though they can work in some solid tumours, they are not tumour antigen specific sensitised and the 
killing efficiency for cancer cells is not high. On the other hand, tumour-infiltrating lymphocytes 
(TILs) mediated therapy becomes more popular as these cells are tumour antigen-specific and has 
higher killing ability for solid tumours like renal cell carcinoma, breast cancer, oral squamous cell 
carcinoma, and non-small cell lung cancer [5-8]. 
TILs based therapy is also a personalised treatment that can be achieved based on expanding these 
lymphocytes ex vivo from surgically excised tumour specimens of patients and then adoptively 
transferring back into the patient [9]. However，tumour-specific TILs can be inactivated in vivo by 
cellular factors that suppress their activation and effector functions, such as T-regulatory and myeloid 
derived suppressor cells, or by signaling pathways through immune checkpoint molecules such as 
PD-1 on TILs interaction with its ligand PD-L1 (also known as B7-H1) expressed on tumour cells. 
There is a growing body of work suggesting that TILs are restrained in vivo by immunosuppressive 
molecules, such as T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), 
lymphocyte activation gene 3 protein (LAG3), PD-1 and cytotoxic T lymphocyte antigen 4 (CTLA-
4) [5, 7, 8]. In particular, expression of the negative regulator, PD-L1 on tumour cells inhibits the 
activation of T cells upon binding to its receptor PD-1, thereby preventing effectiveness of anti-
tumour immunity [10-13]. The expression of PD-1 and PD-L1 is associated with poor prognosis and 
cancer recurrence in breast cancer patients [14, 15]. Moreover, the high-level expression of PD-1 is 
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usually seen in late stage cancer patients [14]. 
Blockade of these negative regulators on T cells in the tumour microenvironment may improve anti-
tumour T cell responses and lead to improved immunotherapeutic outcomes for cancer patients. There 
are several antibodies and inhibitors developed in recent years, including nivolumab (Opdivo), 
pembrolizumab (Keytruda) and pidilizumab. Although inhibitors and antibodies against cell surface 
molecules like anti-CD40L, CTLA4-Ig, PD-1 and PD-L1 can inhibit these negative regulators, they 
have a short half-life and need multiple treatments [16]. Accordingly, the repeating use leads to high 
costs as well as high rates of adverse effects [17].  
RNA interference (RNAi) based therapeutics have been developed as a potential novel class of 
therapeutic agent to treat many human diseases including cancer [18-20]. Small RNA molecules such 
as siRNA and miRNA are highly effective for cancer therapies due to their ability to specifically 
silence the expression of cancer-related genes or selectively regulate the pathways that are involved 
in the development and progression of malignancy. However, RNAi therapy for the treatment of 
cancer have issues of stability and delivery [21]. Thus, a safe and effective delivery system especially 
for T cells is required for effective RNAi therapy.  
The lipid-coated calcium phosphate nanoparticles (LCP NPs) is one kind of non-viral vectors, which 
has been widely applied in delivery of siRNA [22], chemical drug [23], and cDNA plasmid [24]. This 
is because LCP NPs have a versatile formulation depending on the application aims. For this 
nanomaterial, calcium phosphate (CaP) cores are prepared first and coated with a single DOPA layer. 
After this, the CaP-DOPA cores are further coated with an additional lipid layer as an outer leaflet to 
form an asymmetric lipid bilayer [24]. For successful endosome escape, the cationic1,2-dioleoyl-3- 
trimethylammonium-propane (DOTAP) lipid is often added as an outer leaflet to destabilise the 
endosomes [24, 25]. LCP NPs have been studied and proved to be a powerful tool to deliver siRNA 
[22, 26-28].  
In this study, we investigated whether knocking down of PD-1 in TILs or PD-L1 in cancer cells and 
simultaneously knocking down both could improve antitumour immune responses of TILs in an ex 
vivo model. The objectives of this research were: (1) to effectively deliver PD-1 and PD-L1 siRNAs 
to TILs and cancer cells and silence the target genes using LCP NPs; (2) to confirm the enhanced 
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killing efficiency of TILs to breast cancer cells after Down-regulation of either PD-1 or PD-L1 and 
simultaneous both on TILs and breast cancer cell (MCF-7); and (3) to reveal the mechanism of 
enhancing the killing efficiency through understanding the regulation of the relevant cytokines. Our 
data confirm that the down-regulation of PD-1 or PD-L1 or both can significantly enhance T cell 
immunity (cytotoxicity) against breast cancer cells and have an important potential implication for 
TIL based immunotherapy for cancer patients in the future.  
6.2 Results 
6.2.1 LCP NPs and dsDNA loading 
As shown in Fig. 1A, the prepared LCP NPs were sphere-like particles with the typical hollow 
structure in CaP cores, as previously reported [26, 28]. The average hydrodynamic particle diameter 
of LCP NPs was approximately 30 nm after coated with the second lipid layer (Fig. 1B), with a zeta 
potential of +18 mV. The positive charge is mainly attributed to the positively charged lipid DOTAP 
co-coated on the external layers, as described previously [29].  
 
 
 
 
 
Figure 1. Characterisation of LCP NPs. (A) TEM image of LCP-NPs, the scale bar represents 100 
nanometers; (B) the size distribution of LCP NPs.  
When loaded with Cy3-dsDNA into LCP NPs, the average hydrodynamic particle size was kept 
unchanged, with a zeta potential of +14 mV. The slight reduction of the zeta potential is mainly due 
to the excess dsDNA in the core, whose negative charge is not all balanced by the matrix cations, as 
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discussed previously [26, 28]. Quantitative analysis indicated that dsDNA loading efficiency was 
about 50%, comparable with previous reports [30], and the dsDNA/siRNA loading capacity was 
approximately 58 µg/mg (LCP). The loading capacity of siRNA was then calculated based on its 
dsDNA loading.  
6.2.2 Determination of PD-1/PD-L1 expression on isolated TILs and MCF-7 
The TILs were isolated from breast cancer patients and then expanded (Table 1). The PD-1 or PD-L1 
expression levels on expanded TILs or MCF-7 cells were measured by flow cytometry analysis. A 
typical analysis of patient BC011 samples was shown in Fig. 2A and 2C. There were about 41% CD4+ 
and 36% CD8+ T cells in the expanded TIL population. These T cells were found to have a high level 
of PD-1 expression. As shown in Fig. 2B and 2D, 71% CD4+ and 68% CD8+ T cells were PD-1 
positive. As also shown in Table 1, all expanded TILs collected from 15 breast cancer patients of 
stage 3 or above (pT3 or pT4), the samples contained CD4+ and CD8+ T cells with a relatively higher 
level of PD-1 expression. Thus, the current research on the TILs collected from BC011 patient would 
be used as a representative for this group of patients.  
Figure 2. Representative flow cytometry data for PD-1 expression on TILs and PD-L1 expression on 
MCF-7 cells. (A) Sorting of CD4+ T cells and (B) PD-1+ cells in CD4+ T cells; (C) Sorting of CD8+ 
T cells and (D) PD-1+ cells in CD8+ T cells. (E) PD-L1+ cells in MCF-7 cells.  
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Table 1. Basic demographic data for 15 evaluable breast cancer cases. 
Patient Age Tumour 
stage 
Lymph node 
involvement 
Tumour 
grade 
CD8+ PD-1+0 positive cell 
percentage (%) 
BC001 54 pT3 pN1 2 23 
BC002 57 pT2 pN0 2 31 
BC003 76 pT4 pN2 3 38 
BC004 44 pT2 pN1 2 17 
BC005 45 pT2 pN2 3 33 
BC006 54 pT1 pN0 1 25 
BC007 48 pT1 pN0 1 19 
BC008 42 pT2 pN1 2 31 
BC009 63 pT2 pN1 2 29 
BC010 39 pT2 pN0 1 22 
* BC011 72 pT3 pN2 2 42 
BC012 66 pT3 pN1 3 39 
BC013 53 pT2 pN1 2 31 
BC014 40 pT2 pN1 2 21 
BC015 52 pT3 pN2 3 35 
* BC011 is the representative breast cancer case mainly involved in this study.  
For this study, we used breast cancer MCF-7 cells as the cancer cell model. These cells expressed 
reasonable PD-L1 level, with 31% being PD-L1 positive (Fig. 2E). This level of PD-L1 expression 
in MCF-7 would also represent the specific situation for breast cancers, where 15-20% cancer cells 
are PD-L1 positive [15]. Therefore, TILs and MCF-7 cells are both good representatives to test our 
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hypothesis.  
6.2.3 LCP-si-PD-1 silencing PD-1 in TILs 
The expanded BC011 TILs were then treated with LCP-siRNA-PD-1 to knockdown the expression 
of PD-1 for both mRNA and protein levels. As shown in Fig. 3A, compared to the control, PD-1 
mRNA percentage was significantly decreased from 86% to 18% when the siRNA concentration 
increased from 20 to 160 nM. In Fig. 3B, the PD-1 protein level was also remarkably reduced at 40 
nM siRNA and was nearly totally inhibited at 160 nM of siRNA. The efficient silencing of PD-1 gene 
can be largely attributed to the high delivery efficacy of LCP NPs, which is consistent with that 
reported previously [28].  
 
Figure 3. Knocking down PD-1 expression in TILs. (A) Real-time RT-PCR data for the knockdown 
efficiency of PD-1 mRNA in TILs treated with LCP-si-PD-1 at the siRNA concentrations from 20 to 
160 nM; (B) Western-blotting assay shows the reduction of PD-1 protein expression in TILs treated 
with LCP-si-PD-1; (C) Flow cytometry analysis of TILs before and after treatment with LCP-si-PD-
1 at 40 nM. All tests were conducted in 3 biological repeats. *: p<0.05; **: p<0.01; ***: p<0.001. 
TILs treated with LCP-siRNA-PD-1 at 80 nM of siRNA also showed a significant reduction of PD-1 
expression by flow cytometry analysis. As shown in Fig. 3C, the fluorescent peak shifted to the lower 
intensity side, with the mean florescent intensity reduced from 2480 to 960, in consistence with the 
reduction of the PD-1 protein expression (Fig. 3B). All the data indicate that siRNA delivered by LCP 
NPs in this study can effectively down-regulate PD-1 expression in TILs.  
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6.2.4 LCP-si-PD-L1 silencing PD-L1 in MCF-7 
The same delivery system was also used to silence PD-L1 in MCF-7 cells. After treatment with LCP-
siPD-L1, the expression levels of PD-L1 mRNA and protein in MCF-7 cells were shown in Fig. 4. 
PD-L1 mRNA percentage decreased from 58% to 18% when the siRNA concentration increased from 
10 nM to 40 nM (Fig. 4A). In Fig. 4B, the PD-L1 protein expression level reduced significantly at 40 
nM of PD-L1 siRNA. After LCP-si-PD-L1 treatment (40 nM), the fluorescent peak showed a great 
shift to low fluorescent intensity (Fig. 4C). These data demonstrated that siRNA used in this study 
can effectively knockdown PD-L1 expression in MCF-7. The siRNA doses used for MCF-7 cell 
transfection were slightly lower than that for TILs (Figure 3A). This was because the transaction 
efficiency in MCF-7 was about 60% in terms of positive cell population whereas in TILs it was 50% 
(data not shown).  
 
Figure 4. Knocking down PD-L1 in MCF-7 cells. (A) Real-time RT-PCR data for the knockdown of 
PD-L1 mRNA in MCF-7 cells treated with LCP-si-PD-L1 at the siRNA concentrations from 10 to 40 
nM; (B) Western-blotting assay showing the reduction of PD-L1 protein expression in MCF-7 cells 
treated with LCP-si-PD-L1; (C) Flow cytometry analysis of MCF-7 cells before and after treatment 
with LCP-si-PD-L1 at 40 nM. All tests were conducted in 3 biological repeats. *: p<0.05; **: p< 
0.01. 
6.2.5 Enhanced killing efficacy after the knockdown of PD-1 or PD-L1 or both 
The killing efficacy of TILs to MCF-7 cells after co-culture for 48 hours was shown in Fig. 5. The 
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baseline killing efficacy was low (20 ± 3%) when the untreated TILs and MCF-7 cells were used at 
the TILs/MCF-7 cell number ratio of 10:1. This was slightly increased to 25 ± 1% at the ratio of 100:1. 
For the single down-regulation of PD-1 on TILs or PD-L1 on MCF-7, the killing efficacy of TILs 
was greatly increased from 27 ± 3% to 44 ± 3% with the TILs/MCF-7 ratio increasing from 10:1 to 
100:1. The efficacy was significantly (p<0.05) increased at the TILs/MCF-7 ratio of 30:1 and 100:1, 
compared with that of untreated TILs and MCF-7 cells.  
  
 
 
 
 
 
 
 
Figure 5. PD-1 or/and PD-L1 knockdown improves the anti-tumour efficacy of TILs ex vivo. The 
killing efficacy of TILs to MCF-7 cells was measured with cell-mediated cytotoxicity assays, at the 
TILs/MCF-7 cellular ratios of 10:1, 30:1, and 100:1. PD-1+/PD-L1+: both cells were untreated; 
PD-1-/PD-L1+: only TILs were treated; PD-1+/PD-L1-: only MCF-7 cells were treated; PD-1-/PD-
L1-: both cells were treated. All tests were conducted in 3 biological repeats. *: p-value < 0.05.  
As expected, when both PD-1 and PD-L1 were silenced simultaneously, the killing efficacy improved 
greatly from 32 ± 3% with the ratio of TILs/MCF-7 at 10:1 to 39 ± 3% with the TILs/MCF-7 ratio at 
30:1 and final to 60 ± 3% with the TILs/MCF-7 ratio at 100:1 (Fig. 5). These are well above that in 
all other cases, suggesting a significant (p<0.05) improvement for the anti-tumour effect of TILs after 
knocking down both immune check point molecules (Fig. 5).  
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6.2.6 Measurement of characteristic cytokines after PD-1 or/and PD-L1 knockdown 
To examine the gene knockdown effect on TIL biofunction and understand the mechanism of above 
killing ability increase, we measured IFN-γ, TNF-α, IL-17, and IL-10 levels in the co-cultural system. 
Firstly, we measured CD3 positive CD4 and CD8 phenotypes in TILs (Fig. 6A) and their cytokine 
productions (Fig. 6C). We then similarly measured the phenotypes (Fig. 6B) and cytokine productions 
(Fig. 6D) of gene silenced TILs (labelled as TILK in Fig. 6). We did not find any remarkable changes 
in phenotype (Fig. 6A vs 6C) but find some differences in cytokine production (Fig. 6B vs 6D). The 
differences were that: 1) INF-γ increased significantly (p < 0.01) after the gene knockdown of both 
PD-1 and PD-L1; 2) tumour necrosis factor-alpha (TNF-α) also increased significantly (p < 0.01) 
after gene knockdown of both PD-1 and PD-L1 but significantly decreased (p<0.01) after PD-1 
knocking down only; 3) IL-17 and IL-10 did not significantly change.  
6.3 Discussion 
PD-1/PD-L1 based cancer immunotherapy is a popular and promising approach for cancer treatment. 
Using antibodies to block PD-1 and PD-L1 have shown promising outcomes over conventional 
methods in advanced cancers such as melanoma and lung cancers [31, 32]. At present, more and more 
antibody reagents have been approved by FDA for clinical application, which will greatly benefit 
patients suffered with various cancers. In this study, we used a different strategy based on RNAi to 
silence the gene expression of PD-1 and PD-L1 in T cells and cancer cells. Our data indicate RNAi 
approach can be an effective way to enhance T cell cytotoxicity to cancer cells. The use of siRNA to 
silence PD-1 gene in TILs and enhance their kill efficiency to breast cancer cells and combined 
knockdown of PD-1 and PD-L1 are new findings that have not yet been reported previously to our 
best knowledge. Because of the specificity and effectiveness of RNAi based therapy our study 
represents a new strategy for PD-1/PD-L1 based immunotherapy for breast cancer. 
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Figure 6. Cytokine production in the co-culture of TILs and MCF-7 cells. Untreated TILs (TILs) were 
analysed for CD4 and CD8 positive cells with CD3 T cell marker (CD3+CD4+ or CD3+CD8+ 
population) using flow cytometry (A). These cells were co-cultured with MCF-7 cells (MCF-7) for 48 
hours and cytokine production was measured in culture supernatants by ELISA (B). Similarly, TILs 
with (PD-1 silenced (TILsK) were analysed for CD4 and CD8 positive cells (C) and were then co-
cultured with MCF-7 cells for 48 h. The cytokine production was measured in culture supernatants 
by ELISA (D). In both assays, the TILs/MCF-7 cell ratio was 100:1. CLT-6, a murine IL-2 dependent 
cytotoxic T cell line, was used as a control here. **: p<0.01. 
The effective delivery of RNAi therapy is a big challenge. In this study, we chose the LCP NPs, they 
have excellent properties such as high biocompatibility, good biodegradability, and low toxicity [30] 
thus can be used as an effective and safe siRNA carrier for PD-1/PD-L1 delivery. Another important 
property of LCP NPs is their excellent ability of endosome escape and quick release of siRNA [33], 
which ensures effective gene silencing achieved in our study. Indeed, we found that siRNA-mediated 
Down-regulation of PD-1 on TILs and PD-L1 on MCF-7 cells significantly enhances the cytotoxicity 
of TILs to cancer cells. These data suggest that endosome escape has happened in both cell types. 
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Moreover, our strategy will be potentially an alternative or better approach for PD-1/PD-L1-targeted 
cancer immunotherapy compared with antibody blocking. For examples, unlike antibodies against 
cell surface molecules, which have a short half-life and need multiple treatments, RNAi gene 
silencing can result in a lasting reduction of overall protein expression and consequently lead to a 
long-term enhancement of killing efficacy of T cells to cancer cells with only one treatment, 
especially when the lentiviral-shRNA strategy is used in the treatment for long-lasting gene silencing 
as we reported previously [34].  
RNAi therapy is well-known for its effectiveness and low side effects. Therefore, it can be considered 
as an alternative or a combinational therapy with antibody approach. Although in vivo delivery of 
siRNA has some issues, such as off-targeted delivery and potential side effects, ex vivo treatment of 
T cells especially TILs with siRNA-loaded LCP nanoparticles is an effective and less toxic way to 
down-regulate PD-1 before injecting them back to patients. Our current study has proven that RNAi 
approach works well ex vivo using LCP nanoparticle as the delivery carrier. This strategy combines 
with PD-L1 antibody treatment will expect a more positive outcome for breast cancer patients. A 
recent study showed that high levels of PD-1 and PD-L1 expressions are more associated with triple 
negative breast cancer patients [35], suggesting this strategy will be particularly useful for these 
patients. For in vivo delivery of siRNA against PD-L1, we can further modify LCP nanoparticles by 
loading antibody fragment to over-expressed molecules such as HER2 on HER2-positive breast 
cancer cells, which can further increase the specificity in the future application in clinical setting, as 
it was reported that PD-L1 expression was positively associated with worse clinical outcome in HER2 
positive breast cancer patients [36].  
When PD-L1 siRNA delivered by LCP NPs is applied to in vivo settings, the siRNA will not only 
target cancer cells and silence PD-L1 in these cells, but also possibly target tumour associated 
macrophages (TAMs). It has been shown that TAMs express PD-L1 and inhibit T cell function [37]. 
Therefore, the possible knockdown of PD-L1 on TAMs will be an extra benefit for PD-L1 based 
cancer immunotherapy. This is an interesting direction and warrants further investigations. However, 
the in vivo application of LCP NPs may cause side effects, we thus shall consider more biocompatible 
NPs such as our reported LDH [38] or A-C3 polymeric NPs [20] in the future studies.  
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To further characterise TIL responses to gene silences of PD-1 and PD-L1, we analysed the cytokine 
production during the co-culture. The most obvious change was the increase of IFN-gamma 
production after the gene knocking down (Fig. 6). It has been previously shown that TILs with high 
PD-1 expression could lose their function (exhaust) including reduction of INF-gamma production 
[39]. The increase of INF-gamma in our study is thus believed to relate to the increased activity of 
TILs after the knockdown of PD-1 or both PD-1 and PD-L1. The reduction of the exhaust factor 
during the interaction of TILs and MCF-7 cells thus enhances their killing ability, supported by the 
killing efficiency results (Fig. 5).  
TNF-alpha is also a pro-inflammatory cytokine that can induce cell apoptosis, and the increase of its 
production after PD-1 and PD-L1 knockdown further confirms the enhancement of the TIL function 
after reducing the inhibitory factors (PD-1 and PD-L1). However, its significant decrease in the co-
culture of TILK with MCF-7 cells is an interesting point, which could be due to the abundant presence 
of inhibitory PD-L1 by MCF-7. In sharp contrast, silencing PD-L1 on MCF-7 led to a very significant 
increase of TNF-alpha production (Fig. 6D). This is different from IFN-γ response, suggesting that 
their reaction to PD-L1 inhibition is different, which warrants further investigations.  
IL-17 is a cytokine believed to play a promoting role in breast cancer development via increasing 
chemotherapy resistance and cell proliferation [40]. The presence of Th-17 cells (producing IL-17) 
[40] or IL-17 [41] is correlated to the poor prognosis in breast cancer patients. IL-10 is another 
immune regulatory cytokine, and mainly plays an inhibitory role in T cell function in tumour 
microenvironment [42]. We did not observe much changes on these two cytokines before and after 
gene silence, suggesting that there is no much effect on TILs in these aspects, which is consistent 
with the increased TIL killing ability.  
6.4 Conclusions 
Our present study has shown that the combined knockdown of PD-1 and PD-L1 is more effective 
way than either alone in promoting the killing ability of TILs to cancer cells. Meanwhile, the 
combined silence of PD-1 and PD-L1 results in increased secretion of proinflammatory cytokines 
such as IFN-γ and TNF-α. Our research also confirms that LCP NPs are an effective delivery system 
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to T cells and tumour cells. Together these data suggest that simultaneous silence of PD-1 and PD-L1 
genes restore TIL effector functions and may also shift the tumour microenvironment from 
suppressive to proinflammatory.  
6.5 Materials and methods 
6.5.1 Chemicals 
Sample preparation was performed under sterile conditions. Double stranded DNA labelled with 
Cyanine 3 (Cy3-dsDNA) was purchased from GeneWorks. Phospholipids (DOPA, DOPC, DOTAP) 
were purchased from Avanti Polar Lipid. siRNAs for PD-1 and PD-L1 knockdown and other 
chemicals and reagents were purchased from Sigma-Aldrich if not illustrated specifically. Water used 
in experiments was deionised Milli-Q water.  
6.5.2 LCP NP preparation 
LCP NPs were prepared by a modified two-step method based on the previous reports [26, 28]. The 
anionic lipid coated calcium phosphate (CaP) core was synthesised by a water-in-oil microemulsion 
method, and then the CaP core was coated with a second lipid layer to form the bilayer lipid-coated 
CaP (LCP) nanoparticles (NPs) by the film-rehydration method. Briefly, the first microemulsion 
(solution 1a) was prepared by mixing 75 µL of 5 M CaCl2 and 50 µL of H2O with 5 mL of premixed 
cyclohexane/Igepal CO-520 (70/30, v/v,). The second microemulsion (solution 1b) containing sodium 
phosphate was prepared by adding 75 µL of 50 mM Na2HPO4 and 50 µL of H2O into another 5 mL 
of oil phase. Then, the second microemulsion was added with 50 µL of 20 mM DOPA in chloroform 
and then with the first microemulsion drop by drop, followed by stirring for another 15 min. The CaP-
DOPA cores were harvested by adding 10 mL of absolute ethanol and centrifuging at 10,000 g for 20 
min and washed with 10 ml ethanol three times. The collected CaP core particles were then dispersed 
in 1 mL of CHCl3 and mixed with DOTAP/DOPC /cholesterol (2:1:3). After evaporation under 
reduced pressure, the lipid film was then hydrated in PBS buffer (pH = 7.4) to obtain LCP NPs, which 
were normally well dispersed under gentle ultrasound treatment. 
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6.5.3 Loading siRNA/dsDNA into LCP NPs 
Cy3-dsDNA or siRNA was encapsulated in LCP NPs by pre-mixing an equal amount of Cy3-dsDNA 
or siRNA (15 µL 100 µM) in both CaCl2 and Na2HPO4 solutions (75 µL). The following procedure 
for making LCP-Cy3-dsDNA NPs or LCP-siRNA NPs was the same as described in section 2.2. 
The efficiency of dsDNA encapsulation and the dsDNA loading capacity in LCP NPs were 
determined as follows. After LCP-Cy3-dsDNA particles were dissolved in the lysis buffer (2 mM 
EDTA and 0.05% Triton X-100 in pH 7.8 Tris buffer) by incubating at 65 oC for 10 min, the 
concentration of Cy3-dsDNA released from dissolved LCP was determined by measuring the 
fluorescence intensity, and then the amount of dsDNA loaded into the LCP NPs was calculated. All 
data are reported as the mean value plus/minus the standard deviation in three parallel experiments. 
6.5.4 Characterisation of LCP NPs 
To visualise the morphology of LCP NPs, the nanoparticle suspension was dropped onto a 300 mesh 
carbon coated copper grid and dried on a filter paper at room temperature. The grid was then observed 
in a transmission electron microscope (TEM, JEM-3010, ZEOL, Tokyo, Japan). The hydrodynamic 
diameter and zeta potential of LCP NPs were determined by using a dynamic light scattering device 
at room temperature (DLS, Zetasizer Nano, Malvern, UK).  
6.5.5 TIL isolation and characterisation 
Fresh tumour samples were obtained from 15 breast cancer patents. All the patients have provided 
written consent forms before being subjected to blood and/or tumour collection. All the patient related 
work was approved by the Research Ethics Committee of The Sun-Yat-Sen University Cancer Center.  
TILs were isolated from breast cancer biopsy specimens by mincing the tissue into small pieces and 
digesting them with collagenase type IV (0.1 mg/mL) (Sigma-Aldrich) for 2 h, followed by culture 
in X-VIVO-15 medium (Lonza) containing 5% human AB serum and recombinant human IL-2 (150 
IU/mL) in 24-well plates, followed by an expansion using a rapid expansion protocol (REP) [43, 44]. 
Once the sufficient number of T cells (>1×107) was generated, they were cryopreserved for later 
expansion. A REP for “young TILs” that was previously used in melanoma patients was followed. 
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Cryopreserved, pre-REP TILs from patients were thawed and further expanded to treatment levels 
using an anti-CD3 antibody (OKT-3, 30 ng/mL, R&D Systems), rhIL-2 (BD PharMingen) and 
irradiated feeder cells, as previously described [44].  
6.5.6 Fluorescence-activated cell sorting (FACS) analysis 
FACS analysis was performed with a BD Accuri™ C6 (San Jose, CA, USA) flow cytometer and 
CFlow Sampler software (Becton Dickinson, Mountain View, USA). The immunophenotypes and the 
PD-1 expression level of TILs were determined using FACS as reported previously [6]. The PD-L1 
expression levels in MCF-7 cells were similarly analysed by FACS as described before [45]. Briefly, 
after PD-1 or PD-L1 staining, all samples were subjected to flow cytometry analysis. During the 
analysis, dead cells were firstly excluded, and the single cells were gated on FSC-A (area) against 
FSC-W (width). Single cells were then plotted for PD-1 or PD-L1 positive populations with the 
baseline set on negative and isotype controls.  
6.5.7 Knockdown of PD-1 in TILs and PD-L1 in MCF-7 with siRNAs delivered by LCP NPs 
The siRNAs used in the study were synthesised by Sigma-Andrich. The sequences were: PD-1 siRNA: 
sense 5’-AGAccuuGAuAcuuucAAAd-TsdT-3' and antisense 5’-
UUUGAAAGuAUcAAGGUCUdTsdT-3’); PD-L1 siRNA: sense 5'-AGAcG-
uAAGcAGuGuuGAAdTsdT-3' and antisense 5’-UUcAAcACUGCUuACGUCUdTsdT-3’).  
Each siRNA was encapsulated in LCP NPs for cell treatment. For TILs, 1×106 cells were seed in a 
well of 6-well plate and mixed with LCP-Si-PD-1 at 37 oC for 4 h. The culture medium was replaced 
with the fresh medium and transfected TILs were cultured for another 72 h at 37 oC, 5% CO2. For 
MCF-7 cells, 1×105 cells were seeded in a well of 6-well plate and mixed with LCP-Si-PD-L1 at 37 
oC for 4 h. Similarly, the culture medium was replaced with the fresh medium and transfected MCF-
7 cells were cultured for another 72 h at 37 oC, 5% CO2. After transfection, PD-1 and PD-L1 
expression levels were determined by RT-PCR, ELISA assay and FACS, respectively. 
6.5.8 Enzyme-linked immunosorbent assay (ELISA) 
Cytokines such as IFN-γ, TNF-α, IL-17 and IL-10 secretion from T cells were determined utilizing 
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the relevant ELISA kits (R&D Systems, Minneapolis, MN) according to the supplier’s protocols.  
6.5.9 Real-time RT-PCR 
All real-time PCR assays were conducted according to the manufacturer’s instructions. In brief, 1.2 
ml of Trizol/chloroform (1:5, v/v) was added to lyse cells and the supernatant was collected by 
centrifugation (12,500 rpm, 15 min). Then, 2.4 ml of isopropanol was added and the supernatant was 
centrifuged for another 15 min at 12,500 rpm. The collected pellet was washed with 70% ethanol. 
After drying the pellet, 50 µl of H2O was added to resuspend the total RNA. Reverse transcription 
reactions were performed in 20 µl as the manufacturer instructed and the cDNA was diluted with 80 
µl of H2O. For each well, 3.5 µl of cDNA solution mixed with 8.5 µl of PCR Master-Mixture. After 
centrifugation, real-time PCR was conducted (Real-time PCR, iCycler iQTM, Bio-Rad, USA).  
6.5.10 TIL killing efficacy determination 
The killing efficacy of TILs to MCF-7 was determined by CTL assay. MCF-7 cells (PD-L1+) treated 
with LCP-Si-PD-L1 (40 nM) was named MCF-7K (PD-L1-). TILs (PD-1+) treated with LCP-Si-PD-
1 (80 nM) was named TILsK (PD-1-). To prepare target cancer cells, MCF-7 and MCF-7K cells were 
seeded at a density of 1 × 104 cells/well in U-bottomed 96-well microplates, cultured for 18 h, and 
the medium was then replaced by 50μl fresh phenol red-free RPMI 1640 medium (Gibco-BRL) 
containing 5% FCS. To prepare the pre-treated effector cells, TILs and TILsk were incubated for 24 
h in CNE2-CM and then collected and resuspended in phenol red-free RPMI 1640 containing 5% 
FCS. Fifty microliters of the suspensions were added to each well at various T cell/cancer cell ratios 
of 10:1, 30:1, 100:1. After 4 h incubation, the plates were centrifuged and 50μl of the supernatant was 
transferred to new 96-well flat-bottomed plates, cytotoxic activity of TILs was evaluated by standard 
lactate dehydrogenase (LDH) release assay using CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega, WI) in U-bottomed 96-well microplates, following the manufacturer’s instructions.  
6.6 Statistical analysis 
Data presented as the mean ± SEM or the mean ± SE were analysed by one-way ANOVA with Tukey 
post-hoc test to compare all groups, or Student’s t-test was used to compare two groups using 
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GraphPad Prism software. A p-value < 0.05 was considered significant. *, p < 0.05; **, p < 0.01.  
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Chapter 7 
Increased PD-L1 Expression in Breast and Colon Cancer Stem Cells 
Regulated by Insulin and EGF 
The relevant results have been published in two papers. The first part was published in Clin Exp 
Pharmacol Physiol. 2017, 44:602-604, and the 2nd part in BMC Cancer 2019, 19:153. The figure 
sequence and the reference format are adjusted accordingly based on the publication. 
Description of this research: 
This research has found that breast and colon cancer stem cells (CSCs) express more programmed 
cell death ligand 1 (PD-L1) than their non-stem cancer cells. The investigation of the mechanism for 
PD-L1 increase reveals that insulin is responsible for promoting PD-L1 production in CSCs while 
EGF is only involved in PD-L1 transport to cell surface. Using specific antibody to block surface PD-
L1 in CSC resulted in inhibition of the sphere formation.  These findings suggest that breast and 
colon cancers may be sensitive to PD-1/PD-L1 immunotherapy and thus warrant further 
investigations of PD-L1 knockdown in CSC as a potential immunotherapy for inhibiting the tumour 
metastasis and recurrence, which has been suggested as an important future work. 
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Abstract: Cancer stem cells are responsible for drug resistance and metastasis in solid tumours. 
Understanding their expression and regulation of immune inhibitory molecular PD-L1 will inform 
the design of more effective and lasting cancer immunotherapy based on PD-1/PD-L1. Here we report 
the expression of programmed cell death ligand 1/2 (PD-L1/L2) in breast and colon cancer stem cells 
(CSCs). The stemness of these cells was confirmed by their surface markers. Using flow cytometry 
analysis, we demonstrated that PD-L1 expression was higher in CSCs of both cancers compared to 
non-stem cancer cells. Consistent with this, detection of cellular PD-L1 proteins by Western blot assay 
also showed increased PD-L1 protein in CSCs. In contrast, only trance amounts of PD-L2 were 
detected in CSCs of both cancers. Our results suggest that breast and colon cancers may be sensitive 
to PD-1/PD-L1 immunotherapy and thus warrant further investigations of CSC targeted PD-1/PD-L1 
therapy. To understand the mechanism of the increase we found insulin rather than EGF was the key 
component responsible for promoting PD-L1 production in CSCs while EGF was only involved in 
PD-L1 transport to cell surface. Using specific antibody to block surface PD-L1 in CSC resulted in 
inhibition of the sphere formation but didn’t affect the sphere growth, suggesting the PD-L1 may also 
act as an adhering molecule or biomarker for CSCs. 
Keywords: Cancer stem cells; PD-L1, PD-1/PD-L1 immunotherapy; breast cancer; colon cancer; 
PD-L2.  
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7.1 Introduction 
Cancer immunotherapy based on immune check-point blockage such as programmed cell death 
receptor 1 (PD-1) and its ligand 1 (PD-L1) is a popular topic under intensive investigation. The 
therapy has achieved promising results in advanced cancers, including melanoma, renal-cell and non-
small-cell lung cancers [1, 2]. However, owing to the dynamic expression and regulation of PD-L1, 
intratumoural heterogeneity, and the immune inhibitory tumour microenvironment, the response rates 
to these treatments in many solid tumours are limited [3, 4]. Indeed, some studies showed that only a 
few melanoma and thymic cancer cases had 100% positive cells for PD-L1 expression, most cancer 
types have only <60% positive PD-L1 cells [5], however, even negative cancer cells can respond to 
PD-L1 treatment indicating the that a better understanding PD-L1 expression and regulation is 
necessary. In addition, besides the cell surface, PD-L1 also distributes in cytoplasm or nucleus with 
possible different functions, which further suggests a good understanding of the distribution and 
function of PD-L1 in different tumour cell populations, including cancer stem cells, is important for 
developing future more effective immunotherapy for these solid tumours.  
Cancer stem cells (CSCs) are a small population of tumour cells with self-renewal and pluri-potent 
capacities that are responsible for tumour initiation, maintenance, metastasis, drug resistance and 
recurrence [6]. Targeting CSCs represents a promising strategy to achieve a long-lasting outcome 
including possible prevention of recurrence and metastasis. However, currently only very limited 
information is available about PD-L1 expression in CSCs and PD-1/PD-L1 based immunotherapy to 
target them. We therefore studied the PD-L1/PD-L2 expression in CSCs of breast cancer MCF-7 and 
colon cancer HCT-116 [7]. We then further studied PD-L1/2 expression in CSCs of colon cancer cell 
line HT-29 cells and showed that PD-L1 expression markedly increased in CSCs of this cell line, 
followed by an investigation of the regulatory factors led to the increase.  
Insulin and EGF are 2 well-defined metabolic factors having very important biological roles in cell 
proliferation and differentiation [8, 9]. They also play a role in promoting epithelial mesenchymal 
transition (EMT) and maintaining stemness of cancer cells. For example, insulin, an important 
regulator for carbohydrate and lipid metabolism and a growth factor for cell growth, can keep cancer 
stemness and EMT of CSCs of hepatocellular carcinoma and breast cancer [10]. EGF, as another 
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important factor involving in cellular proliferation, differentiation, and survival via binding to its 
receptor EGFR on cell surface [9], can also promote EMT and maintain stemness in head and neck 
cancer [11]. Consequently, they both are utilised as fundamental components in enriching stem cells 
with self-renewing ability [12] and widely used in the tumour sphere culture to enrich CSCs [13, 14]. 
However, beside above well-studied functions in metabolism and stemness, their functions in 
regulating or modulating immune check-point molecules, particularly on PD-L1 expression of CSCs, 
have not been reported before. Understanding their roles in this aspect is essential for the development 
of more effective and lasting PD-1/PD-L1 cancer immunotherapy targeting CSCs. 
It is well-established that INF-γ regulates PD-L1 expression through JAK/STAT and PI3K/Akt 
signaling pathways [15-17]. In several cancer types including colon cancer, PI3K/Akt pathway has 
been up-regulated [18-20] and may be one of the reasons to explain the elevated PD-L1 expression 
in those cancers. Apart from INF-γ, epidermal growth factor (EGF) and its receptor EGFR can also 
up-regulate PD-L1 through PI3K/Akt or Ras-Raf-Erk pathways. A study showed that PD-L1 
expression increased in an EGFR-dependent manner when EGFR signaling was activated and 
decreased when EGFR signaling was blocked in esophageal squamous cell carcinoma, and this was 
through EGFR-PI3K-AKT, EGFR-Ras-Raf-Erk, and EGR-PLC-gamma signaling pathways [21]. 
Similarly, PD-L1 expression was shown to positively correlate with EGFR expression in non-small-
cell lung carcinoma cell lines that were treated in vitro with EGF and the PD-L1 expression was 
evaluated using flow cytometry [22]. They showed that EGFR-tyrosine kinase inhibitors or EGFR 
small interfering RNA (siRNA) could block EGF-induced PD-L1 overexpression in the cell lines and 
that PD-L1 expression was partially regulated via the PI3K/AKT and JAK/STAT pathways [22]. In 
addition, a recent study showed that EGF could stabilise PD-L1 via GSK3beta inactivation in basal-
like breast cancer. Inhibition of EGF signaling by gefitinib destabilised PD-L1, enhanced antitumour 
T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models [23]. 
Besides protein production, Ghebeh reported a doxorubicin-dependent cell surface down regulation 
of PD-L1 that was accompanied by an up-regulation of the protein in the nucleus. This re-distribution 
of PD-L1 was concurrent with a similar translocation of phosphorylated AKT to the nucleus. 
Inhibition of the PI3K/AKT pathway abrogated the doxorubicin-mediated nuclear up-regulation of 
PD-L1, suggesting involvement of the PI3K/AKT pathway in the nuclear up-regulation of PD-L1 in 
 123 
 
breast cancer [24]. Collectively, above data indicate that PI3K/AKT pathway is not only involved in 
upregulating PD-L1 expression but also its translocation to the cell nucleus and EGF/EGFR’s 
involvement in PD-L1 upregulation and stabilisation. 
Despite this information, the study regarding how PD-L1 expression is regulated in CSCs has not 
been reported for any cancers. In this study, we aimed to understand what factors regulate PD-L1 
expression in CSCs and through which pathways and what factors are involved in the transport of 
PD-L1. We found that insulin could increase PD-L1 expressions in total protein and cell surface levels, 
and this increase was through the PI3K/Akt/mTOR pathway. EGF did not directly increase PD-L1 
protein production but increased PD-L1 levels on the cell surface, suggesting EGF may be involved 
in PD-L1 protein transport or stabilisation to cell surface. These results have important implications 
in developing future and new approaches for PD-1/PD-L1 based immunotherapy to target CSCs. 
7.2 Results 
7.2.1 PD-L1 expression in breast CSCs 
We firstly enriched CSCs from MCF-7 cells using a sphere culture method previously described [13, 
14] and characterised the spheres or sphere-forming cells (SFCs) using CD44 and CD24 CSC markers. 
They exhibited a CD44highCD24low pattern (Fig. 1A) consistent with the reported breast CSC 
phenotype [25]. This suggests that after CSC enrichment, more CSCs are present in SFCs. We then 
compared cell surface PD-L1 expression in SFCs and MCF-7 cells using flow cytometry and found 
that the percentage of positive cells in SFCs was significantly higher than the unenriched parental 
MCF-7 cell line (48.8% ± 2.98% vs. 24.6% ± 3.33%, p<0.01, n=3, Fig. 1B). To further confirm this, 
we used Western blotting analysis to detect cellular PD-L1 protein levels. Our data showed that the 
cellular PD-L1 protein remarkably increased in SFCs compared with parental MCF-7 cells (Fig. 1C), 
which was consistent with flow cytometry results.  
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Figure 1. PD-L1 expression in breast CSCs. MCF-7 cells (4×103 cells/ml) were cultured in serum-
free DNAEM/F12 medium with 20 ng/ml of EGF and 4 µg/ml insulin (sphere culture medium) for 7 
days until spheres were formed. Expression of breast cancer stem cell markers, CD44 and CD24, in 
the sphere-forming cells (SFCs) were examined (A). PD-L1 expression in MCF-7 and their SFCs was 
analysed using flow cytometry and (B) is a representative flow cytometry result of three repeats. The 
cellular protein of PD-L1 was detected by Western blotting analysis (C), note that the protein band 
was broad around 45-50 Kd; Tub: tubulin.  
7.2.2 PD-L1 expression in colon CSCs of HCT-116 cells 
To confirm MCF-7 results in other epithelial cancers, we used colon cancer HCT-116 cells. Similarly, 
we enriched colon CSCs from HCT-116 cells and used commonly reported CSC markers for colon 
cancer, CD133 and CD44, to characterise them [26]. We found that SFCs of HCT-116 express higher 
levels of CD133 and CD44 than their parental cells (Fig. 2A, B), and is consistent with several 
previous reports [27, 28]. We then compared PD-L1 expressions in SFCs and parental HCT-116 and 
found that the percentage of positive cells did not increase significantly (12.0% ± 0.55% vs 8.53% ± 
1.12%, P=0.506, n=3). However, the mean fluorescent intensity (MFI) increased significantly (Fig. 
2D, P<0.001), indicating a low-level global increase of PD-L1 expression in SFCs. We conducted 
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Western blot analysis to confirm the flow cytometry results and showed that the cellular PD-L1 level 
remarkably increased in colon SFCs compared with their parental cells (Fig. 2E).  
 
Figure 2. PD-L1 expression in colon CSCs. HCT-116 cells were cultured in sphere culture medium 
for 7 days. The SFCs were separated and the expression of colon cancer stem cell markers, CD133 
and CD44, was examined. (A) shows the increase of CD133 in SFCs comparing with HCT-116 cells 
while (B) shows the increase of CD44 expression. (C) shows a representative (3 repeats) flow 
cytometry analysis of PD-L1 expression in HCT-116 cells and their SFCs. (D) shows a representative 
histogram analysis of PD-L1 expression in HCT-116 cells and their SFCs. (E) shows the Western 
blotting analysis of PD-L1 protein levels. **: P<0.01 by student-t test, n=3; Tub: tubulin.  
7.2.3 PD-L1 expression in colon CSCs of HT-29 cells 
HCT-116 cells are K-ras mutated colon cancer cells [29]. To further verify that wide-type colon cancer 
cells have the same PD-L1 expression level, we enriched CSCs from K-ras wide type HT-29 colon 
cancer cells. The HT-29 spherical cells were then characterised for their stemness by CD133, CD44 
and CD24 expressions (Fig. 3). From the results, we showed that similar to HCT-116, HT-29 SFCs 
express higher levels of these 3 biomarkers than their parental cells, proving the CSC properties. 
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Figure 3. Flow cytometry analysis of CSC markers of HT-29 spherical cells. After sphere culture for 
enrichment of cancer stem cells, the HT-29 spherical (SP) cells were labelled and analysed for the 
expression of CD24, CD44, and CD133 using flow cytometer. The expression of CD24, CD44, and 
CD133 of HT-29 spherical cells were significantly increased (A, HT-29 vs HT-29SP). The fold 
changes mean fluorescent intensity (MFI) from 3 repeated FACS analysis show the same trend (B).  
CSCs from HT-29 cells were assayed for PD-L1 expression. The results showed that PD-L1 protein 
levels were significantly increased in spherical cells (Fig. 4A). The flow cytometry data further 
proved that after sphere culture, PD-L1 positive cells increased to > 8% compared to HT-29 cells (Fig. 
4B) and the mean fluorescent intensity (MFI) of the spherical cells increased much more significantly 
than HT-29 cells (Fig. 4 C, D). These data indicate that after enrichment of cancer stem cells, the PD-
L1 global expression levels increased in HT-29 cells. These data in HT-29 together with above results 
in HCT-116 cells suggest that PD-L1 expression increase is more common in colon CSCs.
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Figure 4. PD-L1 expression increased in colon CSCs HT-29.  (A). Western Blotting analysis of PD-
L1 protein levels in HT-29 cancer cells and tumour spherical cells from HT-29 (HT-29 SP). (B). flow 
cytometry analysis of PD-L1 positive cells. Comparing with the isotype controls (ISO) HT-29 
spherical cells (HT-29 SP) had more (about 8% increase of PD-L1 positive cells. (C). a histogram 
analysis of PD-L1 expression in HT-29 cells and HT-29SP. (D). the fold changes of MFI of C.  
7.2.4 PD-L2 expression in CSCs of colon and breast CSCs  
We compared PD-L2 expression on CSCs from both breast and colon cancers. However, only trance 
amount of PD-L2 expression was seen in these cells of both cancer types and did not differ from their 
parental cell expression (Fig. 5). In human pancreatic and oesophageal cancer, it was shown that PD-
L2 expression was low and not correlated with the poor prognosis [30, 31]. These data indicate that 
PD-L2 may not be a dominant immune checkpoint molecule in cancer cells including CSCs.  
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Figure 5. PD-L2 expression in breast and colon CSCs. (A). PD-L2 expression in MCF-7. (B). PD-
L2 expression in HCT-116. (C). PD-L2 expression in HCT-29. 
7.2.5 Insulin but not EGF is responsible for the increase of PD-L1 in CSCs 
To find out what factors are responsible for PD-L1 increase in CSCs. We investigated the factors from 
the major supplementary components used in the sphere culture, i.e. insulin and EGF, using HT-29 
cells as a model. Our Western blotting (WB) results showed that only insulin treatment for 6 days 
could significantly increase PD-L1 protein levels in HT-29 cells (Fig. 6A). In contrast, EGF treatment 
did not increase PD-L1 level at either 3 or 6 days (Fig. 6A). In addition, we showed that insulin could 
increase PD-L1 protein levels in a dose-dependent manner in 2-D cultured HT-29 cells (Fig. 6B). To 
further confirm this, we used flow cytometry method and found that insulin increased PD-L1 
expression in a dose-dependent manner as well (Fig. 6C). These data collectively suggest that insulin 
can promote PD-L1 production in colon cancer cells and CSCs.  
7.2.6 Insulin increases PD-L1 expression through PI3K/Akt pathway 
To understand whether insulin promotes PD-L1 expression is through PI3K/Akt/mTOR pathway, we 
employed a dual inhibitor of this pathway BEZ235 to examine if it can inhibit the promotional effect 
of insulin on PD-L1 expression. Indeed, our data showed that BEZ235 treatment could inhibit PD-
L1 expression at 25 and 50 nM concentrations by flow cytometry assays (Fig. 7A). Our WB assays 
further confirmed the results in total protein levels (Fig. 7B). These data confirm our hypothesis that 
insulin promote PD-L1 protein production and expression through PI3K/Akt/mTOR pathway. 
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Figure 6. Insulin but not EGF increases PD-L1 production in non-CSCs. Insulin treatment can 
increase PD-L1 expression in non-cancer stem cells of HT-29 but the treatment needs to be 6 days to 
be able to display by Western blotting assay (A). In contrast, EGF treated HT-29 didn’t show PD-L1 
protein band even after 6 days and only have the band after co-treatment with insulin. (B) shows a 
dose-dependent increase of PD-L1 protein from 1µg/ml to 20 µg/ml insulin. Similar to (B), (C) shows 
the dose-dependent increase PD-L1 by flow cytometry analysis.   
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Figure 7. PI3K/Akt dual inhibitor BEZ235 dose-dependent inhibition of insulin-induced PD-L1 
expression. (A) shows flow cytometry results of BEZ235 inhibitory effect on PD-L1 expression. (B) 
shows the inhibitory effect on protein levels of BEZ235 by Western blotting assay. 
7.2.7 EGF helps PD-L1 transport to cell membrane 
Though we did not observe the increase of total protein after EGF treatment by WB assays, we found 
an increase of PD-L1 in the EGF treated cells when we analysed the cells by flow cytometry (Fig. 
8A). This suggests that EGF may play a role in transporting PD-L1 to the cell surface. We have 
repeated flow cytometry assay many times and obtained the similar results (Fig. 8B). A previous study 
showed that EGF could enhance PD-L1 expression by stabilising membrane PD-L1 [22]. Therefore, 
we further investigated if EGF treatment could increase PD-L1 levels in cell membrane. We isolated 
the cell membrane of EGF treated cells and conducted WB. We found that EGF treatment increased 
PD-L1 proteins in cell membrane, and together with insulin treatment it increased even more (Fig. 
8C). These data indicate that EGF plays a role in PD-L1 transport to cell membrane, assuming mainly 
transfer PD-L1 from cytoplasm to membrane and stabilise the protein on the membrane, as the 
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previous study suggested [23].  
 
 
 
 
 
 
 
Figure 8. EGF helps in PD-L1 transport to cell surface. (A) shows that after EGF treatment the PD-
L1 levels on cell surface increases analysed by flow cytometry analysis, compared to isotype control. 
Together with insulin EGF treatment can further increase the level. (B) shows the MFI of repeated 
flow cytometry analysis. EGF treatment alone the MFI increased 44.7%, compared to isotype control. 
When co-treated with insulin, the MFI of EGF treatment further increased 20.4%, suggesting that 
EGF treatment is associated with membrane PD-L1 levels. (C) shows the WB assay for PD-L1 in the 
cell membrane isolated from HT-29 cells treated with insulin or EGF+ insulin.  
7.2.8 Blocking cell surface PD-L1 of CSCs affects sphere formation 
To explore whether the high-level expression of PD-L1 have any biological function in colon CSCs. 
We used the PD-L1 antibody to block PD-L1 in the sphere culture system and examine if the block 
interferes with sphere formation and spherical cell growth. The results showed that addition of the 
antibody significantly reduced the tumour sphere numbers (Fig. 9A) but did not affect the sphere size 
(Fig. 9B). The sphere formation reflects the cancer cell clustering and self-renewal ability while the 
size (determined by cancer cell number per sphere) reflects the cell growing ability. Our data suggest 
that the blocking of PD-L1 on CSCs only interfered with their clustering or self-renewal ability but 
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not cell growing ability.  
 
 
 
 
 
Figure 9. Blocking PD-L1 affects sphere formation: Antibody blocking PD-L1 was added into the 
sphere culture medium and the blockage of PD-L1 inhibited the sphere number (A) but didn’t affect 
the sphere size (cells/sphere, B).  
7.3 Discussion 
In this study, we showed that CSCs from colon HT-29 cells expressed high levels of PD-L1, this 
together with our published work on colon cancer HCT-116 cells and breast cancer MCF-7 cells [7] 
reveal a more common feature of epithelial CSCs expressing high-levels of PD-L1. Previous studies 
reported that the increased levels of PD-L1 in cancer patients with different types of tumours were 
associated with poor prognosis [32-34]. We assume that the high-levels of PD-L1 in CSCs will 
attribute to this, as CSCs are responsible for drug resistance, tumour recurrence and metastasis, and 
now immune escape. From this aspect, CSCs should be targeted in cancer immunotherapy for lasting 
and better treatment outcomes. On the other hand, the reason for PD-1/PD-L1 based immunotherapy 
has achieved promising results in some advanced cancers might be owing to the therapy has targeted 
CSCs in these cancers, because advanced tumour would generally contain more CSCs. Therefore, 
understanding the molecular mechanism of PD-L1 regulation in CSCs has important scientific and 
practical implications for future development of more effective and lasting PD-1/PD-L1 
immunotherapy. Previous reports showed that only a few melanoma and thymic cancer cases had 100% 
positive cells for PD-L1 expression, most cancer types had only <60% positive PD-L1 cells [5]. For 
these cancers, the detection of PD-L1 expression in CSCs may be more useful for guiding whether a 
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PD-1/PD-L1 based immunotherapy should be conducted.  
Insulin and EGF are 2 well-understood growth factors for cell proliferation and differentiation. Their 
functional roles in promoting cancer stemness are also well-known. However, whether they could 
regulate the expression of immune inhibitory molecules on CSCs was not clear. In this study, we 
studied both factors on PD-L1 expression in colon CSCs and demonstrated that during their 
promotion of the stemness in colon CSCs they increased PD-L1 production and transport in these 
cells. As a result, the CSCs expressed substantial high-levels of total and cell surface PD-L1 than the 
parental cancer cells and PD-L1 became a part of cancer stemness. A previous study reported that 
surface PD-L1, E-cadherin, CD24, and VEGFR2 were markers of epithelial cancer stem cells 
associated with rapid tumourigenesis [35], supporting our assumption. To extend to in vivo setting, 
because the two factors can be well present in/around tumour [11, 36], they should be considered as 
essential factors to promote PD-L1 expression in CSCs in at least colon cancer. This also suggests 
that high-levels of both insulin and EGF in tumour microenvironment can be a risk factor for cancer 
escape of immune attack.  
Besides immunological functions, the high-level PD-L1 expression in CSCs seems necessary for 
maintaining cancer stemness. In this study, our data suggest that antibody blocking of surface PD-L1 
of CSCs can reduce sphere formation rate but not sphere growth (Fig. 6), indicating surface PD-L1 
may play a role like the adhering molecule for cell-cell connection rather than involving in signaling 
pathways for cell survival and growth. A recent study showed that down-regulation of intrinsic PD-
L1 compromised the self-renewal capability of breast CSCs in vitro and in vivo, as shown by tumour 
sphere formation assay and extreme limiting dilution assay, respectively [37]. In the same study it 
was demonstrated that PD-L1 promoted OCT4 and Nanog expression in breast CSCs, which are stem 
cell markers [37]. Combining this study with our data, we can conclude that: 1) there is a new function 
role of PD-L1 in sustaining cancer stemness in different types of cancer. The implication of this is 
that for PD-1/PD-L1 based therapy it can not only enhance anti-tumour immunity but also inhibit 
CSC activities; an obvious advantage of the immunotherapy. However, since CSCs are usually located 
in deep tumour niche, the tumour microenvironment may protect CSCs from attack by anti-PD-L1 
antibody and T cells [38] thus for an effective treatment, a delivery system will be necessary for 
breaking the barrier and delivering its therapeutic load; 2) Apart from cell surface, PD-L1 distributed 
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in other cell compartments needs to be considered in the therapy, particularly these in cytoplasm and 
nucleus with possible different functions. Indeed, from literature, PD-L1 proteins are found in 
membrane [39-42], cytoplasm [40, 42, 43], nuclear [24, 44], and soluble format [45] from different 
cancer types. These studies also showed that the increased cytoplasm, nuclear, and even soluble PD-
L1 levels are correlated with poor prognosis. But it is expected that only membrane and soluble PD-
L1 will be blocked by PD-L1 antibody therapy. How the PD-L1 proteins in cytoplasm and nucleus 
relates to the membrane PD-L1 and their activities in cancer cells after blocking the membrane PD-
L1 are interesting topics for investigation and a good understanding of the relationship between of 
PD-L1 distributed in cellular locations will lead to better strategies to more effectively block PD-L1 
functions in cancer cells. A previous study reported that the increased cytoplasmic PD-L1 in all four 
stages of papillary thyroid carcinoma patients was correlated with a greater risk of recurrence and a 
poor prognosis, but increased membrane PD-L1 significantly correlated with a greater risk of 
metastasis or death in stage IV patients [43], supporting that both intracellular and surface PD-L1 are 
playing an important role in tumour development and metastasis thus need to be considered together 
in the therapy.  
Insulin is an important regulator for cell metabolism and growth it also plays a role in keeping cancer 
stemness and epithelial mesenchymal transition (EMT) of CSCs [10]. In the tumour sphere culture 
system, insulin is an essential factor to promote the growth and stemness for enriching stem cells [12, 
13]. In this study, to be sure that this was not just in the sphere culture system, we also tested insulin 
treatment in adherent 2-D culture of HT-29 cells. We observed a dose-dependent increase of PD-L1 
protein expression (Fig. 6B), suggesting that insulin can generally stimulate PD-L1 production in 
colon cancer cells. To the best of our knowledge, this is the first evidence on insulin promotion of 
PD-L1 production.  
It is well-known that PIK3/Akt pathway regulates PD-L1 expression [16, 18] and it has also been 
reported that insulin can activate this pathway in colon CSCs [19]. Therefore, in this study we tested 
if the dual inhibitor of this pathway BEZ235 could stop insulin induced PD-L1 production. We indeed 
confirmed that insulin increased PD-L1 production through PI3K/Akt pathway by using both the 
Western blotting and flow cytometry analysis (Fig. 7). However, our data also showed that insulin 
promotion required a long period (between 3 to 6 days), which was a similar period for the sphere 
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culture. The reason behind this is not clear, one possible explanation is that PI3K/Akt pathway has 
been highly activated in colon cancer [19], and further activation of this pathway needs take a longer 
time. Or an alternative explanation is that other pathways such as hypoxia related HIFs [45] 
production may promote the activation of these pathways, which takes time. Further studies of these 
processes are needed to fully understand the mechanism. Nevertheless, the inhibition of 
PI3K/Akt/mTOR pathway may be an important strategy for PD-1/PD-L1 based immunotherapy. The 
dual inhibitor, BEZ235 can inhibit not only the over-expressed PI3K/Akt/mTOR signaling pathway 
in colon cancer cells but also the PD-L1 expression, the later can then increase the sensitivity of 
cancer cells to T cell-mediated killing. We previously showed that BEZ235 had a remarkable effect 
on colon CSCs [19]. Form this point of view, BEZ235 will be a good dual action chemotherapeutic 
for at least colon cancer treatment.  
Different from insulin, EGF didn’t directly affect PD-L1 production. A previous study showed that 
EGF could stabilise PD-L1 via GSK3beta inactivation in basal-like breast cancer [23]. However, a 
recent study reported that EGF was associated with PD-L1 transport, in which, the PD-L1 expression 
in cancer cell lines of non-small cell lung carcinoma (NSCLC) was shown to be enhanced by EGF 
treatment using flow cytometry analysis, and inhibition of EGFR by EGFR-tyrosine kinase inhibitors 
or EGFR small interfering RNA (siRNA) blocked EGF-induced PD-L1 overexpression in NSCLC 
cell lines [22]. They also showed that PD-L1 expression was partially regulated via the PI3K/AKT 
and JAK/STAT pathways and concluded that PD-L1 overexpression was positively correlated with 
EGFR expression in NSCLC [22]. Supporting this study, Zhang W et al (2017) reported that in 
oesophageal squamous cell carcinoma EGF/EGFR was involved in increasing surface PD-L1 
expression using flow cytometry method [21]. From these studies, it seems that EGF/EGFR play a 
transporting or stabilizing role in PD-L1 regulation. In our present study, we used both Western 
blotting and flow cytometry methods to analyse PD-L1 expression and demonstrated that EGF 
treatment only led to the protein increase on cell surface, suggesting that EGF promote the transport 
or stabilisation of PD-L1 on cell surface. This is further confirmed by our membrane protein WB 
analysis (Fig. 8C).  
Furthermore, our flow cytometry data showed that comparing to insulin treatment alone, the insulin 
+ EGF treatment increased surface PD-L1 levels even more (Fig. 8A, B). This result supports that 
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EGF plays a role to transfer PD-L1 to the cell membrane when insulin has promoted more PD-L1 
protein production in cytoplasm, as if EGF only plays a stabilising role, the membrane PD-L1 level 
may not always correlate with the cytoplasm protein level. This notion is also supported by a previous 
study by Okito R et al (2017) where they observed when PI3K/Akt pathway was activated and PD-
L1 was produced, the surface PD-L1 increased by flow cytometry analysis, when the pathway was 
blocked, PD-L1 production reduced and surface PD-L1 transport also decreased [22]. Our result on 
cellular membrane PD-L1 detection also supports the transport role of EGF as the most increased 
membrane PD-L1 protein level was seen in the group treated with both insulin and EGF but not EGF 
alone. Taken together, all data above suggest that insulin promote PD-L1 protein production through 
PI3K/Akt/mTOR pathways and EGF promote its transport in colon CSCs through EGG/EGFR 
pathway.  
7.4 Materials and methods 
7.4.1 Cell lines and spheroid culture 
Breast cancer cell line MCF-7 and colon cancer cell lines HCT-116 and HT-29 were purchased from 
ATCC as reported [29] and were maintained in Dulbecco’s Modified Eagles Medium (DMEM, 
Invitrogen, Australia) supplemented with 10% fetal calf serum, 1% Penicillin, and 1% streptomycin 
in 75 ml flasks at 37ºC and 5% CO2. Sphere culture method was as previously reported [14]. Briefly, 
HT-29 cells were suspended in sphere cultural media (Dulbecco's Modified Eagle's Medium F-12, 
0.4% BSA, 0.2% epidermal growth factor and 0.2% insulin) at a cell concentration of 4000 cells/mL 
in upright T25 flasks. The sphere culture was maintained in a humidified incubator at 37 ⁰C under 5% 
CO2. and fed every two days with 20% of the original culture volume of sphere media until day 7-8.  
7.4.2 Insulin treatment to HT-29 cells 
HT-29 cells were cultured in DMEM media with 10% fetal calf serum (FCS) for 4-6 hours to allowed 
cell attachment. After the attachment, cells were washed with DMEM media without FCS and then 
added DMEM media with 4% FCS in the presence of 1µg/ml, 5µg/ml, 10µg/ml, 20µg/ml and 
40µg/ml insulin respectively. The cells were incubated for 3 days or 6 days and collected for PD-L1 
expression by flow cytometry or in RIPA buffer (Cell Signal Technology) for Western blotting assays 
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of PD-L1 protein expression.  
7.4.3 Flow cytometry analysis for colon cancer stemness biomarkers 
The spherical cells obtained from sphere culture of MCF-7, HCT-116, HT-29 cells were firstly 
verified by their surface markers before subsequent experiments. This is to ensure the cancer stem 
cells have been enriched after sphere culture. After isolation, 1 x 105 cells were used for staining with 
rabbit anti-human CD133 (prominin-1) antibody (Sigma-Aldrich); mouse anti-human CD44 
conjugated with FITC (Invitrogen, Australia); and mouse anti-human CD24 antibody conjugated with 
RPE (Invitrogen, Australia). For CD133 staining, mouse anti-rabbit IgG-FITC (Sigma-Aldrich) was 
used as the secondary antibody. After 3 washes with 2% FCS/PBS, the cells were fixed in 2% 
paraformaldehyde/PBS and analysed by flow-cytometry (Accuri, BD) and CFlow Sampler software.  
7.4.4 Western blotting analysis 
Cells from cultures were lysed in RIPA buffer (Cell Signal Technology) containing 2 µl/ml protease 
inhibitor cocktail (Sigma-Aldrich). Protein samples were separated by electrophoresis using pre-
casted mini PAGE (Bio-Rad) at 120V for 1.5 hrs. The separated proteins were transferred onto PVDF 
membrane at 100V for 1 hr. The membrane was blocked at room temperature with 5% bovine serum 
albumin in Tris-Buffered Saline and 0.5% Tween 20 (TBST) buffer for 1 hr and washed three times 
with TBST with each wash being 5 minutes. The membrane then was incubated overnight with rabbit 
anti-human PD-L1 antibody (Cell Signal Technology) at 1:500 dilution. After washing three times 
with TBST, the membrane was incubated for 2 hours at room temperature with horseradish peroxidase 
conjugated goat anti-rabbit antibody (Cell Signal Technology) at dilution 1:2500. The membrane was 
incubated with ECL for 5 min and scanned.  
7.4.5 PD-L1 antibody blocking assay 
To investigate PD-L1 antibody block effect on sphere formation and growth, HT-29 cells were 
cultured in sphere culture medium supplemented with anti-PD-L1 antibody (Cell Signaling 
Technology) at a concentration of 0.08 µg/ml on day 1. On day 4, an additional 1 ml of sphere culture 
medium with anti-PD-L1 antibody was added to the culture. The culture continued for another 3 days. 
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On day 7 of culture, the spheres were harvested by gentle centrifugation and the sphere number was 
counted under a microscope. The effect of PD-L1 antibody on cell growth was assessed by sphere 
size. To determine the size of spheres, spheres were collected by gentle centrifugation and trypsinised 
to separate individual spherical cells. Cell number were counted using hemocytometer under a 
microscope. Sphere size was defined as cell number per sphere in average (total spherical cells/ sphere 
number).  
7.4.6 Cell membrane isolation and PD-L1 protein analysis 
To study if EGF plays a role in transferring PD-L1 protein to cell membrane, HT-29 cells were 
cultured in DMEM medium supplemented with 5µg/ml insulin. On day 6, EGF at 20 µg/ml was added 
in the culture for 24 hrs. On day 7, cells were collected to extract membrane protein for Western 
blotting of PD-L1 expression. Cells treated with 5µg/ml insulin and 20 µg/ml EGF alone for 7 days 
served as controls. Extraction of membrane protein was as previously described with minor 
modifications [46]. Briefly, cells were harvested by centrifugation and re-suspended in 
homogenisation buffer and were sonicated for 20 seconds on ice. A volume of 6.6 ml homogeniser 
was transferred into 10 ml ultracentrifuge tubes and under-layered with 2.6 ml 40 % sucrose solution. 
The tubes were centrifuged 96000 X g for 1 hour at 4oC. The interfaces were recovered and transferred 
into 50 ml tube and then was diluted to 20 ml with PBS. After another centrifugation, the supernatant 
was discarded, and the precipitation was re-suspended with 100 µL PBS and was used for Western 
blotting to detect PD-L1 protein.  
7.5 Statistical analysis 
Data collected from experimental and control groups were expressed as mean ± SD. The one-way 
ANOVA and unpaired Student’s t-test (GraphPad Prism 6 program) were used to analyse the 
differences between groups and discriminate the significant differences (two-tails, P<0.05) between 
experimental and control groups.  
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Chapter 8    
Conclusions and Future Directions 
In this chapter all results obtained in previous chapters are summarised and the possible future 
directions are outlined following this PhD research.  
8.1 Conclusions 
8.1.1 Optimisation of LDH-siRNA nanohybrids for efficient cellular uptake 
It has been shown in many studies from our and other research groups that LDH can be an effective 
siRNA delivery vehicle to cancer cells. Various loading procedures and loading capacities are reported, 
but there is no comparison study among the loading procedures and amounts in terms of the loading 
capacity, cellular uptake and gene silencing efficacy. To understand these issues, Chapter 4 first 
investigated the optimal siRNA loading procedure. We found that the optimal loading method was to 
directly add siRNA into LDH nanoparticle (NP) suspension, followed by a dilution with culture 
medium. The optimal cellular uptake time was around 4 h, with >80% cells being transfected. We 
further found that the maximum uptake of gene-loaded LDH nanoparticles by MCF-7 cells occurred 
at the LDH/gene mass ratio of 10:1-20:1, while the gene knockdown using LDH to deliver functional 
CD-siRNA and PD-L1 siRNA seemed to work the best at the mass ratio of around 5:1. “Small details 
have big effects”, and these findings will guide the research and application using LDH for siRNA 
delivery in our following studies.  
8.1.2 LCP NP as an effective platform for siRNA delivery to T cells 
One of the major targeting cells of this study was T cells. Using the optimised nanohybrids of 
LDH:siRNA in Chapter 4, we investigated and compared the delivery efficacy of LDH-siRNA and 
well-established lipid-coated calcium phosphate (LCP) nanoplatform in our lab using T cells as the 
model. Both LDH and LCP NPs transfected and silenced the target gene (PD-1) in T cells (EL4 cells), 
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while LCP NPs were more effective under the similar conditions. To further confirm this finding, we 
demonstrated that LCP NPs effectively delivered PD-1 siRNA and knockdown the gene expression 
at either mRNA or protein levels in human TILs. Since T cells usually are not easily transfected and 
there is not much work on this research, our current finding provides a nanoplatform to effectively 
deliver siRNA or other gene agent to T cells.  
8.1.3 Ex vivo knockdown of PD-1 in TILs and PD-L1 in cancer cells enhances the effectiveness 
of cancer immunotherapy 
PD-1 and PD-L1-based immunotherapies have shown astonishing clinical outcomes in treating 
cancer patients with advanced and metastatic cancers, and most current studies have just focused on 
PD-1 and PD-L1 blockade approaches. Thus, in Chapter 6, a new cancer immunotherapy i.e. 
knockdown of PD-1 expression in TILs and/or PD-L1 expression in breast cancers to enhance the 
TILs’ cytotoxicity to breast cancers, has been proposed. As shown in Chapter 5, LCP NPs more 
effectively deliver siRNA to silence PD-1 in TILs, so LCP NPs were used to deliver PD-L1 siRNA 
to breast cancer MCF-7 cells and PD-1 siRNA to TILs.  We found that silencing either PD-1 in TILs 
or PD-L1 in breast cancer cells enhanced the killing ability of TILs to breast cancer cells. 
Simultaneous silencing PD-1 and PD-L1 significantly enhanced the TILs’ immune cytotoxicity to 
breast cancer cells. Thus, our study has an important implication for a new TILs-based 
immunotherapy.  
8.1.4 Cancer stem cells express high levels of PD-L1 
Cancer stem cells (CSCs) are known to be responsible for tumour initiation, development, and 
metastasis. Therefore, therapeutic strategies targeting CSCs may lead to long lasting treatment effects 
or even offer a complete cure. In Chapter 7, we demonstrated that CSCs from colon cancer (HT-29 
and HCT-116) and breast cancer (MCF-7) cells expressed high levels of PD-L1. These results reveal 
that it is a more common feature of epithelial CSCs expressing high-levels of this immune-inhibitory 
protein. We also demonstrated that the increase of PD-L1 may be induced through PI3K/AKT 
pathway by insulin and the increase of transport promoted by EGF. We further noted that the high-
level PD-L1 expression in CSCs seems necessary for maintaining cancer stemness. Our further study 
showed that antibody blocking of surface PD-L1 in CSCs reduced the sphere formation rate, thus 
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surface PD-L1 may act as the adhering molecule for cell-cell connection. Moreover, the increased 
levels of PD-L1 in cancer patients with different types of tumours are reported to associate with poor 
prognosis, and we believe that the high-levels of PD-L1 in CSCs may attribute to this poor outcome. 
Altogether, we conclude that there is a new function role of PD-L1 in sustaining cancer stemness in 
different types of cancers. The implication of this finding is that PD-1/PD-L1 based immunotherapy 
cannot only enhance anti-tumour immunity but also inhibit CSC activities. Thus, CSCs appear a 
suitable target in PD-1/PD-L1 based cancer immunotherapy for better and lasting treatment outcomes.  
In brief, the PhD studies have demonstrated that it is the time to develop and apply suitable 
nanoplatforms, and combine with relevant cell biology to improve the cancer immunotherapy.  
8.2 Future directions 
8.2.1 More application studies with the optimised protocol of LDH NPs delivering siRNA in 
vitro and in vivo 
LDH is one of the most effective platforms for delivering siRNA. The optimised protocol was 
identified in this study, which was successful and effective in delivering PD-L1 siRNA to one cancer 
cell line MCF-7. More cell lines and even in vivo models should be tested to ensure the effectiveness 
of this optimised protocol. Thus, one direction of future studies is to further testify the optimised 
protocol in more cancer cell lines such as breast cancer MDA-MB-231 and colon cancer HCT-116. 
More interestingly, we can use this protocol to deliver Cell Death siRNA (CD siRNA) and combine 
with chemical drug such as 5-FU or MTX to suppress tumour growth in vivo in xeno-transplant 
models.  
8.2.2 In vivo delivery of siRNA to T cells with a LCP nanoplatform 
One of the interesting finding in this study is that LCP NPs are superior to LDH NPs in delivering 
functional siRNA to T cells (including EL4 cells and human TILs) to silence the target genes. Even 
though treating TILs with LCP NPs is regarded as an ex vivo test, these TILs are not exactly the same 
as in the in vivo settings. Therefore, an in vivo test of siRNA delivery to T cells will be necessary to 
prove their delivery efficacy in mouse model. In this case, fluorescent dye-labelled LCP NPs can be 
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systemically injected to mice and the T cells (CD3 positive) will be collected for FACS analysis to 
quantify LCP NP transfected CD4+ and CD8+ T cells, as described in Chapter 5. In our opinion, such 
PD-1-silenced TILs once confirmed in vivo can be injected to patients in combination with the 
traditional therapy (surgery, chemotherapy, or radiotherapy) for enhanced therapeutic efficacy. 
8.2.3 TILs killing assays extend to other cancer lines and in vivo models 
In Chapter 6 we showed that silencing either PD-1 or PD-L1 successfully enhanced the cytotoxicity 
of TILs to MCF-7 cells, and silencing both genes achieved even better outcomes. To generalise the 
finding, more cancer cell lines such as MDA-MB-231, MDA-MB-468, colon cancers, liver cancers 
or even primary tumour cells from patients can be tested. Moreover, PD-1-silended TILs from mouse 
models can be also used to inhibit PD-L1 positive cancer (such as melanoma B16F0) in vivo.  The 
general findings may have an important implication for TILs-based cancer immunotherapy in clinical 
settings.    
8.2.4 Targeted delivery to breast cancer cells in vivo model 
We showed in Chapter 6 that silencing PD-L1 in breast cancer MCF-7 cells enhances the TILs killing 
ability to the cancer cells, which may be applicable in vivo settings. Therefore, silencing PD-L1 of 
cancer cells in vivo is more important and critical for clinical application. So targeted delivery to 
breast cancer cells in vivo using the antibody against HER2 as targeting molecule or using hyaluronic 
acid to target CD44 should be tested in the future study. This can be further combined with PD-1-
silenced TILs for more effective immunotherapy of breast cancers. 
8.2.5 Whether TILs can kill more CSCs 
We demonstrated that CSCs of both breast and colon cancers express much higher levels of PD-L1. 
However, we did not get chance to test if PD-L1 in CSCs can be silenced using LCP or LDH NPs. If 
so, we may further test whether TILs with or without PD-1 silenced have a high activity to kill these 
CSCs. Obviously, this is a good research project and will provide useful information for future CSC-
targeted immunotherapy.  
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